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Chapter 1 
 
General Introduction 
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Introduction 
 
Eucaryotic cells contain a diverse range of membrane-bound compartments, organelles, each 
with distinct composition and cellular function. To maintain this compartmental organization, 
the cell selectively transports cargo molecules through an elaborate network of vesicle 
trafficking pathways to the appropriate target organelle. Extracellular communication, 
steering this network, is mediated by hormones, neurotransmitters, and growth factors, 
through signal transduction events involving receptors. The study of signal transduction 
pathways and membrane trafficking were once considered unrelated disciplines in cell 
biology. It is becoming evident, however, that membrane trafficking and signal transduction 
events are intimately intertwined (1,2). The temporal and spatial delivery of signals and their 
receptors to different intracellular compartments has been shown to be critical in many 
cellular processes. Furthermore, proteins involved in signaling pathways can also interact 
with and regulate components of the membrane trafficking machinery itself (3). Therefore 
intracellular transport is nowadays considered to be a choreographed program of secretory, 
biosynthetic and endocytic protein traffic that serves the cell’s internal physiological needs, 
propagates its internal organization and allows communication with the environment. 
It is intriguing how this complicated network of communication, in which signaling 
and trafficking molecules have to cooperate, is regulated. One of the fundamental processes 
governing signal transduction events is reversible phosphorylation. The level of protein 
phosphorylation is tightly regulated by the concerted action of kinases and phosphatases. 
Some of these kinases and phosphatases are found specifically at organelles and are now 
implicated in localized signaling and membrane trafficking events. To shed light on this 
complex system of cellular regulation, it is important to identify and understand the 
behaviour of all players involved.  
Prior to the start of this PhD thesis study a signaling molecule, protein tyrosine 
phosphatase PTP-SL, was identified by members of our group. PTP-SL resides on vesicular 
structures that partly belong to the endosomal compartments (4). Subsequently, it was 
revealed that PTP-SL is a member of the PTPRR protein tyrosine phosphatase subfamily that 
is implicated in various MAPK (mitogen-activated protein kinase) signaling pathways (5-7). 
In addition, PTP-SL was found to interact in the yeast two-hybrid system with the β4-adaptin 
of the AP-4 complex, an important component of the vesicular transport machinery. These 
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findings are suggestive of a role for PTP-SL in localized signaling and/or trafficking. In this 
thesis research the PTPRR phosphatase subfamily was investigated in great detail, with 
special emphasis on their (sub)cellular localization and isoform diversity. Before presenting 
the outline and scope of this work I will first provide some general information relevant for 
the studies described in the following chapters.  
 
 
Vesicle transport 
 
In vesicle transport three essential steps can be discerned: vesicle formation, vesicle transport, 
and vesicle fusion. These carefully orchestrated processes require the complex interplay of 
many components (8). There are three known coat complexes; clathrin, coatamer protein I 
(COPI) and COPII (9). Clathrin functions at the plasma membrane and in transport between 
late endosomes and the Golgi-apparatus (Fig. 1) by introducing a membrane curvature. 
Intracellular transport between the endoplasmic reticulum and Golgi-apparatus compartments 
is mediated by the coat protein complexes COPI and COPII that form transport vesicles and 
collect the specified set of cargo (10). 
Adaptor proteins bind the cytoplasmic domains of transmembrane proteins and recruit 
coat proteins to membranes. By providing a link between cargo concentration and vesicle 
formation, they have a crucial role in the sorting of membrane proteins (11-13). One specific 
class of adaptors is that of the adaptor protein (AP) heterotetrameric complexes (14). AP 
complexes interact with short peptide sequences found in the cytosolic tails of cargo 
transmembrane proteins, referred to as “sorting signals”. These motifs determine which 
vesicular traffic pathway is used to transport a particular molecule and hence determine its 
final destination (12,15). AP-1 is involved in trafficking between the trans-Golgi network 
(TGN) and endosomes, AP-2 functions with clathrin at the plasma membrane, and AP-3 is 
involved in the formation of specialized lysosome-related compartments (for example 
melanosomes). The AP-4 complex is localized to the Golgi-apparatus and late endocytic 
vesicles (16). The precise role of AP-4 is unknown at present, but data suggest that it 
mediates sorting processes at the TGN and/or endosomal membranes (17,18). In addition to 
the AP family, the GGA (Golgi-localized, γ-ear containing, ARF-binding protein) family also 
functions in membrane-protein trafficking by linking cargo proteins to transport vesicles (19). 
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The pinching off of the clathrin-coated membrane requires further the action of several 
accessory proteins (20). These include, but are not limited to, epsins, endophilins (proteins 
that are thought to induce the bending of the membrane that is required for vesicle budding), 
dynamin (a protein required for the fission of a vesicle from a donor membrane), and 
amphyphisin (which binds endophilin).  
 
 
 
 
 
Figure 1. The major membrane traffic pathways in endocytosis.  
The different adaptor complexes (AP-1 till 4) involved in specific transport routes are depicted.  
Adapted from ref. 2.  
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Vesicles then have to be sorted and transported to various intracellular destinations for which 
the small GTPases of the Rab family are essential (21). For almost every vesicular transport 
step specific (or combinations of) Rab proteins are required and they function through the 
recruitment of specific effector proteins to the membrane on which they are localized (22).  
Membrane fusion, the final step in vesicular trafficking events, is in part also 
mediated by Rab proteins and furthermore requires proteins such as SNAREs. SNARE 
proteins function in cognate pairs, with one set of the pair being localized to the vesicle and 
the other to the target membrane (23). Membrane fusion of vesicles is crucial for the transfer 
of proteins and lipids between different compartments, and for exo- and endocytotic traffic of 
signaling molecules and receptors (24).  
 
 
Endocytosis and Signaling 
 
Endocytosis is defined as the uptake of material into a cell by an invagination of the plasma 
membrane, ultimately resulting in its internalization in a membrane-bound vesicle. An outline 
of the endocytic pathway is depicted in Figure 1. In mammalian cells, cargo can be 
endocytosed in three ways: via clathrin-coated pits, through a clathrin independent pathway 
and by means of caveolae (25). Clathrin-dependent endocytosis involves the formation of 
vesicles using a clathrin coat; clathrin triskelions assemble at the membrane and form a 
polyhedral lattice. Internalization via the clathrin-independent pathway is poorly understood, 
but evidence for its existence is gradually accumulating (26). Endocytosis via caveolae 
involves the formation of small, flask-shaped membrane invaginations enriched in 
cholesterol, sphingolipids, and caveolin proteins (25). 
After internalization, endocytosed material is delivered to early endosomes, where 
efficient sorting occurs. From early endosomes cargo is either recycled back to the plasma 
membrane, sorted to the late recycling compartment or delivered to the late endosomes. This 
can occur either by means of carrier vesicles or through a “maturation” process, a change in 
biochemical composition and morphology (27). Likewise, late endosomes either mature into 
lysosomes or transfer cargo to lysosomes through vesicular intermediates. It is difficult to 
distinguish between early and late endosomes and the boundary between late endosomes and 
Chapter 1 
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lysosomes is even more elusive, but based on their lipid composition, six different stages 
have been distinguished in the journey from the cell surface to lysosomes (28,29). Transport 
routes also connect the biosynthetic and endocytic pathways, and can send or receive cargo 
from the TGN (Fig. 1).  
Traditionally, endocytosis of cell surface receptors has been considered as a 
mechanism to down-regulate signal transduction by desensitising the cell’s response to 
signaling molecules. However, endocytosis may also increase signaling by associating the 
internalized receptors with their signaling targets on the endosomes and only later on 
decrease signaling by sorting receptors to the lysosomes for degradation. Indeed it has 
become evident that endocytosis can regulate signaling through multiple mechanisms, and 
nowadays the process is viewed as a powerful means to regulate the distribution of signaling 
molecules over distinct organelles thereby creating compartmentalization of signaling events 
(30).  
Subcellular compartmentalization in signaling is well documented for the MAPK 
cascades, that relay extracellular stimuli from the plasma membrane to crucial cellular targets 
distant from the membrane (1-3,31,32). For example, in epidermal growth factor receptor 
(EGFR) signaling, on and off switches are spatially separated. Following specific stimuli, 
EGFR is endocytosed from the cell surface and the resulting endosomes migrate close to the 
endoplasmic reticulum (ER), where the protein tyrosine phosphatase 1B resides, subsequent 
dephosphorylation of EGFR takes place (33). Another example of compartmentalized 
regulation is provided by the human Sef (acronym for similar expression to fgf genes) protein 
(34). Sef resides on the Golgi-apparatus and specifically binds extracellular regulated kinase 
(ERK), thereby blocking ERK nuclear translocation without inhibiting its activity in the 
cytoplasm. Hence, this protein acts as a spatial regulator for ERK signaling (34). 
Recent data even indicate the importance of so-called ‘signaling endosomes’ for the 
initiation of downstream signaling events (35). Nerve growth factor (NGF) signaling, for 
example, occurs over long distances from the cell periphery to the cell body and involves the 
retrograde transport of endocytic vesicles containing activated receptors (trkA and p75). 
These signaling endosomes actually facilitate the trkA and p75 signaling events that are 
temporally and spatially distinct (36,37). Likewise, the activated and phosphorylated EGFR 
associates with its downstream targets, such as Shc, Grb2, PI3K and Ras signaling molecules, 
on the endosome (30,38,39), which then are expected to further relay the signaling cascade.  
                                                 General introduction 
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Regulation of membrane trafficking by phosphorylation 
 
From the preceding section it is clear that vesicle trafficking is a crucial regulator of cell 
signaling but the opposite mechanism, i.e. that signaling events determine vesicular transport, 
is equally true. Protein phosphorylation, being a signal-induced rapid and reversible post-
translational modification, is apparently an ideal mechanism for controlling trafficking events 
since the activity of many proteins that are implicated in endocytosis, including dynamin 1, 
amphiphysins, synaptojananin 1, epsin, Eps15 and AP-180, is regulated in this way (40-43). 
These proteins are e.g. found in the phosphorylated state in resting nerve terminals, and are 
dephosphorylated when a depolarization stimulation evokes a burst of clathrin coated vesicle 
formation (42). It was further shown that phosphorylation of dynamin 1 and synaptojanin 1 
inhibits their binding to amphiphysin, while phosphorylated amphiphysin has an impaired 
affinity for the earlier discussed adaptor protein AP-2 and for clathrin (44). In vivo serine and 
threonine phosphorylation of the different subunits of AP-2 complex has also been reported 
(43). Phosphorylation of the µ2 subunit of AP-2 significantly increases the affinity of AP-2 
for cargo internalization signals in vitro (45) and in vivo (46,47), whereas phosphorylation of 
the α and β2 subunit of the AP-2 complex is inhibitory for clathrin coated vesicle formation.  
There is also increasing data pointing to the importance of tyrosine-specific 
phosphorylation in the regulation of intracellular traffic. Upon ligand-induced EGFR 
endocytosis, for example, the β2 subunit of the clathrin adaptor complex AP-2 becomes 
phosphorylated on tyrosine and this appears to be important in the regulation of EGFR 
turnover (48). Moreover, EGFR endocytosis itself requires tyrosine phosphorylation of 
Eps15, an endocytic protein, by EGFR (49). Much of the work on the regulation of vesicular 
transport by phosphorylation has been focused on protein tyrosine kinase signaling, but 
recent findings now underscore the importance of protein tyrosine phosphatases in these 
processes as well. For example, PTP-MEG2 is localized to the membrane of secretory 
vesicles and it can dephosphorylate and thereby activate the N-ethylmaleimide-sensitive 
factor (NSF), a key regulator of secretory vesicle fusion (50). And inhibition of the tyrosine 
phosphatase activity of PTP-1B, which is located at secretory vesicles of glucagon-producing 
cells, was found to be associated with a strong stimulation of glucagon secretion (51). It is 
therefore to be expected that protein tyrosine phosphatases, being the counteractors of the 
protein tyrosine kinases, will play an equally important role in vesicle traffic.  
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Protein tyrosine phosphatases 
 
The protein tyrosine phosphatase (PTP) superfamily is a large group of enzymes showing 
extensive diversity in structure and biological function (52-55). Tyrosine phosphatases are 
classified into three groups: receptor-type (I), non-transmembrane (II) and dual-specificity 
phosphatases (III) (56). A schematic representation of different types of family members is 
shown in Figure 2. The first group has a transmembrane domain, a receptor-like extracellular 
region and one but mostly two catalytic PTP domains. The second group is cytoplasmic in 
location, and can in turn be subdivided in membrane-associated and true cytosolic PTPs. In 
contrast to these tyrosine-specific PTPs, the third group consists of promiscuous enzymes that 
can dephosphorylate phosphoserine, phosphothreonine as well as phosphotyrosine residues. 
The non-transmembrane PTPs and dual-specificity phosphatases contain one single catalytic 
PTP domain. The approximately 250 residues long PTP domain is highly conserved, and 
contains an essential cysteine residue within its active site that is used in a cyteinyl-phosphate 
enzyme intermediate during dephosphorylation.  
The regulation of PTPs is not completely understood, but includes alternative mRNA 
splicing, modulation of steady state levels, posttranslational modification, dimerization and/or 
subcellular confinement (52). These mechanisms contribute to the diversity of “the 
phosphatome” and add to the complexity of cellular signaling programs. Often, the non-
catalytic regions of PTPs contain domains that target the enzymes to their appropriate 
subcellular locations and interacting proteins, including substrates. These non-catalytic 
regions may even participate in the regulation of phosphatase activity by intra-molecular 
folding mechanisms. As with other signaling molecules, complex formation and regulation of 
enzymatic activity are highly dynamic and tightly regulated in space and time. In addition, 
many PTPs can be phosphorylated on serine, threonine or tyrosine residues, which adds a 
further layer of complexity regarding their regulation.  
 
 
 
                                                 General introduction 
 17
 
 
Figure 2. Schematic representation of the different types of family members of receptor PTPs, non- 
receptor PTPs and dual specificity PTPs. Structural characteristics of PTP regulatory domains are shown in 
the boxed inset. Adapted from refs. 52 and 54.  
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PTPRR protein tyrosine phosphatase isoforms 
 
A decade ago our group cloned the mouse protein tyrosine phosphatase PTP-SL, a product of 
the Ptprr gene (4,57). During the studies described in this thesis it was established that the 
mouse gene Ptprr not only codes for PTP-SL but actually gives rise to multiple neuronal 
protein tyrosine phosphatases through the use of distinct promoters and differential 
translation starts (57-61). The resulting PTPRR protein family consists of the isoforms 
PTPBR7, PTP-SL, PTPPBSγ-42 and PTPPBSγ-37 that differ in their N-terminal part (Fig. 2) 
and have molecular weights of 72, 60, 42 and 37 kDa, respectively (described in Chapter 3 of 
this thesis).  
PTPBR7 and PTP-SL are expressed through developmentally regulated use of 
alternative promoters (4). PTPBR7 is expressed during early embryogenesis in spinal ganglia 
as well as in the developing Purkinje cells. Postnatally, PTPBR7 is expressed in various 
regions of the adult mouse brain, but expression in Purkinje cells then ceases and is replaced 
by the PTP-SL transcript (4). PTPPBSγ mRNAs are found in the hippocampal region, 
cerebellar granular layer and in the gastrointestinal tract (59). In rat, a comparable situation 
exists: a short messenger, encoding PCPTP1-Ce, is exclusively found in adult cerebellar 
Purkinje cells whereas the longer form, PCPTP1, is more generally expressed albeit at lower 
levels (62,63). The human PTPRR family includes PTPPBSα, PTPPBSβ and PTPPBSγ, 
which are the orthologues of mouse PTPBR7, PTP-SL and PTPPBSγ, respectively (58,59). 
However, the human family is even larger and in addition includes PTPPBSδ.  
The mammalian MAP kinase cascades in signal transduction pathways are initiated 
by a wide variety of extracellular stimuli as illustrated in Figure 3A. All PTPRR isoforms 
have an identical C-terminal part that contains the catalytic PTP domain and a so-called 
kinase interaction motif (KIM) that enables binding to the MAP kinases ERK1, ERK2, ERK5 
and p38 (5-7). Binding of these MAP kinases to PTP-SL results in the inactivation of the 
MAPK through dephosphorylation and the blocking of nuclear translocation (6) (Fig. 3B). 
But before it can do so, PTP-SL first serves as a substrate for the MAPK, resulting in its 
phosphorylation on Thr239. Following proper stimuli, PTP-SL itself can become 
phosphorylated on Ser217 within its KIM motif by the cyclic-AMP-dependent protein kinase, 
PKA, which results in the dissociation of PTP-SL and MAPK and translocation to the 
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nucleus of the latter (64). A region termed kinase-specificity sequence (KIS), that is 
responsible for the differential recognition of ERK and p38 as substrates, has been identified 
adjacent to the KIM sequence in PTP-SL (65).  
 
 
 
 
Figure 3. A, Schematic representation of mammalian MAP kinase signal transduction pathways. B, 
Model of MAP kinase regulation by PKA and PTP-SL. Adapted from ref.7.  
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The PTPRR subfamily has the closest homology with the STEP (striatum enriched 
phosphatase) and HePTP/LC-PTP (haematopoietic and leukocyte PTPs) phosphatases (66-
68). The STEP family comprises cytosolic and membrane bound PTP isoforms that are 
preferentially expressed in striatum, hippocampus cortex and other related brain structures in 
primates and rodents (66,69). The human HePTP/LC-PTP is a cytosolic protein and mainly 
expressed in lymphoid tissues. Also these two related PTP families contain a conserved KIM 
sequence just N-terminal of their catalytic domains and serve as substrates for MAPKs 
(5,7,70,71). 
The catalytic PTP domain of the PTPRR isoforms has been crystallized and the 
structure indicates a monomeric PTP domain with an unhindered catalytic site (72). In 
addition to the characteristic PTP-core structure, there is an extending N-terminal helix that 
may possibly orient the KIM motif upon interaction with target MAPKs. Within the PTP-
core, structure the so-called mobile WPD loop was found to adopt an open conformation in 
the absence of the substrate. Upon binding of substrate, the WPD loop undergoes an 
extensive conformational change to adopt the closed state, but it appeared much less flexible 
as for example in PTP-1B. Based on the crystal structure, a docking model for the interaction 
with ERK2 was suggested, in which the phosphorylation of the phosphatase should be 
accomplished first. The subsequent dephosphorylation of ERK2 will only be possible after a 
conformational rearrangement of the two interacting partners has taken place (72).   
Interestingly, the different PTPRR isoforms display distinct subcellular localization 
patterns: PTPBR7 is a true type I plasma membrane protein, and additionally localizes to the 
Golgi apparatus and vesicles, PTP-SL appears membrane-associated at the Golgi complex 
and at vesicles that are in part from endocytic origin (4,73), whereas the PTPPBSγ isoforms 
are true cytosolic proteins (61).  
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Outline of this thesis 
 
The presence of PTP-SL on endosomal structures is intriguing and prompted for further 
research. To gain more insight into the possible role of this protein tyrosine phosphatase and 
its subfamily members in localized signaling and/or trafficking, we studied both the 
localization and the biochemistry of PTPRR isoforms. First, the molecular environment of 
PTPBR7 and PTP-SL was explored and a marked overlap in localization of these PTPs and 
β4-adaptin was found (Chapter 2). Previous work had predicted that multiple isoforms could 
originate from the PTP-SL-encoding gene Ptprr in mouse (4,58,59). We therefore performed 
a careful annotation of transcript and protein products derived from the mouse gene Ptprr, 
and investigated protein expression both in situ and at the subcellular level (Chapter 3). 
These experiments revealed that Ptprr encodes four isoforms through the use of distinct 
promoters, alternative splicing and differential translation starts. Furthermore, these studies as 
well as literature data (5,6,64,74) pointed to the occurrence of posttranslational modifications. 
In Chapter 4, we have analyzed the posttranslational modifications imposed upon the 
PTPRR protein isoforms in great detail. We could show that the PTPBR7 isoform is 
proteolytically cleaved at a furin-like convertase consensus site within its N-terminal 
extracellular segment. Since PTPBR7 and PTP-SL display a great deal of overlap in their 
localization patterns in neuronal cells, we analyzed the subcellular (co-)occurrence of these 
isoforms using confocal laser scanning and electron microscopy (Chapter 5). PTPBR7 and 
PTP-SL were found to co-localize on late endocytic compartments, but PTPBR7 shows an 
additional localization at early endosomes. The implications of the above findings, as 
described in the various Chapters, are then discussed in Chapter 6.  
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Summary 
 
The mouse gene Ptprr encodes the neuronal protein tyrosine phosphatases PTP-SL and 
PTPBR7. These proteins differ in their N-terminal domains, with PTP-SL being a cytosolic, 
membrane-associated phosphatase and PTPBR7 a type I transmembrane protein. In this 
study, we further explored the nature of the PTP-SL associated vesicles in neuronal cells 
using a panel of organelle markers and noted a comparable subcellular distribution for PTP-
SL and the β4-adaptin subunit of the AP4 complex. PTP-SL, PTPBR7 and β4-adaptin are 
localized at the Golgi apparatus and at vesicles throughout the cytoplasm. 
Immunohistochemical analysis demonstrated that PTP-SL, PTPBR7 and β4-adaptin are all 
endogenously expressed in brain. Interestingly, co-expression of PTP-SL and β4-adaptin 
leads to an altered subcellular localization for PTP-SL. Instead of the Golgi and vesicle-type 
staining pattern, still observable for β4-adaptin, PTP-SL is now distributed throughout the 
cytoplasm. Although β4-adaptin was found to interact with the phosphatase domain of PTP-
SL and PTPBR7 in the yeast two-hybrid system, it failed to do so in transfected neuronal 
cells. Our data suggest that the tyrosine phosphatases PTP-SL and PTPBR7 may be involved 
in the formation and transport of AP4 coated vesicles or in the dephosphorylation of their 
transmembrane cargo molecules at or near the Golgi apparatus. 
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Introduction 
Protein tyrosine phosphorylation is one of the important mechanisms that modulate the 
functional properties of neurons in processes like cell migration, axonal guidance and 
synapse formation during development. The level of protein tyrosine phosphorylation is 
tightly regulated by the concerted action of protein tyrosine kinases and protein tyrosine 
phosphatases (PTPs). Several PTPs, most notably the cell adhesion molecule-like receptor-
type PTP LAR, PTPδ and PTPσ, have been shown to be crucial for proper development and 
function of the nervous system. Their homologues in Drosophila are important players in 
motor neuron axonal guidance (1,2). In mice, targeted inactivation of PTP LAR results in 
basal forebrain cholinergic neuron abnormalities and a reduced cholinergic innervation of the 
hippocampal dentate gyrus (3,4). PTPδ deficient mice showed impaired learning with 
enhanced hippocampal long-term potentiation (5), whereas PTPσ deficient mice display a 
much more dramatic neuronal phenotype, including neuroendocrine dysplasia (6,7). For 
many other PTPs their specific neuronal expression pattern in combination with the 
sometimes complex regional-specific generation of isoforms by means of alternative splicing, 
has been viewed as highly suggestive for an important regulatory role in the nervous system 
(8).  
In previous studies, we have cloned a cDNA encoding PTP-SL (9), which is highly 
expressed in brain and is homologous to the rat STEP (striatal enriched phosphatases) family. 
This STEP family of PTPs is comprised of both transmembrane and cytosolic isoforms that 
originate from a single gene by the use of alternative splicing (10-12). Interestingly, the 
mouse gene Ptprr, encoding PTP-SL, also produces an additional isoform, but in this case 
through the use of developmentally regulated alternative promoters (13). The second isoform, 
termed PTPBR7 (14), is identical to PTP-SL in its C-terminal 535 amino acids but has N-
terminally 121 additional residues. PTPBR7 is expressed in brain, especially in the habenula 
and the hippocampal region (14). Although PTPBR7 is initially expressed during Purkinje 
cell development, PTP-SL expression takes over postnatally and remains high in adult 
Purkinje cells (13). In rat, a comparable situation is encountered: a short messenger, encoding 
PCPTP1-Ce, is exclusively found in cerebellar Purkinje cells whereas the long form is more 
generally expressed albeit at lower levels (15). This rat orthologue of PTPBR7, named 
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PCPTP1 (16) or PC12-PTP, is also expressed in PC12 cells and is transiently increased nine-
fold upon treatment with nerve growth factor (10).  
Recently, Augustine et al. presented evidence that PTP-SL and PTPBR7 are members 
of an even larger family of PTP isoforms, called PTPPBS, that includes two additional 
members, PTPPBSγ and PTPPBSδ (17). The closest homologue to the STEP and PTPPBS 
phosphatases is HePTP (or LC-PTP), which is mainly expressed in lymphoid tissues (18,19). 
All three PTP types have in common that they can interact with the extracellular regulated 
kinase (ERK) family (20) via a conserved 16 amino acids kinase interacting motif (21) just 
proximal of the PTP domain, causing retention of the MAP kinases in the cytoplasm through 
tyrosine dephosphorylation (22,23). Following proper stimuli, PTP-SL itself can be 
phosphorylated by the c-AMP-dependent protein kinase PKA on Ser231 residue, resulting in 
the dissociation of PTP-SL and MAP kinase and translocation of the latter (24).  
In previous investigations it was shown that in COS-1 cells ectopically expressed 
PTPBR7 is a transmembrane PTP (14), whereas PTP-SL is localized on intracellular vesicles 
partly belonging to the endocytic compartment (13). Here we describe further studies 
addressing the nature of the intracellular transport vesicles containing PTPRR isoforms in 
neuronal cells. We show that PTP-SL is localized at the Golgi and at vesicles that are in part 
late endosomal structures. In addition, we noted that a conspicuous overlap in the subcellular 
localization of PTP-SL and β4-adaptin, the β-adaptin subunit of the AP4 complex. Upon co-
expression of PTP-SL and β4-adaptin in transfected Neuro-2a cells, however, the subcellular 
localization for PTP-SL is dramatically altered. Instead of the Golgi and vesicle-type staining 
pattern, still observable for β4-adaptin, PTP-SL is now distributed throughout the cytoplasm. 
A possible direct interaction between the PTPRR gene products and β4-adaptin was found 
using yeast two-hybrid, however could not be detected in mammalian cell system. 
Furthermore, PTP-SL, PTPBR7 and β4-adaptin are all endogenously expressed in brain. 
Since we observe a clear overlap in localization our data suggest that PTPRR tyrosine 
phosphatases may be involved in the formation and transport of AP4 coated vesicles or in the 
dephosphorylation of transmembrane cargo molecules at or near the Golgi apparatus. 
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Material & Methods 
 
Expression plasmid constructions 
To create the plasmids pPTP-SL-EGFP and pPTPBR7-EGFP first a plasmid pPTP-EGFP was 
constructed by excising the PTP domain from mPTP13-6 (9) using BamHI (nucleotide 993) 
and BglII (nucleotide 1700) and cloning it into the BamHI site of pEGFP-N3. Then the N-
terminal part of the phosphatases PTP-SL and PTPBR7, cDNA fragments 1- 993 and 1-1567, 
respectively, were acquired by BamHI digestion of the plasmids pSG8/PTP-SL-FL-VSV and 
pSG5/PTPBR7-FL (13) and cloned into the BamHI site of pPTP-EGFP. 
To obtain the plasmid pSG8/PTP-SLcyt-VSV; encoding non-hydrophobic region of 
PTP-SL (142-550 aa), first a PCR was performed on mPTP13-6 with the following primers: 
pEG5SL position 534 (5’ GAAGATCTAGGTTAAAAGAAAGGT-3’) and pEG3SL position 
1779 (5’ CCGCTCGAGCTCTGGTAAATCTTCGG-3’). The 1245-bp PCR product was 
digested with BglII and XhoI and cloned into a modified pSG8-VSV tagged vector (25).  
A construct, pβ4-adaptin-EGFP, for the expression of an EGFP tagged version of 
mouse β4-adaptin was generated as follows. First a PCR on pBluescript-β4-adaptin was 
performed with the general T3 sequencing primer and a specific primer, 5NotKGFP (5’-
ATAAGAATGCGGCCGCTAAAGATTTTATGTCTCCAA-3’); the last 16 nucleotides 
correspond to position 2201-2216 of the mouse β4-adaptin sequence (Acc. No. AF155157). 
The 2.5 kb PCR product was digested with NotI and cloned into pSG8∆b/Not-EGFP-his 
plasmid. This vector is a modified pSG5 in which in between the multiple cloning site a 
sequence has been inserted that introduces a NotI site immediately preceding the startcodon 
and open reading frame of an EGFP variant that C-terminally contains the hexahis tag (details 
available upon request). The resulting pβ4-adaptin-EGFP thus encodes the mouse β4-adaptin 
protein which is C-terminally tagged with EGFP and the hexahis sequence. 
pMyc-2 is a pEGFP-N3-derived vector in which in between the BglII and ApaI site of 
the multiple cloning site a synthetic DNA fragment was introduced that entails an initiator 
AUG codon followed by the cMyc-epitope tag and EcoRI and Xho site respectively. ERK2 
(Acc. no. M84489) and β4-adaptin (aa region 627- 739 of Acc. no. AF 092094) coding 
sequence were both excised from the pJG4-5 prey vector using the restriction enzymes EcoRI 
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and XhoI and cloned into the pMyc-2 vector resulting in the pMyc-ERK2 and pMyc-β4-
adaptin plasmids. 
The plasmids Rab6B-VSV (26), pSG8/PTP-SL-FL-VSV (13) and pNAEGFP which 
encodes a EGFP cDNA placed downstream of sequences encoding the cytoplasmic, 
transmembrane, and stalk region of human N-acetylglucosaminyltransferase I (27) have been 
described elsewhere.   
All constructs were checked by sequence analysis. 
 
Cell lines and antibodies 
COS-1 (ATCC nr: CRL-1650) and Neuro-2a (ATCC nr: CCL-131) cells were cultured in 
DMEM/10% Fetal Calf Serum (FCS) and DMEM/5% FCS, respectively. The generation of 
the antisera α-SL (13), anti-EGFP (28), anti-β glucocerebrosidase (29), anti-cMyc hybridoma 
9E10 (30), and the anti-LBPA (lysobisphosphatidic acid) antibody (31) have been described 
elsewhere. To generate polyclonal antiserum against β4-adaptin, a BamHI restriction 
fragment encoding amino acids 94-548 of human AP4 β-subunit was cloned in BamHI-
digested pGEX-2T. The resulting plasmid was introduced in DH5α strain and GST-fusion 
proteins were induced and isolated as described (32). Purified fusion-protein was used to 
immunize rabbits following established protocols.  
 
Immunofluorescence microscopy 
Neuro-2a cells, cultured on glass cover slips that were coated overnight with 0.5 mg/ml poly-
L-lysine, were transiently transfected with pPTP-SL-EGFP, pPTPBR7-EGFP, pβ4-adaptin-
EGFP or pNAEGFP DNA using Lipofectamine-Plus according to the manufacturer. After 24 
h the cells were washed with PBS (phosphate buffered saline), fixed for 10 min in 1% 
paraformaldehyde in 0.1M Phosphate buffer, washed three times with PBS and mounted on 
glass slides using mowiol containing 2.5 % sodium azide. Some of the coverslips containing 
transfected cells were treated with 10 µg/ml Nocodazole for 3 hours prior to washing and 
fixational mounting. Images were collected using a Bio-Rad MRC-1024 confocal laser 
scanning microscope (CLSM). When cells were co-transfected with either pβ4-adaptin-EGFP 
and pSG8/PTP-SL-FL-VSV or pβ4-adaptin-EGFP and Rab6B-VSV, fixation was followed 
by three wash steps with PBST (PBS, 0.05% Tween-20, 20 mM Glycine) and blocked with 
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1% cold-water-fish-skin-gelatin in PBS. Subsequently, cells were incubated for 1 hour with 
anti-VSV monoclonal antibody P5D4 (ascites, 1: 1000 dilution in PBST (PBS, 0.05% 
Tween-20)). Unbound antibodies were removed by washing with PBST and cells were then 
incubated with Texas Red-conjugated goat-anti-mouse IgG (1: 100 dilution in PBST) for 1 
hour at room temperature. Finally, after three PBST washes coverslips were mounted on 
glass slides using Mowiol containing 2.5 % sodium azide. All immunofluorescence 
microscopy was performed on a Biorad MRC 1024 confocal laser scanning microscope.  
For the transferrin uptake experiments, Neuro-2a cells were transfected with pPTP-
SL-EGFP and 24 hours later cells were washed twice with serum-free medium and 
subsequently incubated with serum-free medium for 30 min at 37 °C. Then 5µg/ml of Alexa-
549-labeled transferrin was added and cells were incubated for various time periods at 37 °C. 
After the incubation the cells were put on ice, washed with ice-cold PBS for three times and 
fixed and mounted as described above.   
 
Immunoelectron microscopy 
Ultrastructural localization studies were performed on Neuro-2a cells transfected with either 
pβ4-adaptin-EGFP, pPTP-SL-EGFP or pPTPBR7-EGFP. After 24 hours the transfected cells 
were sorted by fluorescence activated cell sorting (FACS) for their EGFP content. These 
sorted cells were cultured for an additional 24 hours before fixation in 1% paraformaldehyde 
(PFA) in 0.1M phosphate buffer for 2 hours at room temperature. Fixed cells were stored 
untill use in 1% PFA. Before sectioning, cells were pelleted in 10% gelatin and post-fixed in 
1% PFA for 24 hours. Ultrathin cryosectioning was performed as described before (33,34).  
Sections were incubated with an antiserum against EGFP at a 1: 100 dilution (28) followed 
by protein A complexed with 10 nm gold (33). Electron microscopy was performed using a 
JEOL 1010 electron microscope operating at 80 kV. 
 
Yeast two-hybrid interaction trap 
Plasmid DNAs, pEG202-1 and human foetal brain cDNA library in pJG4-5, and the yeast 
strain used for the interaction trap assay were kindly provided by Drs. Finley and Brent 
(Massachusetts General Hospital, Boston, MA) and used as described (35). The PTP-SL 
cytoplasmic region (amino acid 142-550) was cloned in the pEG202-1 vector by performing 
a PCR with the primers pEG5SL position-534 (5’-GAAGATCTAGGTTAAAAGAAAGGT-
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3’) and pEG3SL position-1779 (5’-CCGCTCGAGCTCTGGTAAATCTTCGG-3’) using 
mPTP13-6 (9) as a template. The PCR product was digested with BglII and XhoI and cloned 
in the BamHI - XhoI site of pEG202-1. Following library screening, positively interacting 
clones were retested in a second round to exclude false positives. Comparison of cDNA 
sequences of interacting clones with database entries were done using the BLAST program 
(36).  
Selected clone inserts were radioactively labelled by random priming (37), and used 
to screen a mouse brain cDNA λ-ZAPII phage library. Hybridisation conditions were 
according to Church and Gilbert (38). In brief, membranes were preincubated in hybridisation 
buffer (7% SDS, 0.5M sodium phosphate buffer (pH 7.4), 1 mM EDTA) for 10-60 min at 65 
°C. After probe denaturation and addition, membranes were hybridised overnight at 65 °C. 
Washing at high stringency (0.1% SDS, 0.04 M sodium phosphate buffer (pH 7.4), 1 mM 
EDTA) was performed three times at 65° C for 20 min. Autoradiography was performed 
using Kodak X-Omat S1 films at -70 °C for 1-2 days using Dupont Cronex intensifying 
screens. Positive phages were plaque-purified and inserts were rescued as pBlueScript SK 
plasmids according to the manufacturer’s protocols. Nucleotide sequences were determined 
by the chain termination method on an ALF express sequence apparatus according to 
established protocols. 
 
Immunoprecipitation 
COS-1 cells cultured on 9-cm dishes were used at 60 % confluency. The cells were washed 
with Optimem and submerged with 6 ml transfection medium (5.7 ml Optimem, 300 µl 1 
mg/ml DEAE-Dextran chloride form (Sigma), 5 µl 100 mM Chloroquine), containing the 
DNA of interest: pPSG8PTP-SLcyt-VSV, pMyc-ERK2, and/or pMyc-β4-adaptin. After an 
incubation of 2 hours at 37 ºC the transfection medium was removed and replaced by 6 ml of 
10% DMSO in PBS. After 3 min, the DMSO shock medium was replaced by normal culture 
medium containing 10% FCS. Twenty-four hours after transfection cells were washed with 
PBS and lysed on the plate with 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% 
(v/v) Triton-X-100, 1 mM PMSF, 1 mM Na3VO4, 50 mM NaF, and 5 mM sodium 
pyrophosphate. Cell lysates were used for immunoprecipitation with protein A-sepharose CL-
4B preloaded with α-SL antiserum, for 3 hours as described (39). The samples were 
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subjected to 10% polyacrylamide gels and transferred to nitrocellulose membranes by 
Western blotting. Blots were blocked using 3% non-fat dry milk in 10 mM Tris-HCl (pH= 
8.0), 150 mM NaCl, and 0.05% Tween 20 (TBST). The blots were then incubated overnight 
at room temperature with a 1: 1000 dilution of the monoclonal anti-Myc antibody 9E10 
culture supernatant. The blots were then washed 3 times with TBST and incubated for 1 hour 
with a 1: 10,000 dilution of peroxidase-conjugated Goat anti-Mouse IgG. Subsequent washes 
were done with TBST and followed by a final rinse with PBS. Immunoreactive bands were 
visualised using freshly prepared chemiluminescent substrate (100mM Tris-HCl, pH8.5, 1.25 
mM p-coumaric acid, 0.2 mM luminol, and 0.009% H2O2) and exposure to Kodak X-omat 
autoradiography films.  
 
Immunohistochemistry 
Brains were removed from C57BL/6 mice anaesthetised with pentobarbital. Ten µm 
cryosections of unfixed frozen tissue were cut and mounted on Superfrost/Plus slides. The 
sections were fixed for 5 min in PBS containing 3% paraformaldehyde. Reactive aldehyde 
groups were blocked by incubating the slides for 60 min in PBST containing 1% normal 
swine serum. Tissue section were incubated with polyclonal antiserum α-AP4 (1: 100 
dilution in PBST) or α-SL (1: 500 dilution in PBST) for 2 h at RT and then washed three 
times for 5 min in PBST. Subsequently, sections were incubated with biotinylated Donkey-
anti-Rabbit IgG (1: 250 dilution in PBST), washed three times in PBS and visualised using 
the Vecta Staining kit according to the manufacturer’s instruction. Samples were mounted in 
Kaisers gelatin and images were collected on a Dialux 20 microscope. For 
immunofluorescence microscopy, fluorescein-conjugated Swine-anti-Rabbit IgG 1: 100 was 
used as a second antibody. After three successive PBS washes, sections were mounted in 
mowiol and images were collected on a Zeiss Axioskop microscope with epifluorescent 
illumination. 
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Results 
 
Previous investigations showed that PTP-SL RNA is expressed in the Purkinje cells of the 
cerebellum, whereas PTPBR7 mRNA is found in the cortex, hippocampus and striatum (13). 
To study the subcellular localization of PTPRR isoforms in neuronal cells, we transiently 
transfected Neuro-2a mouse neuroblastoma cells with constructs encoding enhanced green 
fluorescent protein (EGFP)-tagged PTP-SL (Fig. 1A) or PTPBR7 (Fig. 1B). Transfected cells 
were studied by CLSM, exploiting the endogenous fluorescence of the EGFP tag. As in 
overexpressing COS-1 cells (13) PTP-SL displays a Golgi apparatus-like pattern and in 
addition shows a vesicular localization. This specific localization is also observed without 
fixation in living cells. In addition to these sites, PTPBR7 is detected at the plasma 
membrane. The Golgi association of PTP-SL and PTPBR7 is in line with the observation that 
the fluorescence pattern is dispersed in the transfected Neuro-2a cells upon treatment with 
Nocodazol (Fig. 1C and 1D) and Brefeldin A (data not shown), drugs known to disrupt the 
Golgi apparatus.  
 
Fig. 1 PTP-SL and PTPBR7 are located at perinuclear vesicular structures. 
Analysis of the expression patterns of EGFP fusion protein following transient transfection of mouse Neuro-2a 
cells with constructs encoding PTP-SL-EGFP (A), PTPBR7-EGFP (B). Nocodazole treatment of PTP-SL-EGFP 
(C) and PTPBR7-EGFP (D) transfected Neuro-2a cells leads to fragmentation of the EGFP signal. Confocal 
sections of the EGFP signals were detected by confocal laser scanning microscope. Bar indicates 10 µm. 
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To reveal the nature of the PTPRR-containing vesicles in Neuro-2a cells, 
immunostaining using antibodies against established cell organelle markers was performed. 
Cells, transfected with EGFP-tagged PTPRR expression constructs, were incubated with the 
anti-LBPA specific antibody (31) to determine co-localization with multi vesicular bodies 
(MVB). Lysosomes were detected using an antiserum directed against β-glucocerebrosidase 
(29). Fig. 2 (panels A-F) shows that the vesicles decorated by EGFP-tagged PTP-SL are 
distinct from MVBs and lysosomes. Similar results were obtained using cells transfected with 
an EGFP-tagged PTPBR7 expression plasmid (data not shown). To study whether PTP-SL-
decorated vesicles represent endosomal structures, transferrin uptake experiments using PTP-
SL-transfected Neuro-2a cells were performed. No colocalization was found after 5 min of 
transferrin uptake (Fig. 2G-I), whereas after 10 min late endosomal structures containing both 
PTP-SL and transferrin are apparent (Fig. 2J-L).   
Subsequently, double transfections with the EGFP-tagged Golgi marker Rab6B (26) 
(Fig. 3A-C) and the trans-Golgi network protein β1,2 N-acetylglucosaminyl transferase 
(NAGT) (27) (Fig. 3D-F) with untagged PTP-SL or PTPBR7 gene constructs were 
performed. Immunohistochemistry was done using polyvalent rabbit antiserum against the 
phosphatase moiety of PTP-SL (amino acid residues 241-535) (α-SL), and consequently also 
immunoreactive towards PTPBR7 (13). The PTPRR isoforms co-localize with the TGN to a 
large extend. Especially in the case of PTP-SL, however, quite some α-SL reactive vesicles 
were negative for the TGN markers (compare Fig. 3A, D with B, E). Since the AP4 complex 
has been shown to be present at the Golgi apparatus and at putative late endosomal vesicular 
structures (27), cells were transfected with an expression construct encoding EGFP-tagged 
β4-adaptin (Fig. 3H, K). Remarkably, the localization patterns for EGFP-tagged PTP-SL 
(Fig. 3A, D, J) and β4-adaptin (Fig. 3H, K) are very similar in cells expressing either the 
PTP-SL or the β4-adaptin-EGFP construct, including both the Golgi apparatus and additional 
vesicle-like structures in the cell. 
Intriguingly, we noted that co-expression of PTP-SL and β4-adaptin in one and the 
same Neuro-2a cell (Fig. 3G- I) resulted in a completely distorted localization pattern, in 
which the β4-adaptin protein remained at the Golgi (Fig. 3H), but PTP-SL was redistributed 
throughout the cytoplasm (Fig. 3G). This abnormal distribution was not observed in cells 
where PTP-SL was expressed simultaneously with the other Golgi proteins (Fig. 3A-F). 
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Similarly, when β4-adaptin was co-transfected with Rab6B (Fig. 3L), or with NAGT (data 
not shown), the distribution of the proteins remained unaltered as compared to the single 
transfected situation. This demonstrates that the Golgi exclusion effect seen for PTP-SL upon 
co-transfection with β4-adaptin is specific. A redistribution of one of the two proteins was 
not seen when PTPBR7 was co-transfected with β4-adaptin (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 PTP-SL containing vesicles partly colocalize with late endosomes but not with MVB and Lysosomes ► 
Neuro-2a cells were transiently transfected with a construct encoding EGFP-tagged PTP-SL (A, D, G, J). 
Expression of PTP-SL-GFP was found at the Golgi area and at vesicles that are distinct from multi vesicular 
bodies (B) or lysosomes (E). MVBs were detected immunohistochemically using an antibody directed against 
LBPA (31). Lysosomes were stained with an antiserum against β-glucocerebrosidase (29). GFP fluorescence 
was recorded directly. After 5 min of Alexa-549-labeled transferrin uptake (H) no colocalization with PTP-SL-
containing vesicles (G) is observed. After 10 min of transferrin uptake (K), suggestive for late endosomes, 
overlapping structures start to appear (L). Merged images are shown on the right (C, F, I, L), with PTP-SL-GFP 
fluorescence patterns in green and LBPA (C), β-glucocerebrosidase (F) or transferrin (I, L) signals in red. 
Experiments using GFP-tagged PTPBR7 essentially led to the same conclusion (data not shown). Confocal 
sections of the fluorescence signals were collected by CLSM. Bar indicates 10 µm. 
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Ultimately, we performed immuno-electron microscopy to investigate the precise 
localization of PTP-SL to compare it with the ultrastructural localization of β4-adaptin. 
Unfortunately, our polyvalent rabbit antisera against PTP-SL and β4-adaptin were not 
performing well under the conditions required for this technique, precluding the analysis on 
endogenous proteins. Therefore, we made use of Neuro-2a cells that were transiently 
transfected with constructs encoding GFP-tagged proteins that could be detected with a GFP-
directed antiserum that has demonstrated to be compatible with immunoelectron microscopy 
(28). Figure 4 shows that PTP-SL, PTPBR7 and β4-adaptin are localized to coated structures 
resembling Golgi cisternae and vesicles. However, the architecture of the Golgi is clearly 
affected due to overexpression of PTP-SL, β4-adaptin or, although to a lesser extend, 
PTPBR7 (Fig. 4A- C). This feature was not apparent in the light microscopic studies (Fig. 3) 
and was not observed when other Golgi proteins were overexpressed like NAEGFP (Fig. 4D) 
or Rab6B (data not shown), indicating that the poor morphology observed is specifically due 
to overexpression of these proteins.  
 
   
 
 
 
 
 
 
 
Fig. 3 Co-transfection of PTP-SL and β4-adaptin results in an altered localization for PTP-SL.              ► 
Analysis of localization patterns in mouse Neuro-2a cells co-transfected with constructs encoding PTP-SL and 
EGFP-Rab6B (A-C), PTP-SL and EGFP-NAGT (D-F), PTP-SL and EGFP-β4-adaptin (G-I), and β4-adaptin 
and EGFP-Rab6B (L). Panels J and K show single transfectants for PTP-SL and β4-adaptin, respectively. 
Untagged PTP-SL and β4-adaptin proteins were detected immunohistochemically using the antisera anti-SL and 
anti-β4-adaptin, respectively. Note the cytoplasmic distribution for PTP-SL (G) upon co-transfection with β4-
adaptin construct (H) as opposed to the vesicle-associated appearance in single transfected cells (J) and in cells 
co-expressing Rab6B or NAGT (A, D). Merged pictures are shown on the right (C, F, I, L) with PTP-SL (A, D, 
G) or β4-adaptin (L) immunofluorescence in red and GFP-fusion protein signals (B, E, H, L) in green. Confocal 
sections of the fluorescence signals were detected by confocal laser scanning microscopy. Bar indicates 10 µm. 
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Fig.4 PTP-SL, PTPBR7 and β4-adaptin localize at coated structures belonging to the Golgi network.  
Immuno electron microscopy analysis of transfected Neuro-2a cells expressing PTP-SL-EGFP (A), β4-adaptin-
EGFP (B), PTPBR7-EGFP (C) or NAEGFP (D) showing immunogold staining at the TGN. Ultrastructural 
immunolocalization revealed strong labelling by the anti-EGFP antibody of coated structures resembling Golgi 
cisternae and vesicles. M; mitochondria, N; nucleus, Bar indicates 0.5 µm 
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The distortion of PTP-SL localization upon co-expression with ß4-adaptin as noted 
above (Fig. 3G, I) prompted us to investigate whether there might be a direct interaction of 
PTP-SL and β4-adaptin. Therefore, a yeast two-hybrid interaction trap screening was 
performed using the non-hydrophobic carboxyl-terminal part of the protein (amino acid 
residues 142-550, including the PTP domain) as bait. Screening of a human brain cDNA pray 
library indeed yielded two clones encoding β4-adaptin fragments of different length (Table 
1). In addition, specifically interacting clones representing the MAP kinases ERK2 and p38 
were obtained, confirming data described before in a different experimental set-up (20). The 
specificity of the PTP-SL interaction with β4-adaptin was verified using another adaptin 
protein, human β3B-adaptin, as a prey. No interaction was found in the yeast two hybrid 
interaction assay using this neuron-specific adaptin. The interactions were subsequently 
investigated by co-immuno-precipitation experiments on lysates from transfected COS-1 
cells. An expression vector containing the non-hydrophobic region of PTP-SL (residues 142-
550) was introduced into COS-1 cells with or without constructs encoding Myc-tagged ERK2 
or Myc-tagged carboxyl-terminal part of β4-adaptin (residues 627-739).  
Cell lysates were prepared and PTP-SL-containing protein complexes were 
precipitated using α-SL antiserum and subjected to SDS-PAGE. Following Western blotting, 
co-immunoprecipitating proteins were detected using monoclonal antibody 9E10 against the 
Myc epitope tag (Fig. 5)As expected (20), the MAP kinases were specifically co-precipitated 
by the α-SL antiserum. In contrast, the β4-adaptin could not be precipitated, although the 
protein was readily detectable in the lysate. This may well reflect the exclusion phenomenon 
observed upon simultaneous over-expression of both proteins described above. We therefore 
also tested for an interaction by means of a pull-down assay (data not shown) using soluble 
GST-PTP-SL loaded beads (9). In line with the co-immunoprecipitation data (Fig. 5), cMyc-
tagged ERK2 could be unambiguously identified by Western blot analysis of the isolated 
fractions. β4-adaptin, however, was undetectable under the conditions used.  
 
 
 
 
 
Chapter 2 
                                                                                                                                               42
Table 1: PTPRR phosphatase moiety interacts with β4-adaptin in the yeast two-hybrid system.  
Baits (top row) and preys (left column) expression plasmids in various combinations were transfected into the 
EGY48 yeast strain containing appropriate reporter constructs. The relative strength of the bait-prey interaction 
was scored on the basis of the β-galactosidase activity-dependent blue colouring in combination with growth 
selection on medium lacking leucine. ++++: very strong interaction (blue colonies < 3 days); +++: strong 
interaction (blue colonies ≥ 3 days); ++: (blue colonies > 3 days); -: no interaction (no blue colonies after 7 
days). Amino acid positions that indicate the PTP-SL (Acc. No. Z30313), hβ4-adaptin (Acc. No. AF092094), 
hβ3B-adaptin (Acc. No. AF022152), ERK2 (Acc. No. M84489), p38 Map kinase (Acc. No. L35263) and PTP-
IA2 (Acc. no U 11812) protein portions used are indicated between brackets. Empty vectors were included as 
negative controls. n.d., not determined. 
 
                                  Bait 
Prey 
PTP-SL (aa 142-550)  PTP IA-2  
aa 601-979 
vector control ( pEG202) 
vector control (pJG4-5) - - - 
hβ4-adaptin (aa 549-739) +++ - - 
hβ4-adaptin (aa 293-739) + - - 
hβ3B-adaptin (aa 669-1082) - n.d. - 
ERK2 Map kinase (aa 8-360) ++++ - - 
p38 Map kinase (aa2-360) +++ - - 
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Fig.5 The ERK2 MAP-kinase, but not β4-adaptin, co-purifies with PTP-SL from transfected COS-1 cell 
lysates. Transfected COS-1 cells expressing PTP-SL (aa 142-550) and either cMyc-tagged ERK2 MAP kinase 
(aa 1-360) or β4-adaptin (aa 627-739) parts were lysed. Production of the Myc-tagged proteins was verified by 
Western blotting using monoclonal antibody 9E10 (lanes 1, 2). Immuno-precipitation using α-SL antiserum led 
to the detection ERK2 MAP kinase (lane 4), but not β4-adaptin lane by Western blotting using mAb 9E10. 
Precipitation from COS-1 lysates lacking PTP-SL was negative for all constructs. Molecular mass standards in 
kDa are shown on the right. 
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The exclusion effect as seen in cells co-transfected with PTP-SL and β4-adaptin 
expression constructs thus must be due to indirect effects. To be physiologically relevant, 
endogenous PTPRR isoforms and β4-adaptin should be co-expressed in at least some cells 
and tissues. Northern blot analysis of total RNA isolated from various mouse tissues 
demonstrates that the 3kb mature transcript encoding β4-adaptin is rather ubiquitously 
expressed (40). The level of expression, however, differs between tissues and is high in brain 
the tissue where PTPRR isoforms reside.  
To study endogenous β4-adaptin and PTP-SL/BR7 proteins at the tissue level, 
immunohistochemistry was performed using polyvalent anti-β4-adaptin (against the N-
terminal domain of human β4-adaptin) and α-SL (13) rabbit antiserum. Immunoreactivity 
towards β4-adaptin was detected in all tissues tested and was high in brain (Fig. 6), tubuli of 
the kidney, epithelial cells of the epididymis and the parietal cells of the stomach (data not 
shown). Since PTP-SL and PTPBR7 are expressed exclusively in brain, we examined in 
detail the localization of β4-adaptin in neuronal tissues. In adult mouse brain we observed 
β4-adaptin staining in the cortex, striatum and ependym, all regions known to contain 
considerable levels of PTPBR7 mRNA (13,14). Specific and strong labelling of β4-adaptin 
was also observed in individual neurons of the hippocampus (Fig. 6). Importantly, the typical 
subcellular pattern of the signal is in line with its Golgi localization. Sequential cryosections 
of brain regions were also incubated with α-SL. Using this anti-PTPRR serum, again 
individual neurons of the hippocampus stained positive, indicating that PTPBR7 and β4-
adaptin are endogenously expressed in the same types of neurons (Fig. 6C, D). Both PTPBR7 
and β4-adaptin are also co-expressed in neurons of the cortex (Fig. 6A, B). PTP-SL is 
exclusively expressed in the Purkinje cells of the cerebellum (13). Also these large neurons 
were found to be positive for β4-adaptin (Fig. 6E, F), albeit weakly and staining was more 
uniformly distributed throughout the cell body.  
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Fig. 6 β4 adaptin and PTP-SL/PTPBR7 immunoreactivity in neurons of several brain regions.  
Immunohistochemical staining of sequential sections with antibodies against β4-adaptin (A, C, E), and PTP-SL 
(B, D, F). Colocalization is shown for mouse brain cortex (A, B), pyramidal cells of the hippocampus (C, D), 
and cerebellum (E, F). Bar indicates 100 µm. 
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Discussion 
 
We have previously shown that the mouse gene Ptprr encodes two neuronal PTPs, one of 
which is a cytosolic membrane-associated form of approximately 60 kDa in size, PTP-SL, 
whereas the other, PTPBR7, is a type I transmembrane protein of 74 kDa (13). Here we 
reported on further studies addressing the subcellular localization of the PTPRR gene 
products. PTP-SL is localized to the Golgi and at vesicles throughout the cytoplasm (Fig. 
1A). PTPBR7 is localized to Golgi and vesicles as well, but predominantly in the cell 
membrane (Fig. 1B). Double labeling experiments revealed that the nature of PTP-SL 
containing vesicles is in part late endosomal. We observed a comparable distribution for 
PTP-SL and the β4-adaptin subunit of the AP4 adaptor complex, using immunofluorescence 
(Fig.3) and immuno-electron (Fig. 4) microscopy. Immunohistochemical analysis 
demonstrated further that PTPRR isoforms and β4-adaptin are endogenously expressed in the 
same cells in brain (Fig. 6).  
 Adaptins are subunits of adaptors (APs), which are heterotetrameric complexes, 
consisting of two distinct high-molecular-weight subunits of ~100 kDa (α, β or γ adaptins), a 
medium size subunit of ~47 kDa (µ adaptins), and a small subunit of ~17 kDa (σ adaptins) 
(41). Different adaptors are involved in the formation of clathrin-coated vesicles for different 
transport pathways  (for a review see (42-44)). The αβγ-type subunits contain a hinge and an 
ear domain. The hinge region is thought to be the flexible part of the subunit, and the 
protease-sensitive C-terminal ear domain is thought to mediate association to other proteins 
(41,45,46).   
The precise role of the AP4 complex in subcellular transport routes is still subject of 
investigation, but current data suggest that it mediates sorting processes at the TGN and/or 
endosomal membranes (40,47). Interestingly, both mouse and human β4-adaptin contain a 
rather short carboxyl-terminal ear segment (about 150 residues) as compared to other αβγ-
type adaptin subunits (over 400 residues). Only one other subunit, the γ2-adaptin isoform, 
contains such a truncated ear domain (48) and it is tempting to speculate that this structural 
feature of some of the αβγ-type adaptins reflects a functional difference. Phylogenetic 
analysis revealed that both the C-terminal ear domain and the intermediate hinge region are 
the most variable region within the adaptin subfamily (49), strengthening possible functional 
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divergence in these parts of the protein. In line with this, β-adaptins, but not α and γ types, 
have been shown to interact with clathrin through their hinge/ear domain (50). This raises the 
interesting question whether the short-eared β4-adaptin will be capable of mediating a similar 
interaction with clathrins. 
 RNA transcripts of both PTP-SL and PTPBR7 are restricted to the nervous system. 
β4-adaptin, on the contrary, seems rather ubiquitously expressed. Immunohistochemistry 
shows that PTP-SL/PTPBR7 and β4-adaptin proteins are co-expressed in many neurons, 
including neurons of the hippocampal area. In addition, the subcellular localization of PTP-
SL/PTPBR7 and β4-adaptin, as revealed by transient transfection studies using 
neuroblastoma cells, are very similar. This overlap in localization of PTP-SL/PTPBR7 and 
β4-adaptin was even confirmed by immuno-electron microscopy. A surprising observation 
was made when β4-adaptin and PTP-SL were transiently co-expressed in neuroblastoma 
cells. Double-transfected cells, as opposed to single positive cells, all show a markedly 
disturbed localization pattern of the PTP-SL protein. The majority of the PTP-SL signal was 
not localized to the Golgi anymore, but instead was found in the cytoplasm, whereas the β4-
adaptin localization did not change. This change in localization pattern was consistently 
observed in multiple independent transfections using different DNA preparations, and was 
not observed when either PTP-SL or β4-adaptin was co-expressed with Rab6B (26) or 
NAEGFP (27), which have been described to accommodate also at the Golgi in neurons. 
Additionally, when an unrelated cytosolic PTP, PTP-BL (51), was co-transfected with β4-
adaptin, these abnormalities were also not observed. The above findings suggest a functional 
connection between PTP-SL and β4-adaptin. 
Despite a consistent and significant interaction in yeast, a clearly overlapping 
subcellular localization and an intriguing effect following co-expression of β4-adaptin and 
PTP-SL, we were unable to demonstrate a direct interaction for these proteins using co-
immuno-precipitation or GST pull-down experiments in mammalian cell system (Fig. 5). 
This leaves the possibility that the association is of short duration, perhaps occurring only at 
specific stages during vesicle transport. It is also possible that other factors are necessary for 
interaction, which are not abundantly present in overexpression studies. Finally, the co-
transfection experiments revealed that both proteins might perhaps compete for the same 
subcellular localization, since PTP-SL is specifically redistributed by β4-adaptin. Clearly, 
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these effects are not observed in yeast ectopically expressing PTP-SL and β4-adaptin fusion 
proteins. 
 Could there be a role for PTP-SL and/or PTPBR7 in regulating formation and/or 
transport of AP4 containing vesicles? Several reports present evidence that reversible 
phosphorylation of clathrin coat components can regulate endocytosis/exocytosis either 
directly or indirectly (52-56).  For example, the β2-adaptin of the AP2 complex is 
phosphorylated by a staurosporine sensitive kinase and de-phosphorylated by protein 
phosphatase PP2A (57) or Synaptojanin 1, thereby regulating adaptor protein dynamics (58). 
Evidence is accumulating that vesicle trafficking is regulated by tyrosine-specific 
phosphorylation as well. For example, Nucifora et al. reported that rapid endocytosis is 
controlled by tyrosine phosphorylation (59). Also, the endocytosis of the ROMK1 potassium 
channel is regulated by tyrosine phosphorylation (60). Thus, one may expect that tyrosine-
specific phosphatases will influence the vesicle transport process as well. An alternative 
explanation for the presence of PTP family members, such as PTP-SL, at specific organelles 
within the cell relates to the phenomenon observed by Haj et al (61). They found that after 
internalization of receptor tyrosine kinases (RTKs) from the cell surface, the vesicles travel 
close to the endoplasmic reticulum where the protein tyrosine phosphatase PTP1B resides. 
This enzyme dephosphorylates specific tyrosine residues in the autophosphorylated 
cytoplasmic domains of endocytosed RTKs, which then travel on to the lysosomes. 
Depending on the different destinations of transmembrane cargo proteins, dephosphorylation 
of endocytosed proteins may be organized at other meeting points a well e.g. at the 
endocytotic vesicles or sorting endosomes themselves. It is thus possible that the 
phosphatases PTPSL and PTPBR7 are involved in dephosphorylating cargo proteins of AP4-
containing vesicles at a region in or near the Golgi apparatus. Future research will be aimed 
at investigating these possibilities. 
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Summary 
 
The use of alternative splice sites, promoters and translation start sites considerably adds to 
the complexity of organisms. Four mouse cDNAs (PTPBR7, PTP-SL, PTPPBSγ+ and 
PTPPBSγ-) have been cloned that contain different 5’ parts but encode identical protein 
tyrosine phosphatase PTPRR catalytic domains. We investigated the genomic origin and 
coding potential of these transcripts to elucidate their interrelationship. Mouse gene Ptprr 
exons were identified within a 260 kbp segment on chromosome 10, revealing PTP-SL- and 
PTPPBSγ-specific transcription start sites within introns two and four, respectively, relative 
to the fourteen PTPBR7 exons. Northern and RT-PCR analyses demonstrated differential 
expression patterns for these promoters. Furthermore, transfection studies and AUG codon 
mutagenesis demonstrated that in PTP-SL and PTPPBSγ messengers multiple translation 
initiation sites are being used. Resulting 72, 60, 42 and 37 kDa PTPRR protein isoforms 
differ not only in the length of their N-terminal part but also in their subcellular localization, 
covering all major PTP subtypes; receptor-like, membrane associated and cytosolic. In 
summary, mouse gene Ptprr gives rise to multiple isoforms through the use of distinct 
promoters, alternative splicing and differential translation starts. These results set the stage 
for further investigations on the physiological roles of PTPRR proteins. 
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Introduction 
 
Reversible phosphorylation of specific tyrosine residues within proteins is an essential 
intracellular signal transduction mechanism. Cellular responses like differentiation, 
proliferation, survival, metabolic activity, and more specifically for neuronal cells, migration, 
axonal guidance, synapse formation and activity are all regulated by modulating the 
phosphorylation state of target proteins (1-3). Protein tyrosine kinases and protein tyrosine 
phosphatases (PTPs) are the enzymes that are instrumental in determining the spatial and 
temporal balance between the tyrosine phosphorylated and non-phosphorylated targets, and 
thus coordinately regulate these cellular responses to extracellular cues.  
PTPs have been categorized into two distinct subgroups (4). The first group possesses a 
transmembrane domain that follows a receptor-like extracellular region; the second group is 
cytoplasmic in location, and can in turn be subdivided in membrane-associated and true 
cytosolic PTPs. Interestingly, some PTP genes encode multiple isoforms that belong to 
several of these PTP subgroups. For instance, the STEP subfamily of PTPs consists of 
multiple transmembrane and cytosolic isoforms that are suggested to result from alternative 
splicing (5,6). Likewise, transmembrane, cytosolic and membrane-associated PTPε isoforms 
exist, but these result from the use of alternative promoters, proteolytic processing and 
differential initiation of translation (7). It is commonly believed that the generation of 
multiple isoforms from a single PTP gene through (a combination of) such mechanisms 
warrants fine-tuning of cellular signaling programs, both in time and space dimensions, thus 
adding to the organismal complexity of higher eukaryotes. Consequently, when studying the 
functional potential of a given gene, it is imperative to delineate its catalogue of transcripts 
and the exact nature of the corresponding protein products.  
Several mouse cDNA clones, encoding PTPBR7, PTP-SL and PTPPBSγ, respectively, 
have been reported that contain an identical, PTP-encoding 3’ segment but differ completely 
in their 5’ parts (8-11). We have recently proposed that the messengers that gave rise to the 
PTPBR7 and PTP-SL cDNAs are derived from a single mouse gene, Ptprr, through the use 
of developmentally regulated alternative promoters (12). The origin of two other transcript 
variants, both encoding PTPPBSγ (8), is as yet undefined. Moreover, uncertainties as to the 
translation initiation sites used in PTP-SL and PTPPBSγ-encoding mRNAs has led to 
confusion and, occasionally, discrepancies in amino acid residue numberings (12,13).  
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To clarify the above issues we performed a careful annotation of transcript and protein 
products for mouse gene Ptprr, and investigated protein expression both in situ and at the 
subcellular level. Results reveal a unique gene system in which alternative use of promoters 
and AUG start codons accounts for the generation of distinct protein isoforms. These PTPRR 
proteins differ in their subcellular localization and represent all major PTP subtypes; 
receptor-like, membrane-associated and cytosolic. This work gives important insight in the 
Ptprr gene structure and sets the stage for further investigations on the physiological role of 
the three mouse PTPRR protein isoforms, PTPBR7, PTP-SL and PTPPBSγ. 
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Material & Methods 
 
Expression plasmid constructs and site directed mutagenesis 
Plasmids pSG5/PTP-SL-FL and pSG5/PTPBR7-FL have been described elsewhere (12). To 
obtain a full-length mouse PTPPBSγ expression construct (pSG5/PTPPBSγ-FL) PCR was 
performed on mouse genomic DNA using oligonucleotides 5’-
GGACTAGTCCGTGAACCAGGTAGTTTCCAG-3’ (SpeI restriction site is underlined) and 
5’-TCCTTCTTTGCTCCAGAT-3’, which resulted in a 362-bp fragment encompassing the 
nucleotides (pos. 1-292) that are unique for PTPPBSγ+ cDNA. The PCR product was cloned 
into the pGEM-T vector (Promega, Madison, WI, USA) and analyzed by sequencing to verify 
absence of mutations. The resulting plasmid was treated with endonucleases BglII and SpeI, 
and the obtained fragment was inserted into pSG5/PTP-SL-FL that had been first partially 
digested with BglII (position 441 in the PTP-SL cDNA) and digested to completion with 
SpeI. 
AUG mutants of pSG5/PTPBR7-FL, pSG5/PTP-SL-FL and pSG5/PTPPBSγ plasmids 
were generated using the QuickChange Mutagenesis protocol according to manufacturers 
specifications (Strategene Inc., La Jolla, CA, USA). In Table 1 the primers and nomenclature 
used is listed. Obtained mutant constructs were checked by sequence analysis. 
The bacterial expression plasmid pGEX-SL has been decribed before (10). Deletion 
mutants pGEX-2T-SL1060, pGEX-2T-SL1213, and pGEX-2T-SL1582 were created by PCR 
using specific primers (sequences available upon request) and mPTP13-6 (10) as template. 
Resulting PCR products were cloned into the BamHI site of pGEX-2T. To enable production 
of His-tagged PTP-SL recombinant protein, an NcoI-XhoI cDNA fragment was excised from 
mPTP13-6 (10), blunted with Klenow and cloned into XhoI-digested and Klenow-treated 
pET-15b vector, rendering pET-15b-PTP-SL. 
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Table 1. Mutant nomenclature and primers used for site directed mutagenesis 
mutant 5’primer 3’primer 
BR7-356 caatgcacacactatcagagcggtcg cgaccgctctcctgatagtgtgtgcattg 
BR7-719 ccgacactgcaaatcgatataaccaagctg cagcttggttatatcgatttgcagtgtcgg 
SL-103 gatggaagtcggatccatcgcaacactc gagtgttgcgatggatccgacttccatc 
SL145 ccgacactgcaaatcgatataaccaagctg cagcttggttatatcgatttgcagtgtcgg 
SL-643/759 gacccacagcatcgtccagcccgatc  
cttctcccttcagaatcaagcccataggactc 
gatcgggctggacgatgctgtgggtc  
gagtcctatgggcttgattctgaagggagaag 
PBSγ-401 catagtaacctgtttgatcattatttacagg cctgtaaataatgatcaaacaggttactatg 
PBSγ-530 gacccacagcatcgtccagcccgatc gatcgggctggacgatgctgtgggtc 
PBSγ-647 cttctcccttcagaatcaagcccataggactc gagtcctatgggcttgattctgaagggagaag 
PBSγ-704 cttacgctggacatcagtagcctgggcag ctgcccaggctactgatgtccagcgtaag 
PBSγ-530/647 gacccacagcatcgtccagcccgatc  
cttctcccttcagaatcaagcccataggactc 
gatcgggctggacgatgctgtgggtc  
gagtcctatgggcttgattctgaagggagaag 
 
Several AUG start codons of PTPBR7 (Acc.no.: D31898), PTP-SL (Acc.no.: BN000437) and PTPPBSγ 
(Acc.no.: BN000438) were mutated into AUC using the primers above, and thereby mutating Methionines into 
Isoleucines. Numbers correspond to the position of the first nucleotide of the start codon. The mutated 
nucleotide is indicated in bold. Two numbers indicate mutations of two start codons. 
 
 
Antibodies 
Rabbit polyclonal antiserum against the PTP-containing part of PTP-SL (α-SL) has been 
described (12). In some experiments STEP-absorbed α-SL was used. Briefly, STEP cross-
reactivity was removed from the polyvalent α-SL serum by passing it over glutathion-
sepharose-bound GST-STEP fusion protein (13). To generate monoclonal antibodies against 
PTPRR protein isoforms, the pGEX-SL construct was used for bacterial production of GST-
SL fusion protein as described previously (12). Immunization with purified GST-SL protein 
and later on fusion of mouse spleen B-cells with myeloma line Sp2/0-Ag14 was performed 
according to established protocols. Resulting hybridomas were screened by ELISA using 96-
well plates coated with His-tagged PTP-SL protein. The latter was obtained essentially as 
described (14). Eight clones (6A6, 1E3, 3E11, 8F10, 5E4, 6H11, 11H8, and 6D6) were 
selected on the basis of their immunoreactivity and grown for antibody production and 
further analyses.  
  Mouse Ptprr, from gene to proteins 
   
 59
 Bacterial expression plasmids pGEX-PTP-SL, pGEX-2T-SL1060, pGEX-2T-SL1213, 
and pGEX-2T-SL1582 were used for epitope mapping. In brief, expression of the various 
GST-PTP-SL fusion proteins was induced using 1 mM IPTG applied to DH5α bacterial cells 
containing the respective pGEX-based plasmid. Protein lysates were analyzed by Western 
blot analysis essentially as described below. 
 
Protein isolation, immunoprecipitation and Western blotting 
Neuro-2a cells (ATCC nr. CCL-131) were cultured in 9-cm dishes using DMEM 
supplemented with 5% Fetal Calf Serum. Upon reaching 60% confluency cells were washed 
with OptiMEM (Gibco/BRL, Gaithersburg, MD, USA) and transiently transfected with 
appropriate plasmid DNA using Lipofectamine-Plus (Invitrogen Life Technologies, Breda, 
the Netherlands). Twenty-four hours after transfection, cells were washed with phosphate 
buffered saline (PBS) and taken up in lysis buffer (100mM Na2HPO4, 1% Triton-X-100, 
0.2% BSA, pH 8.0), containing a complete protease inhibitor cocktail (Roche Diagnostics 
GmbH, Mannheim, Germany). 
 For immunoprecipitation purposes, 30 µl mono α-SL (6A6) together with 30 µl of 
protein A-Sepharose CL-4B (Amersham Pharmacia Biotech AB, Uppsla, Sweden) was added 
to 500 µl cell lysate and incubated by overnight rotation at 4°C.  The Sepharose beads with 
immunobound proteins were subsequently washed four times in lysis buffer, once in 0.1 M 
Na2HPO4, pH 8.1, and twice in 0.01 M M Na2HPO4. 2x sample buffer (100mM Tris-HCl, pH 
6.8, 200mM dithiothreitol, 4%SDS, 0.2% bromophenol blue, 20% glycerol) was added to the 
beads, and proteins were subjected to 10% SDS-PAGE.  
 Mouse C57BL/6 tissue lysates were made by mechanical disintegration of whole 
brain or separate brain regions (olfactory bulb, hippocampus, midbrain, brainstem, 
cerebellum and cortex) in 1.5 ml lysis buffer. The lysates were incubated for 1h at 4°C and 
insoluble components were pelleted by centrifugation (14,000 rpm) for 30 min at 4°C. 
Protein concentration in the resulting supernatant was determined according to Lowry (15).  
Protein samples were subjected to 10% SDS-PAGE gels and transferred to 
nitrocellulose membranes by Western blotting or alternatively first immunoprecipitated with 
mono α-SL (6A6) together with protein A-Sepharose CL-4B as described for cell lysates and 
than subjected to 10% SDS-page gel and Western blotting. Resulting membranes were 
blocked for 30 min using 3% non-fat dry milk in TBST (10 mM Tris-HCl (pH 8.0), 150 mM 
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NaCl, and 0.05% Tween 20) and incubated overnight at room temperature with a 1:1000 
dilution of rabbit α-GST-SL in TBST. Blots were washed 3 times with TBST and incubated 
for 1h with a 1:10,000 dilution of peroxidase-conjugated Goat anti-Rabbit IgG (Pierce 
Biotechnology Inc., Rockford, IL, USA) in TBST. Subsequent washes were done with TBST, 
followed by a final rinse with PBS. For the epitope mapping purposes, blots were incubated 
with diluted hybridoma culture supernatant (1:2000) and peroxidase-conjugated Goat anti-
mouse IgG (1:20.000) (Pierce) as first and second antibody, respectively. Immunoreactive 
bands were visualized using freshly prepared chemiluminescent substrate (100mM Tris-HCl, 
pH 8.5, 1.25 mM p-coumaric acid (Sigma Chemical Co., St. Louis, MO, USA), 0.2 mM 
luminol (Sigma), and 0.009% H2O2) and exposed to Kodak X-Omat autoradiography films 
(Eastman Kodak Company, Rochester, NY, USA). 
  
RNA expression analyses 
Total RNA from different brain regions (olfactory bulb, hippocampus, midbrain, brainstem, 
cerebellum and cortex) was purified using RNazol B (Campro Scientific, Veenendaal, The 
Netherlands). Ten µg of RNA was loaded on a 1% formamide agarose gel and after 
electrophoretical size separation, the RNA was transferred onto nylon membrane (Amersham 
Pharmacia Biotech BA, Uppsla, Sweden) according to standard procedures (16). The 
pSG5/PTPBR7-FL construct was 32P-labeled and used as a probe. Hybridization was carried 
out overnight at 65°C (17), and blots were washed several times with 40 mM phosphate 
buffer containing 0.2% SDS at 65°C and exposed to Kodak X-Omat S1 films. Probes specific 
for PTPBR7 (Acc. No. D31898: pos. 414-709), PTP-SL (TPA Acc. No. BN000437: bp1-135) 
and PTPPBSγ (TPA Acc. No. BN000438: bp 1-346) were obtained by PCR on mouse 
genomic DNA, radioactively labeled, and used for hybridization as described above. 
For RT-PCR analyses cDNA was synthesized from 2 µg total RNA by random 
hexamer priming using SuperScriptTM II RNase H- Reverse Transcriptase (Invitrogen Life 
Technologies, Breda, the Netherlands). PTPBR7, PTP-SL, PTPPBSγ and β-actin cDNA 
fragments were amplified by PCR using the following specific primers: BR7-forward, 5’-
CCTCAATGCACACACTATGAGG-3’; BR7-reverse, 5’-TCCTTCTTTGCTCCAGAT-3’; 
SL-forward, 5’-TCCAGGTGACTAAACGAGG-3’; SL-reverse, 5’-
TCCTTCTTTGCTCCAGAT-3’; PBSγ-forward, 5’-GTGAACCAGGTAGTTCCAG-3’; 
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PBSγ-reverse, 5’-AGGGTCCACAACCACGTTCA-3’; β-actin-forward, 5’-
GCTAGAGCTGCCTGACGG-3’; β-actin-reverse, 5’-GAGGCCAGGATGGAGCC-3’. 
Resulting products were analyzed by electrophoresis using a 2% agarose gel for size-
separation and ethidium bromide for fluorescent detection.  
 
Immunohistochemistry 
C57BL/6 mice were anaesthetized with hypnorm/dormicum and perfused with 15 ml 0.9% 
NaCl (saline). Brain tissue was removed, snap-frozen in liquid nitrogen and stored at -80°C 
until further use. Brains were either horizontally or coronally cryo-sectioned in 8 µm slices 
and mounted on Superfrost/Plus glass slides (Menzel-Gläser, Braunschweig, Germany). 
Selected slides that were representative for the different brain regions were used for 
immunohistochemical analysis. Sections were treated for 10 min with ice-cold acetone, dried, 
pre-incubated in horse serum for 10 min, and subsequently incubated for 60 min with a 
mixture of three α-PTPRR monoclonal antibodies (diluted culture supernatant of hybridoma 
clones 1E3 (1:4), 3E11 (1:4) and 6A6 (1:8)) or with α-PTPRR monoclonal antibody 5E4 
(1:16) in PBS with 0.1% BSA. Similar sections were also incubated with STEP-absorbed α-
SL serum. After several washes with PBS and incubation for 30 min with biotin-conjugated 
secondary antibody (Pierce) (1:250 in PBS), immunoreactivity was visualized using the 
Vectastain protocol (Vector laboratories, Burlingame, CA, USA). 3,3’-diaminobenzidine 
tetrahydrochloride (brown stain; Fig. 6, panels A-B) or 3-amino-9-ethyl-carbazole (red stain; 
Fig. 6, panels C-F) were used as substrate. Subsequently, sections were rinsed with water, 
incubated in 0.9% NaCl and 0.5% CuSO4 for 5 min, and counterstained with haematoxylin 
for 3 min. Finally, sections were dehydrated with ethanol and xylene, embedded in Eukitt 
(Electron Microscopy Sciences, Fort Washington, PA, USA) and examined by light 
microscopy. 
 
Immunofluorescence assay 
Neuro-2a cells cultured on glass coverslips were transiently transfected with appropriate 
plasmid constructs as described above. After 24 hours the cells were washed with PBS, fixed 
for 10 min with 1% paraformaldehyde in PHEM buffer (60 mM Pipes, 25 mM Hepes, 10 mM 
EGTA, 2 mM MgCl2, pH 6.9), and permeabilized using 0.1% saponin and 20 mM Glycine in 
PBS for 30 min. Subsequently, cells were incubated for 1h with a 1:200 dilution of α-SL 
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antiserum in SPBS (PBS + 0.1% saponine) at room temperature. Following three washes with 
SPBS, cells were incubated with FITC-conjugated goat-anti-rabbit IgG (10mg/ml; Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) (1:100 dilution in SPBS) at 
room temperature for 1h. Finally, after three washes with SPBS and methanol dehydration, 
cells were mounted on glass slides using Mowiol (Sigma) containing 2.5% sodium azide as 
anti-fading reagent. Images were examined and collected using confocal laser scanning 
microscopy (MRC 1024, Bio-Rad). 
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Results 
 
Genomic structure of Ptprr  
In order to make a full annotation of exonic sequences contained within the mouse gene 
Ptprr, we performed Blast searches using the PTPBR7, PTP-SL and PTPPBSγ cDNA entries 
as queries (Fig. 1). Gene contigs were encountered in commercial (Celera) and public 
databases. In the EnsEMBL Mouse Genome database (release 20.32b.1; mouse species 
C57BL/6J) a single 257251 bp stretch was identified that comprised the full annotation of all 
fourteen PTPBR7 exon sequences (Gene ID number ENSMUSG00000020151; Unigene 
cluster Mm.3771). Searches using PTP-SL and PTPPBSγ transcripts exclusively yielded hits 
within this very same genomic region, underscoring that the above transcripts all originate 
from the single-copy gene Ptprr. As proposed earlier (12), there is a single PTP-SL-specific 
exon in between PTPBR7 exons two and three, defining the PTP-SL-specific promoter to 
reside within the largest intron, intron 2, of Ptprr. For generating the PTP-SL specific 
transcript, this first PTP-SL exon is joined to PTPBR7 sequences in exons 3 to 14 through 
splicing. Thus, PTP-SL transcripts differ from PTPBR7 mRNAs in that sequences contained 
within Ptprr exons 1 and 2 (709 bases in total) are replaced by the 135 nucleotide PTP-SL-
specific exon-derived sequence.  
The unique 5’ segment in the PTPPBSγ cDNAs (8) could be mapped in a 292 bp 
sequence stretch immediately upstream of Ptprr exon 5. Thus, Ptprr intron 4 also harbors an 
alternative promoter, this time giving rise to either PTPPBSγ+ or PTPPBSγ– mRNAs 
depending on whether a small (117 nucleotide) intron is excised from the unique PTPPBSγ+ 
leader sequence. To generate PTPPBSγ– transcripts, therefore, 175 nucleotides, derived from 
exonic sequences unique for both PTPPBSγ mRNA variants, are joined through splicing to 
sequences delivered by Ptprr exons 5 to 14. The complete Ptprr gene structure 
(schematically depicted in Fig. 1A) is summarized in Table 2, where reference is made to 
positions in the four different cDNAs. This gene annotation has also been deposited to the 
mouse genome database under TPA accession numbers BN000439 to BN000454. 
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Fig. 1 Schematic representation of the Ptprr exon-intron structure and its major mRNA products.  
In panel A, mouse genomic DNA is represented by the gray horizontal bar. Exons are depicted as vertical bars 
with exon number or name indicated above. Arrows symbolize the relative positions of the three distinct 
transcription start sites. The black horizontal bar, depicted on the right, indicates 25 kbp of DNA. Resulting 
Ptprr transcripts are depicted in panel B as thick horizontal boxes, with mRNA names indicated on the right. 
Transcript specific nucleotide sequences are indicated in light gray at the left end of the transcript. ORFs are 
depicted as dark gray horizontal bars. The numbers indicate the first nucleotide of potential start codons that 
were included in mutational analyses experiments (Fig. 4). Nucleotide numbers are based on PTPBR7, PTP-SL 
and PTPPBSγ+ cDNA sequences (Acc.no’s. D31898, BN000437 and BN000438, respectively). Bar on the left 
indicates 500 bp. 
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Table 2. Ptprr exon-intron boundries 
 
 
 
Ptprr transcript expression patterns 
Data supporting the differential use of the three distinct transcription start sites within mouse 
Ptprr have been obtained mainly by RNA in situ hybridization studies. The use of transcript-
specific probes has revealed that PTPBR7 messengers appear during early embryogenesis in 
spinal ganglia and developing Purkinje cells. Postnatally, PTPBR7 is expressed throughout 
the brain but expression gradually ceases in maturing Purkinje cells and PTP-SL type 
transcripts take over (12). PTPPBSγ RNAs are quite prominent in the hippocampal region, 
cerebellar granular layer and in the gastrointestinal tract (9). Furthermore, during mouse 
embryo-fetal development of skeletal and intestinal systems the detected hybridization 
signals are believed to reflect PTPPBSγ– mRNA (8). Northern blot analyses, on the other 
hand, have thus far only been performed with probes that hybridize to all Ptprr transcript 
variants (9-11). Using such a pan-PTPRR cDNA probe on Northern blots of cerebral and 
cerebellar RNA samples, the large (4.1 kb) PTPBR7 transcript is detected in cerebellum and 
to a lesser extent in other brain areas, whereas the shorter PTP-SL (3.2 kb) or perhaps 
PTPPBSγ (predicted to be ~3kb) RNAs appear to be exclusively expressed in cerebellum 
(Figure 2A, upper panel).  
Exon Length 
Starting position in 
cDNA   Acceptor splice sitea    Donor splice sitea 
  (bp) PTPBR7 PTP-SL PTPPBSγ+     
1 413     TGCTGCAG/gttatgtcttgcgggg 
2 296 414   gattcttgtcttgtag/GTTGTTTT TTGTGGTG/gtaagtaccaagttag 
SL 
specific 135      CCACACCG/gtaagagagcccatgg 
3 114 710 136  ttcctctgttttccag/ACACTGCA GGCTCATT/gtaagagtttgccttt 
4 156 824 250  ggtgtgttctcactag/GAAAAGAA CCCCTGAG/gtatgtccttgcatgc 
PBSγ 
specific 292     GTTTGATG/gtaagtttgcttcttt 
5 111 980 406 293 gttttgctttcgaaag/AAAAATGT GTTTGATG/gtaagtttgcttcttt 
6 269 1091 517 404 ttttttttttttgtag/ATTATTTA CAGGAGCG/gtaagagcctcaactg 
7 187 1360 786 673 tctttcccccatgtag/ACGAGGTT AATTCATG/gtgagcccgctccttc 
8 85 1547 973 860 atcatttattttccag/GAAATACC TTTGCCAA/gtaagtttctcgagac 
9 80 1632 1058 945 ctggcttcctcctcag/ATCCCCTC ATATTCGG/gtaagtaactatacat 
10 138 1712 1138 1025 tctttactccaaatag/GGCTACAG AAAATGAG/gtatggagcttatccc 
11 111 1850 1276 1163 cttttcccccccgcag/AAATGTGT TCTTAAAG/gtaagatcgtgagctg 
12 158 1961 1387 1274 tggttgctatttccag/CAAGGAAG CACTGCAG/gtaaggcgcgaaccga 
13 114 2119 1545 1432 tttctttcccattcag/TGCGGGGA GTAGACAG/gtacgtggaccggggg 
14 1197 2233 1659 1546 aatctcttccatgcag/GGGTGGTA   
a
 The exonic and intronic sequences are indicated in uppercase and lowercase respectively. 
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To ascertain the identity of the obtained signals we analyzed RNA samples isolated 
from various mouse brain regions by Northern blot analysis, using PCR-generated probes that 
are specific for the unique 5’ mRNA parts in the PTPBR7, PTP-SL and PTPPBSγ type 
transcripts. Indeed, weak hybridization signals that corresponded to the 4.1 kb transcript 
mentioned above were obtained in all samples with the PTPBR7-specific probe (data not 
shown). Use of the PTP-SL-specific probe revealed this shorter transcript to be exclusively 
expressed in cerebellum (Fig. 2A, lower panel). Although PTPPBSγ messengers are 
detectable in brain by in situ hybridization (9), no specific signal resulted upon using the 
PTPPBSγ-specific probe in Northern blot analysis (data not shown), indicating very low 
expression levels for these transcript variants.  
To perform a more sensitive survey of the isoform-specific expression patterns in 
brain we used the same RNA samples in RT-PCR experiments (Fig. 2B). Primer sets were 
chosen in such a way that genomic DNA contaminations would not yield amplicons of the 
appropriate size. β-actin messenger amplification was used as control for RNA integrity and 
reverse transcriptase activity. Except for olfactory bulb, PTPPBSγ transcripts indeed were 
now detectable in the various brain regions. PTPBR7 mRNA was present in all brain tissues, 
including olfactory bulb (Fig. 2B), but was not detected in RNA samples from other mouse 
tissues (i.e. heart, lung, liver; data not shown). PTP-SL transcripts thus far had only been 
detected in cerebellum by in situ hybridization and Northern blot analysis (9,10). RT-PCR, 
however, also reveals PTP-SL messengers in midbrain, brainstem and cortex (Fig. 2B). 
Taken together, these RNA expression data demonstrate that in the mouse cerebrum the 
PTPBR7 promoter is responsible for the vast majority of Ptprr transcripts. In cerebellum 
about two-third of the transcripts arise from the PTP-SL promoter and the remaining one 
third is mainly of the PTPBR7 type (Fig. 2A, upper panel). Only trace amounts of PTPPBSγ 
mRNAs, not detectable on Northern blots, are present throughout the brain. 
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Fig. 2 Expression of Ptprr transcript variants in specific brain regions.  
A, Northern blot analysis on RNA from different brain regions using full-length PTPBR7 cDNA (upper panel) 
or the unique PTP-SL 5’ untranslated region (lower panel) as a probe. PTPBR7 mRNA is expressed in 
cerebellum and, to a lesser extent, in the other brain areas. PTP-SL messengers on the other hand are only 
detectable in cerebellum. PTPPBSγ type transcripts are below detection levels (data not shown). B, PTP-SL and 
PTPPBSγ mRNAs are detectable in total RNA isolated from several cerebral brain parts when using a sensitive 
transcript-specific RT-PCR assay. PTPBR7 transcripts were detected in all brain regions. Isoform-specific 
primer sets used were negative on mouse genomic DNA, and β-actin primers were included as positive controls. 
 
 
Mapping of translation initiation sites in the Ptprr-derived mRNAs 
Open reading frames encompassing 656, 549 and 412 codons in the PTPBR7, PTP-SL and 
PTPPBSγ cDNAs predict the synthesis of 74, 62 and 47 kDa mature proteins, respectively. 
For PTP-SL it has been suggested that not the first AUG of the major predicted open reading 
frame (ORF), but the following in-frame AUG codon is used for initiation of translation (10) 
leaving the exact size of the protein as yet unclear. Likewise, the translation start site used in 
both PTPPBSγ messenger isoforms (9) is enigmatic. To aid in the determination of the start 
codons, a pSG5-based full-length PTPPBSγ cDNA expression construct was generated and 
used, together with similar, existing constructs encoding PTPBR7 and PTP-SL (12), in 
transfection experiments. All three constructs resulted in multiple immunoreactive products 
in protein lysates from transiently transfected Neuro-2a cells upon Western blot analysis 
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using α-SL antiserum (Fig. 3, left three lanes), whereas no signal was obtained for lysates of 
mock transfected cells (data not shown). For PTPBR7, two immunoreactive bands, around 72 
and 65 kDa, respectively, are observed. Expression of PTP-SL cDNA revealed a doublet 
band around 60 kDa and two additional signals at 42 and 37 kDa. Surprisingly, the latter two 
immunoreactive bands also appear as the main products using the PTPPBSγ expression 
construct. These data imply posttranslational modifications, including processing through 
protease cleavage, and / or the use of alternative AUG start codons. 
 
 
 
 
 
 
Fig. 3 The three different Ptprr transcripts give rise to multiple PTPRR isoforms.  
Left panel: Neuro-2a cells were transiently transfected with pSG5/PTPBR7-FL, pSG5/PTP-SL-FL or 
pSG5/PTPPBSγ-FL expression plasmids. Lysates were used for Western blot analysis exploiting the rabbit α-
SL antiserum that is immunoreactive against the catalytic portion in PTPBR7, PTP-SL and PTPPBSγ. Middle 
panel: Western blot analysis of α-SL immunoreactive proteins detected in mouse total brain lysates. The 
rightmost panel shows monoclonal antibody 6A6 immunoprecipitates from different brain regions, visualized on 
blot using STEP-absorbed α-SL that is immunoreactive towards all PTPRR proteins. Please note that the 
polyvalent antiserum may cross-react with the nearest homologue, STEP, on immunoblots but not in 
immunoprecipitation experiments. Molecular mass markers (in kDa) are indicated on the left. 
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To allow unequivocal mapping of the AUG start codons used in the various 
transcripts, we performed site directed mutagenesis on the PTPBR7, PTP-SL and PTPPBSγ 
expression constructs. Mutation of the ATG triplet in PTPBR7 cDNA, at nucleotide position 
356-358 (BR7-356), into an isoleucine-encoding one led to a complete absence of PTPBR7 
expression in transiently transfected Neuro-2a cells (Fig. 4A). A similar mutation at the next 
in-frame ATG triplet (BR7-719) had no effect at all, indicating that in the PTPBR7 
messenger only the start codon at position 356-358 is used and leaving that the 65 kDa 
species must be derived from a 72 kDa precursor through posttranslational processing. In the 
PTP-SL expression construct mutations were incorporated such that either one of the 
suggested two candidate translation start codons (position 103-105 and 145-147 in PTP-SL 
cDNA; mutants SL-103 and SL-145, respectively) is changed into an isoleucine codon. Upon 
transfection, these mutants show that not the first but indeed the second AUG codon in the 
PTP-SL encoding ORF is used for translation initiation (Fig. 4B). The resulting protein 
product subsequently undergoes an as yet uncharacterized posttranslational modification 
resulting in a doublet immunoreactive band at 60 kDa. Remarkably, the production of the 
immunoreactive 42 and 37 kDa proteins are not influenced by these mutations.  
Site directed mutagenesis of ATG triplets within the PTPPBSγ expression construct 
clearly showed that in the PTP reading frame not the first (position 401-403; γ-401) but rather 
the second (pos. 530-532; γ-530) as well as the third (pos. 647-649; γ-647) AUG codon is 
used efficiently for translation initiation (Fig. 4C), thus resulting in two PTPPBSγ variants 
that differ in their N-terminus. Elimination of both of these AUG codons (mutant γ-530/647) 
totally blocked the synthesis of the PTPPBSγ isoforms. In view of the similarity in 
electrophoretic mobility of the two 42 and 37 kDa PTPPBSγ species and the two low-
molecular weight entities in PTP-SL expressing lysates, we wondered whether the 
downstream AUG codons that correspond with the PTPPBSγ translation start sites are also 
being used in PTP-SL messengers for initiation of protein synthesis. Mutation of these ATG 
codons (at positions 643-645 and 760-762) in PTP-SL cDNA indeed resulted in the 
elimination of the 42 and 37 kDa protein bands without affecting the production of the 60 
kDa doublet (Fig. 4B). These data demonstrate that two downstream AUG codons in PTP-SL 
mRNA serve as alternative translation initiation sites and result in protein isoforms 
indistinguishable from the 42 and 37 kDa PTPPBSγ isoforms. 
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Fig. 4 Determination of the sites of translation initiation in the Ptprr-derived transcripts.  
Neuro-2a cells were transiently transfected with plasmids containing wild type or mutated full-length PTPBR7 
(BR7), PTP-SL (SL) and PTPPBSγ (γ) cDNAs. Nomenclature of mutants (indicated above the lane) corresponds 
to the position of the first nucleotide in the ATG codon that was altered by site-directed mutagenesis within the 
respective isoform cDNA (Table 1). Proteins produced were immunoprecipitated using α-PTPRR monoclonal 
antibody 6A6 and analyzed on Western blots using the α-SL antiserum. A, Mutating the ATG triplet at 356 in 
PTPBR7 cDNA results in complete loss of protein expression (BR7-356), whereas the BR7-719 mutant displays 
unaltered synthesis. Mock transfected cells revealed a 50 kDa background signal. Note the doublet band for 
PTPBR7, indicative for posttranslational modifications. Molecular mass markers are indicated (in kDa) on the 
right. B, Similar experiments on PTP-SL cDNA show that mutations at positions 145,643 and 760 interfere with 
synthesis of the 60, 42 and 37 kDa immunoreactive bands, respectively. Note the doublet band for PTP-SL 
around 60 kDa that is reminiscent of posttranslational modification. C, Production of the 42 and 37 kDa 
PTPPBSγ isoforms is abrogated when ATG triplets at positions γ-530 and γ-647 are mutated, respectively. 
When these AUG mutations are combined (γ-530/647 mutant) both prominent PTPPBSγ bands disappear. The 
γ-401 and γ-704 mutants have no effects. D, Schematic diagrams of the Ptprr protein isoforms that result from 
translation of the corresponding full length messengers in mouse Neuro-2a cells as determined in this study. 
Signal peptide (SP), hydrophobic region (HR), transmembrane segment (TM), kinase interacting motif (33) and 
catalytic phosphotyrosine phosphatase domain (PTP) are indicated in the appropriate isoforms. 
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The resulting four different PTPRR isoforms that are encoded by the gene Ptprr are 
schematically depicted in figure 4D. To investigate whether this catalogue of PTPRR 
isoforms can actually be detected in brain tissue lysates, we performed Western blot analysis 
of mouse total brain lysate. Three major immunoreactive proteins, with sizes of 
approximately 70, 60 and 40 kDa, are apparent using the rabbit α-SL serum (Fig. 3, middle 
panel). The two upper major bands correspond with the ones seen for PTPBR7 and PTP-SL 
in the in vitro studies, especially when taking into account possible in vivo posttranslational 
modifications as witnessed by the occurrence of double bands for these isoforms in figure 4 
(e.g. BR7-719 and SL-643/760). The smaller, 40 kDa band in brain may correspond to a 
PTPPBSγ isoform.  
 
PTPRR protein localization in mouse brain  
To aid in the study of the in situ localization of PTPRR proteins in mouse brain tissue, 
monoclonal antibodies against the common part in all four isoforms were raised. To this end, 
the GST-SL fusion protein encompassing the PTP domain-containing carboxyl terminal 294 
residues (10) was used to immunize mice. Absence of unique amino acid sequences in PTP-
SL and PTPPBSγ precluded the generation of PTPRR antibodies that would have been 
specific for either one of these isoforms. Obtained hybridomas were screened by ELISA 
using a His-tagged PTP-SL fragment as antigen to eliminate GST-reactive hybridomas. Eight 
different clones were obtained that secreted antibodies reacting with Neuro-2a cells 
ectopically expressing PTP-SL in Western analysis (Fig. 5A) and immunofluorescence 
assays, and remaining negative on mock-transfected cells. Various deletion mutants of the 
GST-SL fusion protein were exploited to map the epitope-containing region for these 
monoclonal antibodies. All were found to be immunoreactive towards amino acids 227-292 
in PTP-SL (aa numbering according to TPA accession number BN00037), spanning the 
region just downstream of the KIM domain present in all four PTPRR isoforms.  
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Fig. 5 Immunoreactivity of monoclonal antibodies and polyvalent antiserum directed against the common 
part in PTPRR protein isoforms.  
Neuro-2a cells were transiently transfected with PTP-SL or STEP expression plasmids, as indicated above the 
lanes. Mock transfected cells were included as negative controls. Lysates were directly subjected to Western 
blot analysis using (A) monoclonal antibodies (6A6, 5E4) or (C) polyvalent antiserum (α-SL, STEP-absorbed 
SA-α-SL) directed against the PTPRR PTP moiety. The other six PTPRR monoclonal antibodies that were 
obtained displayed reactivities similar to 6A6. Proteins were also immunoprecipitated from transfected cell 
lysates using the different antibodies, and analyzed on Western blots. All eight monoclonal antibodies 
demonstrated specificities in immunoprecipitation applications that are identical to that of the polyvalent α-SL 
antiserum shown in panel B. Molecular mass markers (kDa) are indicated on the left. 
 
 
 
On the basis of signal intensities on mouse tissue sections three monoclonal 
antibodies (designated 6A6, 1E3 and 3E11) were selected for use in immunohistochemical 
assays. Mouse brain horizontal and coronal sections were incubated with a mixture of these 
anti-PTPRR monoclonal antibodies and specific brain regions revealed immunoreactivity. 
Clear staining was observed in the Purkinje cells of the cerebellum (Fig. 6A), in both the 
neuropil and the neurons of the striatum (Fig. 6B). Close to the striatum the major Islands of 
Calleja and the ventral pallidum also stain positive, and furthermore the hippocampal 
CA2/CA3 region, subthalamic nucleus, substantia nigra area, and large neurons between the 
medial and dorsal lateral septum stain very bright (data not shown). Of the five remaining 
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monoclonal antibodies all except one (5E4) gave similar but much weaker staining patterns 
(data not shown). To our surprise monoclonal antibody 5E4 firmly stained Purkinje cells of 
the cerebellum (Fig. 6C), but remained negative in all other brain regions, most notably the 
striatum (Fig. 6D). This suggested to us a possible cross-reactivity of all other antibodies with 
striatum-enriched phosphatase (STEP), which is 45% identical in the PTP domain. Indeed, 
exploiting bacterial and mammalian cells ectopically expressing PTP-SL or STEP proteins, 
we found that all monoclonal antibodies, except 5E4, as well as the previously used 
polyvalent α-SL antiserum recognized STEP, both on immunoblots (Fig. 5A) and in 
immunoflorescence assays (data not shown), while remaining negative on mock-transfected 
cells. In immunoprecipitation  experiments, however, all antibodies were specific for PTP-SL 
(Fig. 5B). We could successfully remove the STEP cross-reactivity from the polyvalent α-SL 
serum by passing it over glutathion-sepharose-bound GST-STEP fusion proteins (Fig. 5C), 
and the resulting PTPRR-specific rabbit serum performed comparable to 5E4 on brain 
sections (Fig. 6 E-F). Taken together these data show that PTPRR protein isoforms are only 
present at detectable levels in the cerebellar Purkinje cells, and that previously observed 
staining patterns in other brain regions (12,18,19) may reflect cross-reactivity with STEP 
proteins.  
The possible cross-reactivity of the α-SL serum with the STEP family of phosphatases 
made us re-evaluate the immunoblot analysis of PTPRR protein expression in different brain 
areas. To maximise sensitivity and to eliminate STEP cross-reactivity, we performed 
immunoprecipitations followed by Western blot analysis on protein lysates of mouse 
olfactory bulb, hippocampus, midbrain, brainstem, cerebellum and cortex brain areas using 
monoclonal antibodies and STEP-absorbed α-SL serum. One major immunoreactive band of 
approximately 65 kDa was seen in all lysates tested (Fig. 3, right panel), which corresponds 
well with the lower protein band seen for PTPBR7 in the in vitro studies. The minor bands at 
70 and 75 kDa detected in most brain parts probably represent a processing intermediate and 
the full-length PTPBR7 protein, respectively. No other potential in-frame AUG start sites 
could account for these alternative sizes. Reflecting the lower and more restricted expression 
of PTP-SL and PTPPBSγ mRNAs, specific signals for these protein isoforms are not apparent 
in the immunoprecipitation experiment, although the lower band may correspond with 
PTPPBSγ-37. 
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Fig. 6 Immunolocalization of PTPRR protein in mouse brain.  
Brain cryosections were stained using a mixture of three different monoclonal antibodies (1E3, 3E11 and 6A6) 
immunoreactive towards the common part in PTPRR isoforms and that cross-react with STEP. Positive staining 
is observed in the Purkinje cells of the cerebellum (A), both the neurons and neuropil of the striatum (B). 
Similar sections were incubated with monoclonal antibody 5E4, which does not cross-react with STEP. 
Exclusively Purkinje cell staining was observed (C), and no signal could be detected in the striatum (D). The 
STEP-absorbed α-SL serum also shows a clear Purkinje cell staining (E) and does not react with striatum (F), 
suggesting that staining of the striatum (B) reflects STEP immunoreactivity. 
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PTPRR isoforms comprise cell surface, vesicle-associated and cytosolic variants 
The presence of hydrophobic protein domains in the PTPBR7 and PTP-SL isoforms has led 
to the prediction that they may represent receptor-type PTPs (Fig. 4D). Indeed, for PTPBR7 a 
functional signal peptide and a transmembrane segment have been mapped (11,12). The N-
terminal hydrophobic segment in PTP-SL, however, is unable to exert a signal peptide ‘start 
transfer’ effect (12) and, consequently, the membrane topology of PTP-SL remains elusive. 
The construction of the PTPPBSγ expression plasmid now enabled us for the first time to 
make a comparison of the subcellular localizations for the PTPBR7, PTP-SL and PTPPBSγ 
PTPRR protein isoforms. Transiently transfected Neuro-2a cells were immunostained using 
the rabbit α-SL antiserum and analyzed by confocal laser scanning microscopy (Fig. 7). The 
three different PTPRR expression constructs resulted in markedly different subcellular 
localization patterns. As described before, PTPBR7 and PTP-SL are localized at the Golgi 
apparatus and at late endosomal vesicles, additionally PTPBR7 is also found at the cell 
membrane (12,18,19). In contrast, the 42 and 37 kDa PTPPBSγ variants are genuine cytosolic 
proteins that are excluded from the nucleus. Similar results were obtained when other cell 
types, e.g. COS-1 cells, were used (data not shown). 
 
 
 
 
Fig. 7 PTPRR isoforms differ in their subcellular localization.  
Neuro-2a cells, transiently transfected with expression plasmids encoding PTPBR7 (A), PTP-SL (B) or 
PTPPBSγ (C), were stained using α-SL antiserum and analyzed by confocal laser scanning microscopy. Distinct 
localization patterns for each isoform type can be discerned. PTPBR7 displays a predominant cell surface 
staining, but also at the Golgi and vesicles throughout the cytoplasm (A). PTP-SL resides at the Golgi apparatus 
and on vesicles (B). The PTPPBSγ 42 and 37 kDa proteins diffusely stain the cytosol (C). Bar indicates 10 µm. 
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Discussion 
 
Here we have characterized the full collection of transcript and protein isoforms that are 
derived from the mouse gene Ptprr. Three different alternative promoters (Fig. 1) were found 
to give rise to messengers encoding PTPBR7, PTP-SL and two PTPPBSγ protein variants 
(Figs. 3,4) that differ in their brain expression (Fig. 2) and subcellular localization (Fig. 7) 
patterns. Results from the human genome project have demonstrated that the phenotypic 
complexity of higher organisms is achieved only in part by higher gene numbers and that 
mechanisms that result in the production of multiple protein isoforms from a single gene 
locus contribute substantially to this (20). A well-studied mechanism to create diversity at the 
RNA level is alternative splicing, now thought to occur in some two-third of the mammalian 
primary transcripts (21). Indeed, two Ptprr transcript variants arise through an alternative 
splicing event: PTPPBSγ+ and PTPPBSγ- (8). However, they contain identical open reading 
frames and thus do not contribute differentially to the collection of PTPRR protein isoforms. 
The PTPPBSγ splice variants only differ in their 5’ non-translated region due to alternative 
removal of a 117 nucleotide intronic sequence that according to our genomic analysis spans 
positions 176-292, rather than 174-290 as reported earlier (9), in the PTPPBSγ+ cDNA.  
 An alternative, well-studied means to produce multiple protein isoforms from a single 
gene is through the use of alternative translation initiation sites (22). Also this strategy is used 
in mouse to create isoform diversity within the Ptprr protein products. From the large open 
reading frame present in PTPPBSγ mRNA variants it is not the first AUG codon that is used 
as translation start, but instead the second and the third methionine codon (Fig. 4C). 
Likewise, the first AUG codon in the PTP-SL reading frame is ignored by the ribosome, and 
rather the one at position 145-147 and to a lesser extend those at 643-645 and 760-762 are 
used to generate 60, 42 and 37 kDa isoforms, respectively. This translation initiation site 
choice appears to be depending on the expression system used. COS1 cells transiently 
transfected with the PTP-SL expression construct show predominance of the start at position 
145-147, whereas PC12 cells mainly produce the isoforms known as PTPPBSγ by using the 
alternative start codons at positions 643-645 and 760-762 (unpublished data).  
The pioneering work of Marylin Kozak has provided detailed knowledge on the 
translation initiation behavior of mammalian ribosomes. Although surrounding RNA 
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secondary structure elements are certainly of influence as well, the optimal context for start 
codon recognition has been determined as GCCRGaugG, with the most important nucleotide 
types in bold (23). Less optimal start codons may cause ‘leaky scanning’ resulting in 
translation initiation on further downstream AUGs. Alternatively, direct entry of ribosomes at 
internal AUG sites in the mRNA might occur (24). Finally, ‘reinitiation’ by ribosomes after 
translation of small upstream ORFs could explain alternative start site choices (23). Since 
certain initiation factors dissociate only gradually from the ribosome during the elongation 
phase, they enable the 40S subunit to resume scanning for AUG start sites after terminating 
from such very small ORFs. In the case of PTP-SL and PTPPBSγ mRNAs indeed very small 
upstream ORFs near or overlapping the predicted start sites are present. We exclude cryptic 
promoters or splice sites in the pSG5-based expression constructs as the cause for the 
synthesis of 60, 42 and 37 kDa PTPRR proteins since identical staining patterns were 
obtained using pRK5 as vector (data not shown) or when performing in vitro translation 
experiments (9,10).  
Yet another key mechanism for generating organismal complexity is alternative use of 
promoters (25). Alternative promoters may display differences in expression level, tissue 
specificity or developmental activity. Furthermore, the resulting alternative 5’ mRNA ends 
may impose differences in mRNA stability and translatability or, most importantly, in the 
encoded proteins. The three alternative promoters present in the Ptprr gene create differences 
both in expression pattern as well as in coding potential of the distinct mRNA types. PTPBR7 
is a receptor-type PTP that is expressed throughout the brain (11). PTP-SL is located at 
perinuclear vesicular structures (18) and during postnatal Purkinje cell maturation PTP-SL 
specific transcripts replace the PTPBR7 messenger (12), a developmental expression pattern 
that is conserved in rat (26). The third, cytosolic protein isoform PTPPBSγ is, in contrast to 
the other two, not only expressed in brain but also during cartilaginous skeleton development 
and in the gastrointestinal tract (8).  
The orthologous human gene, PTPRR, has a very similar exon-intron build-up (27) 
and also encodes multiple isoforms (9). Human PTPPBSα and PTPPBSγ correspond to 
mouse PTPBR7 and PTPPBSγ, respectively, and expressed sequence tag BQ957212 may 
represent human PTP-SL. Interestingly, in human tissues yet another isoform has been 
identified. This PTPPBSδ cDNA has a unique 5’ stretch of 23 nucleotides, containing an 
ATG sequence, which replaces the first 799 basepairs of PTPPBSα and will result in a 
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protein with 3 unique amino acids (9). We could map the human PTPPBSδ-specific stretch in 
PTPRR just 2 nucleotides upstream of the PTPPBSγ-specific exon, meaning that the 
PTPPBSδ and PTPPBSγ promoters are arranged in tandem. In mouse, no PTPPBSδ-like 
isoform has been described so far. We could locate a putative PTPPBSδ-like 5’leader 
sequence (sharing 83% sequence homology) just in front of, and partly overlapping with, the 
first mouse PTPPBSγ exon, nicely coinciding with the position of the human PTPPBSδ 
promoter. However, cDNAs containing the implicated mouse genomic segment could not be 
identified in the databases and even if a mouse PTPPBSδ-type transcript is generated this will 
not give rise to a mouse PTPPBSδ protein since the human PTPPBSδ ATG start codon reads 
GTG in mouse. 
To monitor PTPRR protein expression in situ, we raised monoclonal antibodies 
against the PTP part that is present in all isoforms. Delineation of protein expression patterns 
for individual PTPRR isoforms is hampered by the absence of unique sequence stretches in 
the PTP-SL and 42 and 37 kDa PTPPBSγ proteins. Furthermore, we stumbled upon the 
finding that a polyvalent antiserum and seven out of eight monoclonal antibodies directed 
against the common part in the PTPRR isoforms cross-reacted with STEP, that is only 45% 
identical in its catalytic domain (Fig. 5). Therefore, our previous immunohistochemical data, 
showing expression in Purkinje cells of the cerebellum, striatal neurons, hippocampal 
CA2/CA3 region and brain cortex (12,18) should be reconciled. Our present survey by 
immunoprecipitation and Western blot analysis (Fig. 3) now reveals that PTPRR isoforms, 
most notably of the PTPBR7 type, are present at low levels in various brain regions but by 
immunohistochemistry are only detectable in cerebellar Purkinje cells (Fig. 6). The apparent 
discrepancy between immunoprecipitation and Western blot experiments may be explained in 
several ways but most likely is due to low sensitivity and limited antigen accessibility. 
Furthermore, mRNA and protein stabilities are crucial parameters for the ultimate detection 
levels. 
On the basis of the initial mapping of Ptprr on chromosome 8 (28) and the 
conspicuous PTPBR7 to PTP-SL isoform switch during postnatal Purkinje cell development 
we have considered Ptprr a candidate gene for the recessive neurological mouse mutation nr 
(nervous) (12). During the fourth postnatal week 90% of the cerebellar Purkinje cells in nr 
mutant mice start to degenerate and, as a consequence, adult nr mice display ataxia and poor 
motherhood (29). We have PCR amplified and sequenced all Ptprr exonic regions in nr mice 
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but no differences were found when compared to wild type controls (data not shown). 
Furthermore, normal levels and sizes of PTPRR transcripts and proteins were detectable in nr 
mice. Meanwhile, the Mouse Genome Project has revealed that Ptprr is located on 
chromosome 10 rather than 8 (30). Indeed, using a Ptprr containing genomic clone from the 
consortium, we could confirm the chromosome 10 location by fluorescence in situ 
hybridization (data not shown). Obviously, a chimeric genomic clone compromised our 
original mapping result, and the above eliminates Ptprr as nr candidate. 
Taken together, through the use of three alternative promoters, a single alternative 
splicing event and alternative use of AUG start codons, the mouse gene Ptprr produces four 
different PTPRR mRNA and protein isoforms. Although the PTPRR isoforms occupy 
different niches in the cell (Fig. 7), they all have a C-terminal part in common that contains in 
addition to the catalytic PTP domain a so-called KIM (Kinase Interaction Motif) sequence 
that allows them to interact with MAP kinases (13,31). Intriguingly, the spatio-temporal 
regulation of MAP kinase activation is a crucial determinant in cell signaling as demonstrated 
in the paradigm example of PC12 cell response to growth factor stimulation (32). It is 
tempting to speculate that the various PTPRR isoforms perform distinct tasks in determining 
signaling specificity, having PTPBR7 counteracting MAP kinases at the cell surface, with 
PTP-SL being active during growth factor receptor endocytosis, and PTPPBSγ variants in 
keeping cytosolic MAP kinases unphosphorylated. Clearly, elucidation of the cell biological 
impact of the multiple Ptprr gene products awaits further experiments. 
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Summary 
 
The single-copy mouse gene Ptprr gives rise to different protein tyrosine phosphate isoforms 
in neuronal cells through the use of distinct promoters, alternative splicing and multiple 
translation initiation sites. In the current study, we examined the array of posttranslational 
modifications that are imposed upon PTPRR protein products PTPBR7, PTP-SL, PTPPBSγ-
42 and PTPPBSγ-37, which have distinct N-terminal segments and localize to different parts 
of the cell. All PTPRR isoforms were found to be short-lived proteins, with half-lives of 
around 3-5 hours, and are constitutively phosphorylated on one or two of the previously 
identified protein kinase A and MAP kinase target sites. No evidence was obtained for the 
predicted N-linked glycosylation of the extracellular segment in the receptor-type PTPRR 
isoform PTPBR7. Rather, the 72 kDa PTPBR7 protein is subjected to N-terminal proteolytic 
processing in vitro as well as in vivo, resulting in yet another PTP isoforms: PTPBR7-65. 
Mutational analyses revealed that proteolytic cleavage of PTPBR7 occurs C-terminal in 
between residues 135 and 136, at a site that fits the consensus for furin-like convertases. 
Labeling and internalization experiments suggest that this cleavage occurs predominantly at 
the cell membrane and is enhanced by serum-derived factors. However, unlike for other 
receptor-type PTPs, the resulting N-terminal ectodomain does not remain associated with 
PTPBR7-65 but appears to be released into the surrounding medium. This regulated shedding 
of PTPBR7-derivated polypeptides at the cell surface further adds to the molecular 
complexity of PTPRR biology. 
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Introduction 
 
Protein tyrosine phosphorylation is one of the key mechanisms in cellular signaling and as a 
consequence determines many cellular processes. The extent of protein-tyrosine 
phosphorylation is dictated by the balance of activities of protein-tyrosine kinases and protein 
tyrosine phosphatases (PTPs)1 (1-3). The family of PTPs includes both intracellular and 
transmembrane enzymes (4,5). Receptor-linked transmembrane PTPs contain an extracellular 
domain, a single transmembrane domain and an intracellular region consisting of one or two 
catalytic domains. 
Interestingly, some PTP genes give rise to multiple (transmembrane and cytoplasmic) 
isoforms by the use of different promoters, alternative splicing, differential initiation sites and 
post-translational modification (3,5). For example, the STEP (striatal enriched phosphatase) 
subfamily of PTPs consists of multiple transmembrane and cytosolic isoforms that are the 
result of alternative splicing (6,7), or proteolytic cleavage (8). Likewise, transmembrane, 
cytosolic and membrane-associated PTPε isoforms exist, as a result of the use of alternative 
promoters, differential initiation of translation and proteolytic processing (9,10). It is 
commonly believed that the generation of multiple isoforms from a single PTP gene through 
(a combination of) these mechanisms warrants fine-tuning of cellular signaling programs, 
both in time and space dimensions, thus adding to the organismal complexity of higher 
eukaryotes. 
Recently, we described that the mouse PTP gene, Ptprr, harbors the information for 
the regulated production of multiple messenger RNAs, and ultimately four different PTPRR 
protein isoforms (PTPBR7, PTP-SL, PTPPBSγ-42, and PTPPBSγ-37) through the use of 
three distinct promoters, alternative splicing and multiple translation initiation sites (11). The 
four isoforms have molecular weights of 72, 60, 42 and 37 kDa, respectively, and differ in the 
length of their N-terminal part (Fig. 1) which result in distinct subcellular localizations. The 
PTPBR7 protein is a type I transmembrane protein, that localizes at the cell membrane and 
additionally at vesicles and the Golgi apparatus. PTP-SL is probably membrane-associated 
and localizes at late endosomal vesicles and the Golgi area (12,13). The 42 and 37 kDa 
PTPPBSγ proteins are genuine cytosolic proteins that are excluded from the nucleus (11). 
During these studies, isoform-specific expression experiments in intact cells pointed to post-
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translational modifications as an additional mechanism to exacerbate the PTPRR isoform 
diversity (11). 
In the current study we have analyzed in detail the biochemical events imposed upon 
the PTPRR isoforms following their initial biosynthesis. We report on the fate determination 
and importance of constitutive phosphorylation for all isoforms. Moreover, we reveal that one 
protein, PTPBR7, is subjected to conditional proteolytic processing, thus introducing a fifth 
member, PTPBR7-65, to the PTPRR isoform collection. 
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Material & Methods 
 
Expression Plasmid Constructs and Site-directed Mutagenesis 
To obtain the tetracycline inducible construct pNRTIS/PTPBR7-GFP, the plasmid pPTPBR7-
EGFP (13) was linearized with HindIII and subjected to a Klenow DNA polymerase fill-in 
reaction to make it blunt. Subsequently, the PTPBR7-GFP encoding fragment was released 
by a NotI digestion and cloned into the EcoRV-NotI digested pNRTIS-21 vector (14). 
Plasmids pSG5/PTP-SL-FL (12), pSG5/PTPBR7-FL (12), pSG5/PTPPBSγ-FL (11) and phSI 
(15) have been described elsewhere. Point mutations were introduced into pSG5/PTPBR7-FL 
and pSG5/PTP-SL-FL using the QuickChange Mutagenesis protocol according to 
manufacturers specifications (Strategene Inc., La Jolla, CA, USA). The PTPPBSγ 
S51A/T73A mutant was expressed using plasmid pLXSN/PTPPBSγ/S51A/T73A, the 
generation of which will be described elsewhere. In Table 1 the primers used and the mutant 
nomenclature are listed. All constructs were verified by sequence analysis. 
 
 
Table 1. Mutant nomenclature and primers used for site directed mutagenesis 
mutant 5’primer 3’primer 
BR7-35/36 ttggctattcgtcaagcggcgagttggaagccggtg caccggcttccaactcgccgcttgacgaatagccaa 
BR7-51/52 cattcacaggatatcgcggctagcctggacatcgcac gtgcgatgtccaggctagccgcgatatcctgtgaatg 
BR7-158/159 taaccggctcattgaagcggcgaaccaggttgagttg caactcaacctggttcgccgcttcaatgagccggtta 
BR7-171/172 gtgtctcccggaaacgcggcaccaggagaaacgcag ctgcgtttcccttggtgccgcgtttccgggagacac 
BR7-R133A gaacataaccctgcttgcgatcttccgccaaggag ctccttggcggaagatcgcaagcagggttatgttg 
BR7-R136A ctgcagctactccttgggcgaagatccgaagcag ctgcttcggatcttcgcccaaggagtagctgcag 
BR7-
 R133A/R136A 
gaacataaccctgcttgcgatcttccgccaaggag 
ctgcagctactccttgggcgaagatccgaagcag 
ctccttggcggaagatcgcaagcagggttatgttg 
ctgcttcggatcttcgcccaaggagtagctgcag 
BR7-
S338A/T360A 
caggagcgacgaggtgccaatgtatctcttacg 
cctttgtggccgtctcagccccccgggagaaggtagc 
cgtaagagatacattggcacctcgtcgctc 
gctaccttctcccggggggctgagacggccacaaagg 
 
Several codons of PTPBR7 (Acc.no.: D31898), PTP-SL (Acc.no.: BN000437) and PTPPBSγ (BN000438) were 
mutated into alanines using the primers above. Numbers correspond to the amino acid position of the different 
isoforms. The mutated nucleotides are indicated in bold. The SL-217A/T239A and γ-S51A/T73A mutants were 
obtained using the same primer-sets as for BR7-S338A/T360A. Two numbers indicate mutations of two amino 
acids.  
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Antibodies 
To generate a polyclonal antiserum (α-BR7) against the unique, N-terminal part of PTPBR7, 
the segment of mouse PTPBR7 cDNA (Acc. No. D31898) that encodes amino acids 25-118 
was obtained by PCR and cloned into pGEX-4T. The resulting pGEX-4T/PTPBR7/25-118 
plasmid was introduced into DH5α strain and GST fusion proteins were induced and isolated 
as described (16). Purified fusion protein was used to immunize rabbits following standards 
protocols. The polyvalent rabbit antiserum α-SL (12) and the monoclonal antibody 6A6 (11), 
both raised against the C-terminal 295 amino acid residues present in all PTPRR isoforms, 
and the monoclonal antibody directed against sucrase isomaltase, HBB 2/614/88 (17), have 
been described previously. Beta-tubulin antibody E7 was obtained from the hybridoma bank 
(DHSB, university of Iowa, Iowa city).  
 
Cell Lines 
Neuro-2a (ATCC number: CCL-131) and LoVo (ATCC number: CCL-229) cells were 
cultured in DMEM/5% Fetal Calf Serum (FCS) and DMEM/10% FCS, respectively. FCS 
was heat inactivated for 30 min at 56°C, unless otherwise stated. Transient transfections were 
performed using Lipofectamine-Plus according to the manufacturer’s instructions (Invitrogen 
Life Technologies, Breda, the Netherlands). To obtain a tet-off inducible PTPBR7 stable cell 
line, Neuro-2a-BR7, Neuro-2a cells were transfected with pNRTIS/PTPBR7-GFP using 
Lipofectamine-Plus (Invitrogen Life Technologies, Breda, the Netherlands). Six hours after 
transfection the cells were cultured in tet-off medium, being DMEM/5% FCS containing 800 
µg/ml G418 (Gibco Europe, Breda, The Netherlands) and 0.1 µg/ml doxycycline (Clontech). 
Ten to fourteen days after transfection, individual clones were selected, expanded for another 
2 weeks, and then split in half. One half was cultured in Tet-on medium (DMEM/5% Tet-
system-approved FCS, lacking doxycycline; Clontech). After 1, 2 and 3 days of induction 
cells were checked for PTPBR7-GFP protein expression. The uninduced counterhalfs of 
positive clones were expanded and used for further studies. 
 
Metabolic Pulse-chase Labeling Experiments 
Neuro-2a cells transiently expressing PTPBR7, PTP-SL and PTPPBSγ, or PTPBR7-GFP 
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upon induction, were starved in methionine- and cysteine-free medium for 1 hour at 37 °C. 
Cells were then pulse-labeled for 15-30 minutes with methionine- and cysteine-free medium 
supplemented with 100 µCi/ml Tran35S-label (ICN Radiochemicals) and chased with normal 
culture medium for different periods. Subsequently, the cells were washed three times with 
PBS (phosphate-buffered saline) and lysed (lysis buffer: 100 mM Na2HPO4, 1% Triton-X-
100, 0.2% bovine serum albumin (BSA), pH 8.0, 1 mM PMSF, 25 mM NaF, 1 mM Na3VO4, 
2 mM EDTA, and 1 mM sodium pyrophosphate, containing a complete protease inhibitor 
cocktail; Roche Diagnostics GmbH, Mannheim, Germany). Immunoprecipitations and SDS-
PAGE were performed as described previously (11). Radiolabeled proteins were detected 
using Kodak X-omat autoradiography films at -70°C.  
 
Deglycosylation Experiments 
Neuro-2a cells, transiently transfected with PTPBR7, PTP-SL or sucrase isomaltase 
expression constructs (as a positive control (15)), were metabolically labeled for 3 hours and 
cell lysates were prepared as described above. Following immunoprecipitation of PTPBR7 or 
PTP-SL with monoclonal antibody 6A6, or sucrase isomaltase using HBB 2/614/88, the 
proteins were subjected to digestion with Endoglycosidase H (Endo H) or Endoglycosidase F 
(Endo F) according to the manufacturers protocol (Roche Diagnostics). Proteins were 
resolved by SDS-PAGE and visualized by autoradiography.  
 
In vivo [32P]Orthophosphate Labeling 
Transiently transfected Neuro-2a cells were grown for 20 hours in DMEM/5% FCS, washed 
with phosphate-free medium and cultured in phosphate-free medium containing 0.2 µCi/ml 
[32P]-orthophosphate (Amersham Pharmacia Biotech, UK) for 30 min. Preparation of cell 
lysates and subsequent immunoprecipitations were done as described above. Proteins were 
resolved by SDS-PAGE and detected using autoradiography.  
 
Immunofluorescence Assays 
Neuro-2a cells transiently transfected with a PTPBR7 expression construct were put on ice, 
washed three times with PBS and incubated for 1h with a 1:2000 dilution of α-BR7 
antiserum. After three subsequent washes with PBS the cells were incubated for 1 hour on ice 
with a 1:100 dilution in PBS of goat anti-rabbit Alexa-568 (10mg/ml; Jackson 
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ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Following successive washes 
with PBS, cells were fixed for 10 min with 1% paraformaldehyde in PHEM buffer (60 mM 
Pipes, 25 mM Hepes, 10 mM EGTA, 2 mM MgCl2, pH 6.9), and permeabilized using 0.1% 
saponin and 20 mM Glycine in PBS for 30 min at room temperature. Subsequently, these 
cells were incubated for 1h with a 1:2000 dilution of monoclonal antibody 6A6 in SPBS 
(0.1% saponine in PBS) at room temperature. Following three washes with SPBS, cells were 
incubated for 1h at room temperature with a 1:100 dilution in SPBS of Alexa-488-conjugated 
goat anti-mouse IgG (10mg/ml; Jackson ImmunoResearch Laboratories, Inc., West Grove, 
PA, USA). After three final washes with SPBS and methanol dehydration, cells were 
mounted on glass slides using Mowiol (Sigma) containing 2.5% sodium azide as anti-fading 
reagent. Images were examined and collected using confocal laser scanning microscopy 
(MRC 1024, Bio-Rad). 
 
Immunoprecipitation of Mouse Brain Lysates 
Mouse C57BL/6 cerebellar lysates were made by mechanical disintegration in 1.5 ml lysis 
buffer. The lysates were incubated for 1h at 4°C and insoluble components were pelleted by 
centrifugation (14,000 rpm) for 30 min at 4°C. Protein concentration in the resulting 
supernatant was determined according to Lowry (18). Supernatants were first precleared with 
Sepharose beads and then subjected to immunoprecipitation with α-SL or α-BR7 antisera as 
described above. Obtained proteins were size-separated by SDS-PAGE, and subsequently 
visualized by Western blot analysis using monoclonal antibody 6A6.  
 
Metabolic Labeling of Brain Tissue Slices 
Brains were removed from decapitated 3-week old C57BL/6 mice and directly placed in ice-
cold artificial CSF (aCSF: 126 mM NaCl, 26 mM NaHCO3, 10 mM glucose, 3 mM KCl, 1.2 
mM NaH2PO4, 1 mM CaCl2, 3 mM MgCl2). Horizontal slices (450 µm thick), including 
striatal, hippocampal and cerebellar tissue, were prepared on a vibratome (Leica, Nussloch, 
Germany) and incubated for at least 1h at room temperature in aCSF with increased CaCl2 (2 
mM) and decreased MgCl2 (2 mM) levels, under continuous perfusion with 95% O2, 5% 
CO2. After placing the perfusion chambers, each containing three tissue slices, in a 37°C 
water bath, the medium was supplemented with 350 µCi of 35S-methionine. Following a 1h 
incubation period the slices were transferred into an eppendorf tube and washed twice with 
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ice-cold PBS through centrifugation. Subsequently, the tissue slices were treated with 500 µl 
lysis buffer for 1 hour on ice. Remaining debris was removed by centrifugation at 4°C. 
Immunoprecipitations with the antisera α-BR7 or α-SL were performed as described above. 
Proteins were resolved by SDS-PAGE and radiolabeled proteins were detected using 
autoradiography at -70°C for 2 weeks.  
 
Cell Surface Biotinylation 
Neuro-2a cells transiently expressing PTPBR7 were metabolically labeled with Tran35S-label 
as described above. Cells were washed twice with ice-cold PBS and once with ice-cold 
biotinylation buffer (10mM boric acid, 150mM NaCl, pH 8.0) before being incubated for 45 
min at 4°C in biotinylation buffer supplemented with 0.5 mg/ml Sulfo-NHS-Biotin (Pierce, 
Rockford, IL, USA). Subsequently, the cells were incubated for 20 min at 4°C in quenching 
solution (15 mM glycine in PBS) and rinsed twice with cold PBS. Cells were taken up in 500 
µl lysis buffer and transferred to Eppendorf tubes.   
Obtained lysates were precleared with protein A sepharose beads, then 40 µl 
monoclonal antibody 6A6 together with 30 µl of protein A-Sepharose CL-4B was added to 
500 µl cell lysate and incubated by overnight rotation at 4°C. Sepharose beads with 
immunobound proteins were subsequently washed four times in lysis buffer, once in 0.1 M 
Na2HPO4 (pH 8.1) and twice in 0.01 M Na2HPO4. One-third of the beads was removed and 
transferred to another tube containing 2x sample buffer. From the remaining beads the bound 
proteins were eluted by adding 500 µl elution buffer (1% triton X-100, 100mM Glycine-HCl 
pH 2.8) and rotating for 10 min at RT. The resulting supernatant with eluted proteins was 
transferred to a tube containing 100 µl 1M Na2PO4 (pH 8.1), 50 µl 10% BSA and 15 µl 1M 
NaOH. 60 µl of streptavidin beads (Pierce, Rockford, IL, USA) were added to this 
neutralized eluate and the mixture was rotated for 60 min at RT to pull down biotinylated 
proteins. Finally, the streptavidin beads were washed multiple times as described above and 
2x sample buffer was added. Proteins were separated by SDS-PAGE and subjected to 
autoradiography.   
To assess internalization of surface proteins, PTPBR7-expressing Neuro-2a cells on a 
9 cm culture dish were washed as indicated above but this time incubated with 8 mM of the 
cleavable Sulfo-NHS-SS-Biotin (Pierce, Rockford, IL, USA) in 10 mM triethanolamine (pH 
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7.6), 250 mM sucrose, and 2 mM CaCl2 at 4°C for 45 min. Subsequently, cells were washed 
with DMEM containing 0.25% BSA to remove extensive biotin. To allow for biotin 
internalization, cells were transferred to 37°C for various times, at the end of which the cells 
were placed on ice and washed twice with PBS containing 10% FCS. To remove remaining 
cell surface biotin the cells were treated with reducing solution (containing 50 mM 
glutathione, 0.3 M NaOH, 75 mM NaCl, and 10% serum added just before use) for 20 min at 
4°C. Subsequently, the cells were incubated with quenching solution (15 mM glycine and 1% 
BSA in PBS) at 4°C and rinsed twice with cold PBS before being taken up in 500 µl lysis 
buffer. Cell lysates were subjected to immunoprecipitation and pull down experiments as 
described for cell surface biotinylation. Proteins were separated by SDS-PAGE, and 
visualized by Western blot analysis using the monoclonal antibody 6A6.  
 
Characterization of proteases involved in PTPBR7 cleavage 
Furin-negative LoVo cells (19) were transiently transfected with PTPBR7 and PTPBR7-GFP 
encoding constructs. The next day, cell lysates were made and used for immunoprecipitation 
and Western blotting as described above. Neuro-2a cells transiently expressing PTPBR7 or 
PTPBR7-GFP were used to test the influence of the proprotein convertase inhibitor decanoyl-
Arg-Val-Lys-Arg-chloromethylketone (Alexis Biochemicals, Lausen, Switzerland). 
Immediately following transfection, the cells were treated for 20 hours with 25, 50 and 100 
µM (final concentration) inhibitor that was added to the medium. Subsequently, cell lysates 
were made and used for immunoprecipitation and Western blotting as described. 
 
Quantification of Cleavage Products 
To induce synthesis of PTPBR7-GFP fusion protein, the pNRTIS/PTPBR7-GFP-containing 
Neuro-2a cells were cultured for three days in tet-on medium with or without 5% FCS. Cell 
lysates were made as described above, and following incubation on ice for 30 min the lysates 
were cleared by centrifugation at 4°C for 10 min. Protein concentrations in the supernatants 
were determined according to Bradford (20). Equal protein amounts were loaded onto SDS-
PAGE gels and subsequently blotted onto nitrocellulose membranes and subjected to 
immunodetection as described previously (13). The upper half of the blot, containing the 
proteins larger than 60 kDa, was incubated with α-SL antiserum (1:2000 dilution in 3% non-
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fat dry milk, 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 0.05% Tween-20). The lower 
part, with proteins of an apparent molecular weight smaller than 60 kDa, was incubated with 
the anti-tubulin monoclonal antibody E7. Following respective washes and incubations with 
appropriate secondary antibodies, immunoreactive bands were visualized by 
chemiluminescence (Lumilight, Roche Diagnostics, Manheim, Germany). For quantification 
purposes, detection was performed using a BioChemi imaging system and 
chemiluminescence signals were analyzed using the Labworks 4.0 program (UVP 
BioImaging systems, Cambridge, UK). 
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Results 
 
Biosynthesis and Processing of the PTPRR Isoforms 
Previous studies on PTPRR isoforms indicated post-translational modifications for these 
phosphatases (11). We therefore investigated possible precursor-product relationships by 
metabolic labeling experiments using Neuro-2a cells transfected with PTPBR7, PTP-SL or 
PTPPBSγ-42/37 encoding constructs. Cells were pulse-labeled with 35S-methionine for 15 
minutes and chased with normal medium for several different time periods (Fig. 1). Fig. 1A 
shows that de novo synthesized PTPBR7 precursor protein is readily detectable following the 
applied pulse-labeling period, and after 15 min of chase an additional band just above the 72 
kDa precursor protein is appearing. In addition, after 2 hours chase a third band of 
approximately 65 kDa becomes discernable (indicated with arrow). This 65 kDa protein was 
repeatedly detected, and only at later time points, indicating that it is derived from the 72 kDa 
precursor protein by post-translational modification.  
A similar analysis was performed for Neuro-2a cells transfected with PTP-SL cDNA 
(Fig 1B). After 15 min 35S-methionine pulse labeling, newly synthesized PTP-SL protein of 
60 kDa is detected. An additional, slower migrating band was observed after 15 min of chase 
with normal medium, indicative for post-translational modification. As described previously 
(11), expressing PTP-SL cDNA also results in the production of the 42 and 37 kDa PTPPBSγ 
protein isoforms through the use of alternative start codons. Indeed these proteins are not the 
result of PTP-SL processing; they are already present from the 15 min pulse onward and do 
not reveal altered mobilities over time in this assay. This is corroborated in a parallel 
experiment using the PTPPBSγ expression construct in Neuro-2a cells, which resulted in the 
synthesis of the PTPPBSγ-42 and PTPPBSγ-37 isoforms that display unaltered apparent 
molecular weights over time (Fig. 1C).  
From figure 1 it is also clear that all PTPRR isoforms have a rather moderate life 
span, since the amount of labeled protein detected after 2 hours of chase has decreased 
significantly. The relative signal intensities allowed us to estimate the half-lives of PTPBR7, 
PTP-SL, PTPPBSγ-42 and PTPPBSγ-37 to be around 3 hours, 2 hours, 3 and 5 hours, 
respectively. 
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Fig. 1 Biosynthesis and processing of the PTPRR isoforms.  
Neuro-2a cells were transiently transfected with pSG5/PTPBR7-FL (A), pSG5/PTP-SL-FL (B) or 
pSG5/PTPPBSγ-FL (C) expression plasmids. Schematic representations of encoded proteins are shown above 
the relevant panel. Signal peptide (SP), hydrophobic region (HR), transmembrane segment (TM), kinase 
interacting motif (KIM) and catalytic phosphotyrosine phosphatase domain (PTP) are indicated. After being 
metabolically labeled with 35S-methionine for 15 min, cells were chased with normal medium for the indicated 
time periods (in min). Cell lysates were subjected to immunoprecipitation with monoclonal antibody 6A6. 
Radiolabeled PTPBR7 (A), PTP-SL (B) and PTPPBSγ (C) protein isoforms were separated by SDS-PAGE and 
detected by autoradiography. Arrows indicate the appearance at later time points of a 65 kDa PTPBR7 variant. 
Molecular mass standards are indicated on the right. 
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No Evidence for N-glycosylation of the PTPRR Isoforms 
The upper band that appeared rapidly after the de novo synthesis of PTPBR7 and PTP-SL 
may reflect N-glycosylation or phosphorylation. Glycosylation of PTPBR7 has been 
suggested before, on the basis of the presence of potential glycosylation sites in the 
extracellular domain (21). To assess whether glycosylation indeed occurs, Neuro-2a cells 
were transiently transfected with PTPBR7 and PTP-SL expression constructs and 
metabolically labeled for 3 hours. This was followed by an immunoprecipitation using the 
monoclonal antibody 6A6. Part of the obtained PTPRR proteins was also treated with Endo F 
or Endo H to remove all Asn-linked oligosaccharide chains or only high mannose Asn-linked 
sugars, respectively. The sucrase isomaltase protein, known to be heavily glycosylated, was 
taken along as a positive control for the activity of the two deglycosylation enzymes (15). No 
effect on electrophoretic mobility was observed upon Endo F or Endo H treatment of 
PTPBR7 and PTP-SL, whereas the sucrase isomaltase protein displayed the expected shifts 
(Fig. 2A). This indicates that the observed post-translational modification that results in the 
upward shift of newly synthesized PTPBR7 and PTP-SL is not due to classical N-
glycosylation. 
 
PTPRR Isoforms are Phosphorylated 
PTP-SL contains two putative phosphorylation sites at serine 217 and threonine 239 (21,22) 
(NB: position numbers are according to the newly updated database entry BN000437). We 
therefore investigated whether the upward shift in PTPBR7 and PTP-SL results from 
phosphorylation, with special emphasis on these sites. Neuro-2a cells expressing either wild-
type or mutant PTPBR7, PTP-SL and PTPPBSγ isoforms, were labeled with 32P-
orthophosphate for 60 min, and the PTPRR proteins were immunoprecipitated with 
monoclonal antibody 6A6. Surprisingly, 32P label was detectable in all wild-type isoforms, 
including the unprocessed as well as the upward shifted PTP-SL and PTPBR7 proteins (the 
latter is not clearly discernable in the left panel of Fig. 2B). The γ42-S51A/T73A (and γ37-
S12A/T24A) mutant cannot be phosphorylated at all. Importantly, an almost complete 
reduction in 32P levels was observed when BR7-S338A/T360A and SL-S217A/T239A 
mutants were assayed, but these PTPBR7 and PTP-SL mutants still resulted in doublet bands 
(indicated with arrows) upon immunoblot analysis (Fig. 2B, right panel). These findings rule 
 Proteolytic Cleavage of PTPBR7 
 97
out phosphorylation as the post-translational modification causing the upward shift of newly 
synthesized PTPBR7 and PTP-SL.  
 
 
Fig. 2 PTPRR proteins are phosphorylated, but not N-glycosylated.  
A, No evidence for N-glycosylation. Neuro-2a cells were transfected with pSG5/PTPBR7-FL (PTPBR7), 
pSG5/PTP-SL-FL (PTP-SL), or phSI (Sucrase Isomaltase) expression constructs and metabolically labeled with 
35S-methionine for 3 hours. Cell lysates were subjected to immunoprecipitation with 6A6 antibody in the case of 
PTPBR7 and PTP-SL or with HBB 2/614/88 for sucrase isomaltase. Immuno-purified protein samples were 
either left untreated or incubated with endoglycosidase F (Endo F) or endoglycosidase H (Endo H). 
Subsequently, proteins were resolved by SDS-PAGE and visualized by autoradiography. Molecular mass 
standards are indicated. B, Orthophosphate labeling of PTPRR isoforms. Neuro-2a cells were transfected with 
expression plasmids containing wild-type PTPBR7 (BR7-wt), PTP-SL (SL-wt) or PTPPBSγ (γ-wt) cDNAs, or 
with corresponding mutant constructs (BR7-S338A/T360A, SL-S217A/T239A, γ-S51A/T73A) in which codons 
for two candidate phosphorylation sites had been changed into alanine-encoding ones (see Table I for details). 
Mock transfected cells were taken along as controls. Cells were metabolically labeled with 32P-orthophosphate 
for 30 min, and lysed. Proteins that were immunoprecipitated with monoclonal antibody 6A6 and separated by 
SDS PAGE, were subsequently detected by autoradiography (left panel) or by Western blot analysis using α-SL 
antiserum (right panel). The doublet bands observed for PTPBR7 and PTP-SL are indicated by arrows. The 
doublet bands observed for PTPBR7 and PTP-SL are indicated by arrows. Molecular mass markers are 
indicated on the right. 
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N-terminal Proteolytic Cleavage of PTPBR7 
The pulse-chase experiments for PTPBR7 (Fig. 1A), pointed to a 65 kDa protein band that is 
gradually derived from the 72 kDa PTPBR7 precursor through post-translational modification 
reminiscent of the proteolytic cleavage as described for several other receptor-type PTPs. If 
true, the shorter, 65 kDa PTPBR7 variant will lack either C- or N-terminal protein parts. To 
test this we made use of Neuro-2a cells that had been stably transfected with plasmid 
pNRTIS/PTPBR7-GFP (Neuro-2a-BR7 cells), which allows conditional expression of a 
PTPBR7-GFP fusion protein upon removal of doxycycline from the medium. When it is N-
terminally cleaved the ~100 kDa GFP-tagged PTPBR7 protein will be turned into a ~90 kDa 
protein band, whereas C-terminal cleavage would result in a ~65 kDa protein. After two days 
of PTPBR7-GFP protein induction the Neuro-2a-BR7 cells were metabolically labeled with 
35S-methionine for 30 min and chased for up to 24 hours. Fig. 3A shows that detectable 
amounts of the 100 kDa PTPBR7-GFP precursor protein are present following the applied 
pulse-labeling period. 30-60 min after biosynthesis, a 90 kDa protein band becomes 
detectable that gradually replaces the upper precursor. These results strongly suggest N-
terminal proteolytic cleavage of the PTPBR7 isoform. Moreover, the gradual increase of the 
90 kDa product over time excludes non-specific proteolysis during sample preparations as a 
cause. Steady-state levels of the PTPBR7-GFP protein in this experiment are presented in the 
lower panel of Fig. 3A.  
To be able to analyze this proteolytic cleavage in more detail, we generated a rabbit 
polyclonal antiserum against the N-terminal residues of the PTPBR7 protein (α-BR7) using a 
bacterially produced GST-BR7 fusion protein as antigen (Fig. 3B). The obtained antiserum 
recognized exclusively PTPBR7 protein in transfected cells but not in un-transfected control 
cells using Western blotting and immunofluorescence techniques, demonstrating its 
specificity. In addition, by performing a surface labeling of Neuro-2a cells expressing 
PTPBR7 using the α-BR7 antiserum at 4°C before cell fixation (Fig. 3C left panel) the type I 
transmembrane topology of the PTPBR7 protein could be confirmed. To reveal also the 
intracellular PTPBR7 molecules the same cells were fixed, permeabilized and stained with 
monoclonal antibody 6A6 (Fig. 3C right panel). Importantly, no surface staining was 
observed when PTPBR7 expressing Neuro-2a cells were labeled with the α-SL antiserum or 
the monoclonal antibody 6A6 without prior fixation and permeabilization (data not shown).  
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Subsequently, the α-BR7 antiserum was used in immunoprecipitation and Western 
blotting experiments to test its reactivity towards the PTPBR7 precursor and its cleavage 
product in PTPBR7 expressing cells. Both Neuro-2a-BR7 as well as transiently transfected 
Neuro-2a cell-lysates were subjected to immunoprecipitation using the α-BR7 and α-SL 
antiserum, followed by immunoblot analysis using the monoclonal antibody 6A6. The α-SL 
antiserum precipitated the two expected protein bands but the α-BR7 antiserum indeed only 
detected the uncleaved precursor protein (Fig. 3D). These experiments confirm the N-
terminal proteolytic cleavage of the PTPBR7 72 kDa precursor into a 65 kDa protein product. 
The fate of the N-terminal segment that is released following PTPBR7 cleavage was 
investigated by immunoprecipitation experiments on cell lysates as well as on culture 
medium using α-BR7 antiserum. In some, but not all experiments, indeed a protein fragment 
of approximately 12 kDa could be immunoprecipitated from the culture medium (data not 
shown). No specific PTPBR7-derived low molecular weight protein fragment was obtained 
from cell lysates in these experiments. Our current belief is therefore that the N-terminal 
PTPBR7 fragment is shedded from the cell surface and rapidly degraded extracellularly. 
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Fig. 3 The PTPBR7 protein is N-terminally cleaved.                                                                                             ► 
A, Precursor-protein relationship for GFP-tagged PTPBR7. Neuro-2a-BR7 cells were cultured under 
doxycycline-free conditions for 2 days to induce expression of the PTPBR7-GFP fusion protein before 
metabolic labeling with 35S-methionine for 30 min. Cells were then chased with normal culture medium for the 
indicated time periods (in min), including an overnight incubation (o/n). Following cell lysis, proteins that were 
immunoprecipitated using monoclonal antibody 6A6 were size-separated by SDS-PAGE and visualized by 
autoradiography (upper panel) or by immunoblot analysis using α-SL antiserum (lower panel). Molecular mass 
markers are indicated on the right. B, Schematic diagram of full-length PTPBR7 protein. Signal peptide (SP), 
hydrophobic region (HR), transmembrane segment (TM), kinase interacting motif (50) and catalytic 
phosphotyrosine phosphatase domain (PTP) are indicated. The regions recognized by α-BR7 and α-SL antisera 
and by monoclonal antibody 6A6 are indicated. C, The α-BR7 antiserum binds to the N-terminal part of 
PTPBR7 on the cell surface. Intact Neuro-2a cells transiently transfected with pSG5/PTPBR7-FL  (BR7-wt) 
were incubated on ice with the α-BR7 antiserum and subsequently with an appropriate Alexa-568-conjugated 
second antibody (surface label). Following fixation and permeabilization, cells were also immunostained with 
monoclonal antibody 6A6 and a suitable Alexa-488-conjugated second antibody (intracellular label). D, The α-
BR7 antiserum solely detects the 72 kDa PTPBR7 precursor protein. Cell lysates of Neuro-2a cells transiently 
expressing PTPBR7 (right panel), or of Neuro-2a-BR7 cells conditionally expressing PTPBR7-GFP fusion 
protein (left panel), were subjected to immunoprecipitation with α-SL (IP α-SL) or α-BR7 (IP α-BR7). Proteins 
were separated by SDS-PAGE and visualized by immunoblotting using monoclonal antibody 6A6. Molecular 
mass markers are indicated on the right. 
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Endogenous PTPBR7 Processing in the Mouse Brain 
Above experiments were conducted with transfected cells. To investigate whether similar 
processing of PTPBR7 can be observed in vivo, we used the α-SL and α-BR7 antisera on 
mouse cerebellar lysates. Previous immunoprecipitation studies using the monoclonal 
antibody 6A6 or α-SL antiserum on mouse brain tissue lysates had revealed PTPRR proteins 
of around 75, 70 and 65 kDa (11). Using the α-BR7 antiserum only the 75 kDa protein is 
immunoprecipitated (Fig. 4A), supporting the precursor-product relationship as observed in 
the in vitro studies. However, the presence of an additional, possibly intermediate, 70 kDa 
species in brain points to a more complex processing in vivo. Notably, the abundance of the 
65 kDa PTPRR protein in brain lysates demonstrates that the majority of PTPBR7 is 
proteolytically processed.   
To substantiate this, brain slices including striatal, hippocampal and cerebellar tissues 
were metabolically labeled with 35S-methionine for 60 min, homogenized and subjected to 
immunoprecipitation using the α-SL or α-BR7 antisera. Indeed, the α-BR7 antiserum again 
results in a single, 75 kDa protein band, whereas the α-SL precipitate contains multiple 
proteins (Fig. 4B). Irrespective, the fact that the 75 kDa PTPBR7 precursor and the 65 kDa 
cleavage product were detectable amongst de novo synthesized brain proteins strongly 
supports in vivo processing of PTPBR7. 
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Fig. 4 PTPBR7 steady-state levels and de novo synthesis in mouse brain.  
A, Endogenous PTPRR expression in mouse cerebellum. Mouse cerebellar protein lysates were subjected to 
immunoprecipitation using α-SL (IP α-SL) or α-BR7 (IP α-BR7) antiserum. Proteins were separated by SDS-
PAGE and visualized on immunoblots using the monoclonal antibody 6A6. Molecular mass markers (kDa) are 
indicated on the right. B, Newly synthesized PTPBR7 proteins in mouse brain slices. Horizontal mouse brain 
slices were metabolically labeled with 35S-methionine for 60 min before being lysed. Proteins were 
immunoprecipitated using α-SL (IP α-SL) or α-BR7 (IP α-BR7) antiserum, resolved on SDS-PAGE and 
visualized by autoradiography. Molecular mass markers are indicated on the right. 
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Determination of the PTPBR7 Cleavage Site 
To establish the position of the cleavage site within PTPBR7 we mutated potential protease 
recognition sites in the involved N-terminal region. Dibasic cleavage recognition sites are 
present at multiple positions (Lys35/Lys36, Lys51/Lys52, Lys158/Lys159 and 
Arg171/Lys172) in PTPBR7, and an Arg-Ile-Phe-Arg-Gln sequence at position 133-137 
resembles the RXXRX consensus for furin-like convertases. Appropriate PTPBR7 mutant 
proteins were expressed in Neuro-2a cells, immunoprecipated using monoclonal antibody 
6A6 and analyzed by SDS-PAGE and western blotting. Mutating the paired lysine/arginine 
residues into alanines had no effect on PTPBR7 cleavage (data not shown). The changing of 
Arg136 within the potential convertase site into an alanine, however, significantly reduced 
PTPBR7 cleavage (Fig. 5A). When both Arg133 and Arg136 were mutated, as in BR7-
R133A/R136A, PTPBR7 cleavage was completely abolished. We can exclude that this 
relates to a protein folding and transportation defect since both mutants are being expressed at 
the plasma membrane as revealed by cell surface immuno-labeling (Fig. 5B). 
Since mutations in the potential proprotein convertase target site within PTPBR7 
abrogated cleavage, we tested whether convertases like furin are involved. Transient 
transfection of furin-negative LoVo colon carcinoma cells (19) with expression constructs 
encoding PTPBR7 or PTPBR7-GFP revealed normal processing of PTPBR7, as witnessed by 
the presence of the 65 kDa cleavage product on immunoblots (data not shown). Also, 
treatment of Neuro-2a cells transiently expressing PTPBR7 with different concentrations of 
the peptide-based convertase inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone (24) 
did not result in reduced PTPBR7 cleavage (data not shown), arguing against processing of 
PTPBR7 by proprotein convertases. 
Earlier experiments had already indicated that the N-terminal PTPBR7 segment is 
detectable at the plasma membrane (Fig. 3B), but did not reveal whether the immunostaining 
reflected the precursor or the cleavage product. To pinpoint the subcellular location where 
PTPBR7 is being cleaved, metabolic 35S-methionine pulse-chase labeling of PTPBR7-
expressing Neuro-2a cells was followed by cell surface biotinylation at 4°C. To monitor 
exclusively newly synthesized PTPBR7 that had reached the plasma membrane, an 
immunoprecipitation with monoclonal antibody 6A6 was performed and, subsequently, 
eluted immuno-purified proteins were applied to streptavidin beads (Fig. 5C). Newly 
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synthesized PTPBR7 precursor proteins were found to reach the cell surface after some 30 
min. After two hours, also the cleaved PTPBR7 product is discernable at the cell surface.  
Cleavage of cell surface receptors, including receptor tyrosine kinases and 
phosphatases can take place at the trans-Golgi network on the way to the cell surface, at the 
cell surface itself, and even after subsequent internalization. The latter options are still open 
for PTPBR7 cleavage, and were examined by exploiting cleavable Sulfo-NHS-SS-Biotin. 
Cells expressing PTPBR7 were biotinylated at 4°C and chased for 0, 15 and 60 min at 37°C 
before remaining surface biotin was removed by glutathione treatment. Subsequently, cells 
were lysed and PTPBR7 proteins were immunoprecipitated using monoclonal antibody 6A6 
and, after elution, affinity-purified over streptavidin beads (Fig. 5D). Although PTPBR7 was 
readily biotinylated at the cell surface, we could not detect internalized PTPBR7 proteins 
after 15 or 60 minutes. Taken together, the data strongly suggest that cleavage of PTPBR7 
occurs predominantly at the cell surface, and that PTPBR7 is not significantly endocytosed 
under these conditions or is degraded very rapidly following internalization. 
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Fig. 5 PTPBR7 is proteolytically cleaved upon reaching the cell surface.                           ► 
A, Cleavage site determination. Neuro-2a cells were transiently transfected with pSG5/PTPBR7-FL (BR7-wt) or 
mutant versions resulting in alanine substitutions for Arg-133 and/or Arg-136 in PTPBR7 (BR7-R133A, BR7-
R136A, BR7-R133A/R136A; for details see Table 1). PTPBR7 proteins were immunoprecipitated using 
monoclonal antibody 6A6 and analyzed on Western blot using the α-SL antiserum. Molecular mass markers 
(kDa) are indicated on the right. B, Cell surface expression of PTPBR7 mutants. Transiently transfected Neuro-
2a cells expressing mutant PTPBR7 forms (BR7-R136A, BR7-R133A/R136A) were stained at 4°C with the α-
BR7 antiserum (surface label). After fixation and permeabilization, the same cells were immunostained using 
monoclonal antibody 6A6 (intracellular label). C, PTPBR7 is processed at the cell surface. Neuro-2a cells 
transiently transfected with pSG5/PTPBR7-FL were metabolically labeled with 35S-methionine for 15 min and 
subsequently cultured in normal medium for the indicated time period (in min). Cell surface proteins were 
biotinylated immediately before the cells were lysed, and subsequently PTPBR7 proteins were 
immunoprecipitated using monoclonal antibody 6A6. Immuno-purified proteins were eluted from the beads and 
one part was used for SDS-PAGE and subjected to autoradiography to reveal newly synthesized PTPBR7 
proteins (top panel). The other part was subjected to a streptavidin pull-down assay. Obtained samples were then 
resolved by SDS-PAGE and proteins were visualized by autoradiography. The middle panel displays 
intracellular, non-biotinylated, newly synthesized PTPBR7 proteins. In the bottom panel the newly synthesized 
PTPBR7 proteins that were on the cell surface during biotinylation are displayed. Arrows indicate the 65 kDa 
PTPBR7 cleavage product. Molecular mass markers are indicated on the right. D, No detectable internalization 
of surface-exposed PTPBR7 proteins. Neuro-2a-BR7 cells were induced for 2 days to express PTPBR7-GFP 
before being labeled extracellularly with Sulfo-NHS-SS-Biotin for 45 min at 4°C. Next, the cells were incubated 
at 37°C for the indicated times (in min) to allow internalization. Subsequently, except for the control sample 
(crtl), the surface biotin tag was removed by glutathione treatment at 4°C. Cells were then lysed and PTPBR7-
GFP proteins were immunopurified using monoclonal antibody 6A6. One part was used for SDS-PAGE and 
immunoblotting to visualize steady-state PTPBR7-GFP levels with α-SL serum (top panel). The other part was 
depleted of biotinylated (and thus internalized) proteins using streptavidin beads, and remaining (untagged) 
proteins were size-separated on SDS gels and visualized through immunoblotting with α-SL (middle panel). 
The biotinylated PTPBR7-GFP proteins that had been captured on the streptavidin beads were analyzed in the 
same way (bottom panel). Molecular Mass standards are indicated on the right. 
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Serum-enhanced Proteolytic Cleavage of PTPBR7 
On average, steady-state levels of PTPBR7 and its cleavage product displayed a molar 
ratio of about 2:1 in the previous experiments (e.g. Fig. 3A). Because environmental triggers 
may influence the proteolytic cleavage process, we also tested the effect of several culture 
conditions on PTPBR7 cleavage efficacy using Neuro-2a-BR7 cells. No differences in 
precursor-product ratios were observed when cells were treated with EGTA, ionomycin, 
CaCl2, the PKC inhibitor staurosporin, phorbol ester TPA, NH4Cl2, chloroquine, PMSF, E64 
or wortmannin, nor when cells were grown at different cell-densities (data not shown). 
However, a significantly different precursor-product ratio was found when cells were 
cultured without serum (Fig. 6). Quantification of the observed immunoblot signals for the 
two protein bands revealed that 90% of PTPBR7 protein remains uncleaved in the absence of 
serum. Although apparently the total PTPBR7 protein level is increased under serum-free 
conditions, pulse-labeling studies revealed that this is not due to altered protein stability (data 
not shown).  
The above raises the possibility that PTPBR7 cleavage is performed by serum 
proteinases with specificity for basic residues. Indeed the former experiments were all 
performed using serum that had been heat-inactivated through a 30-minute incubation at 
56ºC, which may allow residual proteinase activity. We therefore investigated PTPBR7 
cleavage in Neuro-2a cells that were transiently expressing PTPBR7 or PTPBR7-GFP using 
serum that had been heat-inactivated at 56°C, at 60°C, or had been left untreated. A partial 
reduction of PTPBR7 cleavage was noticed for cells cultured in 60°C heat-inactivated FCS 
when compared to cells incubated with untreated or 56°C-treated FCS (data not shown). 
Thus, serum components strongly contribute to PTPBR7 cleavage in vitro, but in the end do 
not result in full depletion of the PTPBR7 precursor protein.   
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Fig. 6 PTPBR7 cleavage is enhanced by serum.  
A, Effect of serum withdrawal on PTPBR7 cleavage. Neuro-2a-BR7 cells were grown in tet-on medium with (+) 
or without (-) serum for three days. Equal amounts of lysates were separated by SDS-PAGE and blotted onto 
membranes of which the upper part (proteins >60 kDa) was immunoblotted with α-SL antiserum (PTPBR7, 
upper panel) and the lower part with α-tubulin antibody E7 (tubulin, lower panel). A representative example out 
of five experiments is shown. B, Quantitative representation of PTPBR7-GFP processing efficacy. Relative 
intensities of the ~100 and ~90 kDa α-SL immunoreactive bands were determined from the immunoblot results 
(as in A) by direct imaging and quantification of the respective luminescent signals. The percentage contributed 
by the ~90 kDa cleavage product was determined for cells grown with (white bar) or without (black bar) serum. 
Results are the means ± S.D. of five individual experiments; p < 0.005 according to Student’s t test. 
Chapter 4                                                                        
 
                                                                                                                                                 110
Discussion 
 
The current study shows that post-translational modifications considerably add to the 
complexity of the PTPRR isoform collection. Interestingly, all PTPRR isoforms are being 
constitutively phosphorylated and display relatively short half-lives of 3-5 hours. 
Furthermore, both PTPBR7 and PTP-SL undergo an as yet uncharacterized modification that 
results in a slight reduction of their electrophoretic mobility in SDS-PAGE, leaving open the 
possibility of sugar modifications that differ from the classical N-glycosylation. Finally, the 
72 kDa PTPBR7 protein was found to undergo N-terminal proteolytic processing in vitro as 
well as in vivo, pointing to a physiological role for this process. 
Cells must be able to respond to rapid changes in both their internal and external 
environments. Post-translational modifications like proteolytic cleavage of specific proteins, 
represents such a sensitive and rapid response to environmental cues that enables a 
programmatic change in cell state. Over the last years several papers have reported 
proteolytic cleavage of PTPs and progress has been made in understanding the molecular 
details. Intracellular proteolytic cleavage by the enzyme calpain has been observed for e.g. 
PTPε (10), PTP-STEP (8), and PTP-MEG (25). For PTPε this results in an altered subcellular 
localization pattern (10). Proteolytic cleavage of PTP-STEP61, a PTP that is rather similar to 
PTPBR7, is calcium dependent (8) and is enhanced by ischemia-induced calcium influx in rat 
brain (26). Cleavage within extracellular domains, probably mediated by the endopetidase 
furin, has been reported for LAR (27,28), PTPσ (16,29,30), PTPµ (29) and IA-2 (32). 
Interestingly, the resulting extracellular and transmembrane parts of these PTPs remain non-
covalently associated at the cell surface. Subsequent shedding of the LAR extracellular 
segment was shown to require an additional, inducible, extracellular proteolytic cleavage step 
(29). In contrast, the cleaved IA-2 phosphatase-like receptor also undergoes an inducible 
second processing step, but this concerns an intracellular calpain-mediated cleavage that 
appears instrumental in the mobilization of secretory granules (33). 
 The R-I-F-R-Q sequence within the PTPBR7 precursor protein that appeared crucial 
for its processing fits the consensus cleavage site for proprotein convertases, broadly 
expressed endopeptidases that generally cleave their targets after the second R in the 
recognition site (34). They act along the constitutive, unregulated secretory pathway, thus at 
the trans-Golgi network or close to the membrane. Results obtained with a furin-negative cell 
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line and with a broad proprotein convertase inhibitor, however, argue against convertases as 
the responsible enzymes for PTPBR7 cleavage. Furthermore, biotinylation experiments 
suggest that cleavage of the PTPBR7 precursor takes place at the plasma membrane.  
The physiological effect of PTPBR7 cleavage remains as yet unresolved. It is 
conceivable that proteolytic processing of PTPBR7 results in the release of a soluble 
intercellular regulator into the extracellular space (35,36). For example, proteolytic cleavage 
of the extracellular domain of an interleukin-1 decoy receptor generates a soluble molecular 
trap that binds free interleukin–1, thereby down-regulating IL-1 signaling (37,38). The 
signaling potential of RPTP ectodomains is well documented for phosphacan, that 
corresponds to the extracellular domain of RPTPβ/ζ (39,40) and is an important regulator of 
neuronal development (41-43). Phosphacan is a high-affinity ligand of several 
immunoglobulin superfamily neural cell adhesion molecules and binds to the extracellular 
matrix proteins tenascin-C and R (44-46). It is unclear as yet whether the PTPBR7 
ectodomain is released following cleavage and may perform similar functions. Results thus 
far exclude that it remains non-covalently attached to the transmembrane PTPBR7-65 part. 
Unfortunately, we could not unequivocally demonstrate the presence of this ~ 12 kDa 
PTPBR7 ectodomain in the surrounding medium, which may imply rapid degradation.  
The half-lives of the PTPRR isoforms are relatively short, around 3-4 hours, which is 
fairly comparable to that of some other PTPs, such as RPTPµ (31). There are many PTPs, 
however, that are far more stable, like the heavily glycosylated RPTPα and RPTPε (10). The 
relative instability of proteins has been related to the presence of proline (P), glutamic acid 
(E), serine (S), and threonine (T) rich regions (PEST sequences) within them and that would 
serve as a signal for rapid proteolytic degradation (47). We screened PTPRR isoforms for 
possible PEST sequences using web-based search tools, but no such motifs could be 
discerned. For several proteins it has been shown that rapid degradation is important for 
differentiation and developmental programs, for example in the IκB signaling pathway (48). 
Thus the high turnover of the PTPRR isoforms may reflect an additional regulation 
mechanism in the signal transduction pathways.  
 Extracellular triggers may influence the proteolytic cleavage process. For example, 
proteolytic cleavage of RPTPµ is upregulated when cell density is increased (31), and also 
staurosporin administration or serum starvation has been reported to affect cleavage of 
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proteins (49). Although many regulators did not to affect PTPBR7 cleavage (data not shown), 
serum deprivation had a pronounced influence (Fig. 6). Steady-state levels of the ectopically 
expressed PTPBR7 appear higher under serum-free conditions, but metabolic pulse-chase 
labeling experiments revealed unaltered protein stability in the absence of serum. 
Furthermore, a normal location at the plasma membrane under these conditions excluded 
transport defects as the cause of the altered precursor-product ratio (data not shown). We 
conclude, therefore, that the proteolytic processing of PTPBR7 is enhanced, either directly or 
indirectly, by serum-derived factors. This is corroborated by the finding that heat-inactivation 
of the FCS at 60 instead of (our default) 56ºC partly impairs PTPBR7 processing. Since 
PTPBR7 cleavage also does occur under serum-free conditions (Fig. 6) and can be witnessed 
in in vivo brain material (Fig. 4) the physiological enzymes remain undefined.  
All PTPRR isoforms contain a KIM (kinase interacting motif) sequence by which 
they can interact with the MAP kinases ERK1/2/5 and p38 (22,50,51) and, as a result, block 
their nuclear translocation (50). PKA-mediated phosphorylation of a crucial serine residue 
within the KIM sequence abolishes the interaction and allows MAP kinase signaling to 
proceed (23). Proteolytic cleavage of PTPBR7 as observed in this study may provide an 
additional way to regulate the impact of PTPRR isoforms on MAP kinase signaling 
pathways. 
Intriguingly, in vivo the major PTPRR isoform is apparently the proteolytically 
processed PTPBR7 65 kDa species (Fig. 4). This processing of the larger PTPBR7 precursor 
into an N-terminally truncated PTPBR7-65 protein is in a way reminiscent of the Ptprr gene 
promoter switch that occurs during cerebellar development and that results in the replacement 
of the PTPBR7-encoding transcript by the shorter PTP-SL mRNA in Purkinje cells (12). To 
unravel the functional consequences of both phenomena provides a further challenge. 
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Summary 
 
The precise subcellular localization of protein tyrosine phosphatases (PTPs) is a crucial factor 
in defining their physiological functions. Neural expression of the mouse gene Ptprr results 
in multiple neuronal PTPs, among which PTPBR7 and PTP-SL. The PTPBR7 isoform is a 
type I transmembrane protein and localizes to the plasma membrane, the Golgi apparatus and 
vesicles. PTP-SL is membrane-associated and found at the Golgi apparatus and at vesicles 
that are in part from endocytic origin. In the current study, we compared in detail the 
vesicular localization of these two PTPRR isoforms. We show by immunofluorescence and 
immuno-gold labeling that PTPBR7 and PTP-SL are mainly located and co-localize in late 
endosomes and in the Golgi area in Neuro-2a cells. PTPBR7, however, shows additional 
localization on early endosomes as well. Intriguingly, distinct vesicles can be discerned that 
are positive for PTP-SL alone, for PTPBR7 alone, or that contain both PTPRR isoforms. 
PTPBR7 and PTP-SL vesicles are highly motile in both anterograde and retrograde 
directions. The dynamic aspects of the positive vesicles together with their differential 
presence suggest a specific role for these PTPRR isoforms in the endocytic pathway. 
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Introduction 
 
Protein tyrosine phosphatases (PTPs) and protein tyrosine kinases (PTKs) are the enzyme 
classes that are instrumental in determining the spatial and temporal balance between 
tyrosine-phosphorylated and non-phosphorylated targets. Thus they coordinately regulate 
cellular responses to intra- and extracellular cues. For many cellular proteins these 
phosphorylation and dephosphorylation events take place at separate cellular locations (1-3).  
Subcellular compartmentalization indeed is an important paradigm in signaling pathways as 
nicely demonstrated for epidermal growth factor receptor (EGFR) and the protein tyrosine 
phosphatase 1B (4,5).   
In previous studies we have shown that the mouse PTPRR protein tyrosine 
phosphatase family consists of five isoforms, PTPBR7, PTP-SL, PTPPBSγ-42 and PTPPBSγ-
37, and an proteolytic product PTPBR7-65, that are derived from the single-copy Ptprr gene 
through the use of different promoters and differential translation initiation events (6,7). 
These PTPRR isoforms differ in the length of their N-terminal part and in subcellular 
localization, variables that also differ between all other major PTP subtypes: the receptor-
like, membrane associated and cytosolic members of this huge protein family. PTPBR7 is a 
type I transmembrane protein, which localizes to the plasma membrane, the Golgi apparatus 
and vesicles. PTP-SL is membrane-associated, although lacking a functional signal peptide, 
and localizes to the Golgi apparatus and vesicles that are in part from endocytic origin (6,8). 
The PTPPBSγ isoforms on the other hand are cytosolic proteins (7). All isoforms have an 
identical C-terminal core containing the catalytic PTP domain and a so-called kinase 
interaction motif (9) that allows them to asssociate with the MAP kinases Erk1/2/5 and p38 
(10-12). Binding of MAP kinases to KIM-containing PTPs results in inactivation of the MAP 
kinases, through dephosphorylation of the regulatory tyrosine residue, and prevents their 
nuclear translocation (11).  
Since the precise subcellular localization of the PTPs is of importance for the 
regulation of phosphorylation cascades we performed a detailed analysis of PTPBR7 and 
PTP-SL decorated vesicles to increase our knowledge about the extend of overlap between 
these two major PTPRR gene products. PTPBR7 and PTP-SL were both found to be present 
on late endocytic compartments, but PTPBR7 shows an additional localization in early 
endosomes. We also observed that PTPBR7 and PTP-SL decorated vesicles are highly motile 
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in both anterograde and retrograde directions. Our observations therefore suggest a role for 
these phosphatases in the endocytic pathway. 
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Material & Methods 
 
Expression plasmid constructs 
The tetracycline-responsive pNRTIS/PTP-SL-EGFP construct was generated as follows. The 
pPTP-SL-EGFP plasmid (8) was first linearized with HindIII and sticky ends were blunted 
using Klenow DNA polymerase. Subsequently the PTP-SL-EGFP encoding part was released 
from the plasmid backbone with NotI. The obtained DNA fragment was cloned in between 
the EcoRV and NotI site of the pNRTIS-21 plasmid (13; kindly provided by dr. Frank 
Böhmer, Jena, Germany). The mammalian expression constructs pSG5/PTP-SL-FL, 
pSG5/PTPBR7-FL, pSG8/PTPBR7-FL-VSV and pPTPBR7-EGFP have been described 
elsewhere (6,8).  
 
Cell lines and Antibodies  
Neuro-2a cells (ATCC number: CCL-131) were cultured in DMEM supplemented with 5% 
Fetal Calf Serum. To obtain the Neuro-2a-SL cell line, which carries an inducible tet-off 
PTP-SL-EGFP expression construct, Neuro-2a cells were transfected with pNRTIS/PTP-SL-
EGFP DNA using Lipofectamine-Plus (Invitrogen Life Technologies, Breda, the 
Netherlands). Six hours after transfection the cells were cultured in medium containing 800 
µg/ml G418 (Gibco Europe, Breda, The Netherlands) and 0.1 µg/ml doxycycline (Clontech) 
(tet-off medium). Ten to fourteen days after transfection, several individual clones were 
selected and plated on 96 well dishes. After expanding the individual clones for 2 weeks, 
cells were split in two halves. One half of the cells was cultured in tet-off medium whereas 
the other half was cultured in tet-on medium (DMEM supplemented with 5% tet-system 
approved Fetal Bovine Serum (Clontech) lacking doxycycline). After 1, 2 and 3 days of 
induction cells were checked for PTP-SL-EGFP expression by fluorescence microscopy. The 
uninduced counterparts of positive clones were expanded and used for further studies. The 
tet-off inducible PTPBR7 stable cell-line, Neuro-2a-BR7, was generated similarly and is 
described elsewhere (14). 
The polyvalent antisera α-SL (6), α-BR7 (14), and α-EGFP (15), and the monoclonal 
antibodies 6A6 (7), and P5D4 (against the VSV-G epitope tag) (16) have been described. The 
polyclonal α-SL antiserum and the monoclonal antibody 6A6 recognize the C-terminal PTP 
region of the PTPRR isoforms, whereas α-BR7 recognizes the N-terminal part that is unique 
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for the PTPBR7 isoform. For some applications the α-SL antiserum was first preabsorbed 
over a GST-STEP fusion protein column (7) in order to eliminate cross reactivity with the 
striatum-enriched phosphatase STEP. The beta-tubulin antibody E7 was obtained from the 
hybridoma bank (DHSB, university of Iowa, Iowa City).  
 
Immunofluorescence assay 
Primary hippocampal neurons were prepared and cultured as described previously (17). 
Neurons were fixed for 30 min with 1% paraformaldehyde in PHEM buffer (60 mM Pipes, 
25 mM Hepes, 10 mM EGTA, 2 mM MgCl2, pH 6.9) and permeabilized using 0.1% saponin 
in PBS containing 20 mM Glycine (SPBS) for 30 min. Subsequently, cells were incubated for 
1h with a 1:200 dilution of STEP-absorbed α-SL antiserum or a 1:2000 dilution of α-BR7 
antiserum in SPBS at room temperature. Following three washes with SPBS, cells were 
incubated with Alexa488-conjugated goat-anti-rabbit IgG (1:100 dilution in SPBS of 
10mg/ml; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) at room 
temperature for 1h. Finally, after three washes with SPBS and methanol dehydration, cells 
were mounted on glass slides using Mowiol (Sigma). Images were collected using confocal 
laser scanning microscopy (MRC 1024, Bio-Rad).  
To perform double labeling experiments with PTPBR7-EGFP or PTP-SL-EGFP and 
tubulin, the Neuro-2a-BR7 and Neuro-2a-SL cell lines were plated on glass coverslips and 
protein expression was induced for two days. Then the cells were fixed, permeabilized and 
stained as described above. To visualize tubulin, the E7 antibody (1:2000 dilution) was used 
followed by Alexa568-conjugated goat-anti-mouse. Fluorescence of the EGFP-fusion 
proteins was recorded directly. PTPBR7-EGFP or PTP-SL-EGFP expressing cells grown on 
coverslips were treated with 10 µg/ml Nocodazole for 3 hours prior to washing, fixation and 
mounting to disrupt the Golgi apparatus. 
 
Dextran uptake experiment 
Neuro-2a cells cultured on glass cover slips were transiently transfected with pPTPBR7-
EGFP or pPTP-SL-EGFP using Lipofectamine-Plus (Invitrogen Life Technologies). To 
visualize endocytic vesicles and late endosomes, cells were first washed and incubated for 1 
hour with serum-free medium. Then the medium was replaced by serum-free medium 
containing 5 mg/ml Dextran-AlexaFluor-546 (Molecular Probes). Cells were incubated at 
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37°C for 5, 10, 20 or 60 minutes to allow for endocytosis, at the end of which the cells were 
placed on ice and washed twice with cold PBS to stop membrane and Dextran trafficking in 
the cell. Subsequently, the cells were fixed for 30 min with 1% paraformaldehyde in PHEM 
buffer. This was followed by washing and mounting as described above.  
For triple labeling purposes Neuro-2a cells were first co-transfected with pPTP-SL-
EGFP and pPTPBR7-VSV as described above. To visualize whether PTPBR7 and PTP-SL 
co-localize in endosomal compartments, cells were allowed for 2 mg/ml Dextran-AlexaFluor-
633 uptake as described for the double labeling experiments. Subsequently, the cells were 
washed, fixed, permeabilized and stained as described above. To visualize PTPBR7-VSV the 
P5D4 antibody (1:200) was used followed by Alexa568-conjugated goat-anti-mouse IgG 
(10mg/ml; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Images 
were collected using confocal laser scanning microscopy (MRC 1024, Bio-Rad). 
 
BSA-gold uptake experiment 
Ultrastructural localization studies were performed on Neuro-2a cells transfected with 
pPTPBR7-EGFP or pPTP-SL-EGFP. After 24 hours the transfected cells were incubated with 
serum-free medium for 1 hour at 37°C. Then the cells were incubated with BSA complexed 
to 5nm gold particles in serum-free medium for 5, 15, 30, and 60 minutes at 37°C. 
Subsequently, cells were fixed for 30 min with 1% paraformaldehyde in PHEM buffer. Fixed 
cells were stored until use in 1% PFA. Before sectioning, cells were pelleted in 10% gelatin 
and post-fixed in 1% PFA for 24 hours. Ultrathin cryosectioning was performed as described 
before (18,19). Sections were incubated with α-EGFP (1:2000 dilution) followed by Protein 
A complexed to 10 nm or 15nm gold. Electron microscopy was performed using a Jeol 1010 
electron microscope operating at 80 kV. 
 
Live cell studies 
Stable cell lines conditionally expressing PTPBR7-GFP (Neuro-2a-BR7) or PTP-SL-GFP 
(Neuro-2a-SL) were used for live-cell imaging. Cells were plated on 35-mm-diameter glass-
bottom dishes (Willco wells BV, Amsterdam, The Netherlands) and protein expression was 
induced for two days. Live cell confocal microscopy was performed on a Zeiss LSM510Meta 
confocal microscope (Carl Zeiss GmbH, Jena, Germany) equipped with a temperature-
controlled stage and CO2 incubator (type S). 
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Measurements on vesicle dynamics were made from movies that were taken at ~ 1 
frame/s. Analyses were performed with the public domain image analysis package ImageJ 
(Version 1.32j; Wayne Rasband, NIH, USA; http://rsb.info.nih.gov/ij/) using the Kymograph 
plugin (http://www.embl.de/eamnet/html/kymograph.html). In short, maximum projections 
were made highlighting the trajectories over which vesicle movement had occurred. From 
these projections tracks were selected to generate kymographs - or time-space-plots - from 
which velocities were obtained by extracting slope values (dx/dt). 
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Results 
 
Localization of endogenous PTPRR isoforms in primary neurons 
For the functional understanding of the PTPBR7 and PTP-SL PTPRR isoforms, knowledge 
on their precise subcellular localization is of relevance. We first studied the endogenous 
subcellular localization of the PTPRR isoforms in primary hippocampal neurons, using the α-
SL and the α-BR7 antisera. The α-SL antiserum recognizes the C-terminal region of all 
PTPRR isoforms. To eliminate its cross-reactivity with the STEP phosphatases this α-SL 
antiserum was first passed over a column carrying GST-STEP fusion protein before being 
used (7). The α-BR7 antiserum specifically recognizes the unprocessed ~72 kDa PTPBR7 
(14).  
Both antisera resulted in a punctate staining pattern throughout the neurons (Fig. 1A 
and C). Higher magnification (Fig. 1B and D) shows a clear dotted fluorescence pattern in 
dendrites, indicating that endogenous PTPRR isoforms also localize to vesicles. In view of 
the reported RNA and protein expression profiles in mouse brain (6,7), it is most likely that 
the observed vesicular pattern in hippocampal neurons solely represents the PTPBR7 
isoform. This endogenous localization is remarkably similar to the vesicular staining 
observed in transfected cell lines earlier (8). As the level of endogenous PTPRR proteins in 
the hippocampal primary neurons is very low, and these cells are not easy to manipulate we 
continued our studies using ectopic expression in Neuro-2a cells. 
 
Co-localization of PTPBR7 and PTP-SL vesicles with endosomal markers     
In previous investigations both PTPBR7 and PTP-SL were found at vesicles that are, at least 
in part, from endocytic origin (6,8). To relate the PTPRR-positive vesicles more precisely to 
different stages of the endocytic pathway and reveal the extent of overlap in PTP-SL and 
PTPBR7 localization, we performed experiments using fluorescent Dextran uptake in Neuro-
2a cells transiently expressing EGFP-tagged PTPRR isoforms (Figs. 2 and 3). After 5 min of 
Dextran uptake, revealing the early endosomes (20), no co-localization with Dextran was 
obtained for either one of the PTPs (Fig. 2A-C and 3A-C). After 10 minutes of endocytotic 
labeling, numerous Dextran-containing vesicles were also found positive for PTPBR7, 
predominantly at the periphery of the cells (Fig. 2D-F). Co-localization of PTP-SL and 
Dextran at this time point could also be detected, albeit to a much lesser extent (Fig. 3D-F). 
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After 20 min of Dextran uptake the localization of both phosphatases showed a high degree 
of overlap with that of endocytosed Dextran, mainly in vesicles close to the Golgi area (late 
endosomes) (Fig. 2G-I and 3G-I). These experiments corroborate our finding that PTPBR7 
and PTP-SL are present on endosomes (8). Furthermore, they demonstrate that whereas PTP-
SL locates predominantly to the late endosomes, PTPBR7 is also present at endosomes from 
earlier stages. 
 
 
 
 
 
Fig. 1 Endogenous localization of PTPRR isoforms in neuronal cells.  
Primary hippocampal neurons were isolated and cultured for two weeks. PTPRR proteins were 
immunohistochemically detected using the antisera α-BR7 (A and B) or STEP-absorbed α-SL (C and D). Bars 
in A and C indicate 10 µm and in B and D 1 µm. 
 
 
 
  Subcellular localization of PTPRR isoforms 
  127  
 
 
 
Fig. 2 PTPBR7 localizes to early and late endosomes.  
Neuro-2a cells were transiently transfected with construct pPTPBR7-EGFP. PTPBR7-EGFP fluorescence (A, D, 
and G) and Alexa549-labeled Dextran uptake (B, E, and H) after 5 min (A-C), 10 min (D-F) and 20 min (G-I) 
were recorded directly using confocal microscopy. Yellow color in panels C, F and I indicates overlap of 
PTPBR7-EGFP (green) and Alexa549 Dextran (red) signals. Arrows point to dextran-containing vesicles, which 
are also positive for PTPBR7  (D and E). Bar indicates 10 µm. 
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Fig. 3 PTP-SL localizes to late endosomes.  
Neuro-2a cells were transiently transfected with construct pPTP-SL-EGFP. PTP-SL-EGFP fluorescence (A, D, 
and G) and Alexa549-labeled Dextran uptake (B, E, and H) after 5 min (A-C), 10 min (D-F) and 20 min (G-I) 
were recorded directly using confocal microscopy. The yellow color in panels C, F and I shows the overlap of 
PTP-SL-EGFP (green) and Dextran (red) signals. Bar indicates 10 µm. 
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To substantiate this finding we next studied localizations in the earlier stages of the 
endocytic pathway in more detail, at the ultrastructural level. To this end, we performed an 
endocytosis assay using uptake of 5nm BSA-gold in Neuro-2a cells transiently transfected 
with PTPBR7-EGFP or PTP-SL-EGFP (Fig. 4). The tagged PTPBR7 and PTP-SL proteins 
were detected using a EGFP-directed antiserum with proven suitability for immunoelectron 
microscopy (8,21). After 5 min BSA-gold uptake, gold particles were found at invaginations 
of the plasmamembrane (coated pits) and small vesicles (Fig. 4A and B). Co-localization 
with these early endosomal organelles was only found for PTPBR7-EGFP (Fig. 4B) and not 
for PTP-SL-EGFP (Fig. 4A). In contrast, after 15 min of continuous uptake the BSA-gold-
containing vesicles, representing endocytic organelles at later stages, were positive for both 
PTPBR7-EGFP and PTP-SL-EGFP (Fig. 4C and D). Both PTP-SL-EGFP (Fig. 4E and 4F) 
and PTPBR7-EGFP (data not shown) displayed extensive colocalization after 30-60 min of 
BSA-gold internalization, in larger, late endosomes (Fig. 4E) and in structures near the Golgi 
apparatus (Fig. 4F). These results firmly establish the differential localization of these two 
PTPRR isoforms over the early stages of endocytosis. 
 
Partial co-localization of PTPBR7 and PTP-SL  
The apparent overlap in localization observed between PTPBR7 and PTP-SL at the late 
endosomal compartments, prompted us to answer the question whether PTPBR7 and PTP-SL 
themselves co-localize at single vesicles. Neuro-2a cells were co-transfected with expression 
plasmids encoding EGFP-tagged PTP-SL and VSV-tagged PTPBR7, and the resulting 
immunofluorescence patterns revealed that there is indeed a substantial overlap between 
PTPBR7 and PTP-SL at the Golgi apparatus and in vesicles surrounding it (Fig. 5 A-C). In 
addition, we also observed single positive vesicles, with fluorescence derived from only 
PTPBR7 or PTP-SL. Interestingly, single-positive PTPBR7 vesicles are particularly found in 
the vicinity of the plasma membrane, reminiscent of the early endocytic compartment in 
which PTP-SL is sparse (Fig. 5A-C). We also used the double transfected Neuro-2a cells in a 
20 min fluorescent Dextran uptake experiment, to label the late endosomal compartment. The 
triple labeling experiments demonstrated that indeed PTPBR7 and PTP-SL co-localize at late 
endosomal vesicles in these cells (Fig. 5D-F). 
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Fig. 4 Differential localization of PTPBR7 and PTP-SL to endosomal organelles. Immunoelectron 
microcopy analysis of transiently transfected Neuro-2a cells expressing PTP-SL-EGFP (A, C, E and F) or 
PTPBR7-EGFP (B and D) after BSA-gold uptake (5nm gold) for 5 min (A and B), 15 min (C and D) and 30-60 
min (E and F). The EGFP fusion proteins were visualized using α-EGFP antiserum and Protein A complexed to 
15 nm (A, B, C, E, and F) gold or to 10 nm gold (D). The arrows point to early endosomes in A and B, to late 
endosomes in C and E, or to structures near the Golgi in F. 
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Fig. 5. Some endocytic vesicles contain PTPBR7 as well as PTP-SL.  
Neuro-2a cells were co-transfected with pPTP-SL-EGFP and pSG8/PTPBR7-FL-VSV. EGFP fluorescence of 
PTP-SL-EGFP was recorded directly (B and E) and PTPBR7 proteins were visualized immunohistochemically 
using the P5D4 antibody against the VSV tag (A and D). Yellow color in panel C indicates overlap of PTP-SL-
EGFP (green) and PTPBR7 (red) signals. After 20 min of Alexa-633-labeled Dextran uptake triple-labeled 
vesicles that are positive for PTPBR7 (D), PTP-SL (E) and Dextran (F) can be detected  (arrows). Bar indicates 
10 µm. 
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PTPBR7 and PTP-SL dynamics in live cells 
Vesicular trafficking pathways, essential for delivering membrane components, ligands and 
solute molecules to various intracellular compartments, commonly involve so-called 
recycling/shuttling mechanisms to ensure membrane homeostasis throughout the cell. Hence 
the dynamics and directionality of vesicle movement are relevant characteristics. To 
investigate whether PTPBR7 and PTP-SL are present on anterograde and/or retrograde 
vesicles traveling between the plasma membrane and the Golgi apparatus we analyzed the 
dynamics of these vesicles exploiting the intrinsic fluorescence of EGFP-tagged PTPRR 
isoforms. To exclude over-expression artifacts we generated stable cell lines, Neuro-2a-BR7 
and Neuro-2a-SL, in which expression of PTPBR7-EGFP or PTP-SL-EGFP fusion proteins 
can be induced up to moderate levels upon removal of doxycycline from the medium. The 
subcellular localization of the tagged PTPBR7 and PTP-SL proteins as displayed in these 
stable cell lines (Fig. 6 A and C) is in concordance with that observed in transiently 
transfected Neuro-2a cells (Figs. 2-3). The Golgi association of PTPBR7 and PTP-SL in 
these stable cell-lines was confirmed by the observation that the fluorescence pattern was 
dispersed upon Nocodazole treatment (not shown), a drug known to disrupt the Golgi 
apparatus.  
Monitoring of the dynamics of the PTPBR7-EGFP and PTP-SL-EGFP proteins in 
living cells revealed a stable Golgi region and highly motile vesicles (Fig. 6 B and D) that 
move both to and from the Golgi apparatus (Fig. 6E). Also in other areas of the cell 
anterograde and retrograde movement of both PTPBR7 and PTP-SL positive vesicles were 
observed. Vesicles moved with quite different velocities (speeds up to 1.6 µm/s could be 
measured), but when we calculated the average vesicle speed no significant differences were 
found between PTPBR7 (0.14 ± 0,036 µm/s) and PTP-SL (0.17 ± 0,027 µm/s) positive 
vesicles. 
The observed trafficking pattern of the PTPBR7 and PTP-SL vesicles is reminiscent 
of movement along microtubule tracks in the cell (Fig. 6B and D). To test this, we performed 
an immunofluorescence assay using an anti-tubulin antibody (E7) on the Neuro-2a cells 
stably expressing PTPBR7-EGFP and PTP-SL-EGFP fusion proteins (Fig. 7). This revealed 
that indeed PTPBR7-EGFP and PTP-SL-EGFP positive vesicles localize mainly along 
microtubuli.   
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Fig. 6  Dynamic aspects of PTPBR7 and PTP-SL positive vesicles.  
Neuro-2a-BR7 (A and B) and Neuro-2a-SL (C and D) cells were cultured under doxycycline-free conditions for 
2 days to induce expression of the EGFP fusion proteins. Images of the fluorescence of PTPBR7-EGFP (A) and 
PTP-SL-EGFP (C) were acquired from live cells. 600 images for PTPBR7-EGFP and 300 images for PTP-SL-
EGFP were collected with 1 s time interval. The projections of the images of PTPBR7-EGFP (B) and PTP-SL 
(D) reveal the motility of the vesicles. Representative kymograms for PTP-SL-positive vesicles (E) demonstrate 
bi-directional movement. PTPBR7 positive vesicles yielded the same results (data not shown). Bar indicates 10 
µm in A-D. 
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Fig. 7 PTPBR7 and PTP-SL positive vesicles localize along microtubule tracks.  
Neuro-2a-SL (A-C) and Neuro-2a-BR7 (D-F) cells were cultured under doxycycline-free conditions for 2 days 
to induce expression of the EGFP fusion proteins. Fluorescence of PTP-SL-EGFP (B) and PTPBR7-EGFP (E) 
was recorded directly.  Microtubuli (A, D) were stained immunohistochemically using an antibody directed 
against β-tubulin.  Panels C and F display merged images of EGFP-tagged PTPRR autofluorescence (green) and 
the microtubuli immunostaining (red). Bar indicates 10 µm. 
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Discussion 
 
The PTPRR isoforms PTPBR7 and PTP-SL both localize at the trans-Golgi network and on 
endocytic vesicles in neuronal cells (8). In the current study we show by immunofluorescence 
and immuno-gold labeling studies that PTPBR7 and PTP-SL display clear but subtle 
differences in their endosomal localization. Proteins that are internalized first end up in the 
early endosomes and can be recycled to the cell surface via a rapid or a slow route through 
recycling endosomes, but a direct route can also connect these endosomes to the late 
endosomes, multivesicular bodies and ultimately the trans-Golgi network or lysosomes (22). 
To facilitate these transport processes in the endocytic compartment, a dynamic network of 
endocytic vesicles can be discerned (e.g. (23)). Indeed, labeling of these PTPRR isoforms 
revealed highly motile vesicles trafficking to and from the Golgi apparatus, which appeared 
rather stable by itself. In addition, vesicles trafficking in both anterograde and retrograde 
fashion were observed outside the trans-Golgi area, in other parts of the cell (Fig. 7). 
Especially for PTPBR7 vesicles in the periphery of the cells were noted, most likely 
representing early endosomes. Together, our data reveal that PTPBR7 is present on vesicles 
throughout the endocytic pathway from the plasma membrane to the Golgi apparatus. In 
contrast, PTP-SL is only present on vesicles participating in the later stages of endocytosis, 
close to the trans-Golgi network. 
 The differential localization of PTPBR7 and PTP-SL on vesicles of the endocytic 
machinery leaves us with three options with respect to their functioning. To start with, it 
could be that the PTPRR isoforms are merely cargo proteins that for example need to be 
delivered to lysosomes for degradation. In line with this, all PTPRR isoforms are short-lived 
proteins with half-lives varying from 3 to 5 hours (14). However, we did not observe any 
colocalization of PTPRR proteins with lysosomal marker proteins (8). Furthermore, as cargo 
proteins these phosphatases would rather be expected to travel in one direction and to 
accumulate at a certain location within the cell. We did, however, observe both anterograde 
and retrograde movements for PTPRR-positive vesicles. We therefore favor the two 
remaining options, namely that these phosphatases are either involved in localized signaling 
or make part of the endocytic transport machinery itself. 
Besides its main function of  delivering membrane components, ligands and solute 
molecules to various intracellular compartments, endocytosis is also intricately coupled to 
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regulated signal transduction (3). For many growth factor signaling pathways indeed the 
impact of receptor internalization and timely signal shutdown through dephosphorylation has 
been documented. The prototypic example is the EGF tyrosine kinase, which can be 
internalized upon ligand binding (5). Phosphorylation dynamics of the EGF receptor were 
successfully imaged and revealed that EGFR at the plasma membrane is phosphorylated and 
hence internalized upon ligand binding and subsequently dephosphorylated by PTP1B, which 
resides at the ER membrane, resulting in receptor silencing (signal termination) and RTK 
break down in lysosomes (24). In addition, tyrosine phosphorylation of Eps15, an endocytic 
protein, by EGFR itself is also required for ligand-induced EGFR endocytosis (25). Recently, 
localized signaling has been demonstrated for human sef (acronym of similar expression to 
fgf genes), a new MAPK scaffold (26). Sef resides on the Golgi apparatus, and acts there as a 
spatial regulator for ERK signaling by specifically blocking ERK nuclear translocation 
without inhibiting its activity in the cytoplasm (26). A comparable role for PTPRR isoforms 
is easy to imagine since these phosphatases interact with the MAP kinases ERK1/2/5 and p38 
through their KIM domain. The interaction not only results in the dephosphorylation of the 
MAP kinase but it also blocks its translocation to the nucleus, thus eliminating downstream 
responses at the transcriptional level (12,27). Up to now, these effects have been reported 
following overexpression of PTPRR isoforms; whether they are capable of performing these 
tasks under more physiological circumstances remains to be investigated. 
The third option, involvement of PTPRR proteins in endocytic vesicle transport itself, 
is also still open. Accurate packaging of cargo and (coated) vesicle formation and membrane 
fusion in vivo requires tight regulation, for which phosphorylation is indeed one of the 
mechanisms (28). Four different heterotetrameric adaptor protein complexes, AP-1 to AP-4, 
are involved in the sorting of cargo proteins into transport vesicles that traffic between the 
different organelles of the cell (29,30). It has been shown that phosphorylation of serine and 
threonine residues within the clathrin coat proteins plays an important role during clathrin-
mediated endocytosis (31,32). Also growth factor or hormone induced tyrosine 
phosphorylation of coat proteins, like clathrin heavy chain and dynamin, has been reported to 
influence clathrin redistribution and MAP kinase signaling (33,34). Likewise, EGF-induced 
tyrosine phosphorylation of the β2 subunit of AP-2 turned out to be important in regulating 
EGFR protein turnover of (35). And very recently, the direct impact of PTP activity on 
intracellular trafficking was established for PTP-MEG2, which is localized to secretory 
  Subcellular localization of PTPRR isoforms 
  137  
vesicle membranes. PTP-MEG2 can bind and dephosphorylate NSF, a key regulator of 
vesicle fusion, thereby local releasing NSF activity and promoting secretory vesicle fusion 
(36). 
We have previously shown that the phosphatase domains of PTPBR7 and PTP-SL 
interact with the β4-subunit of the AP-4 complex in a yeast two-hybrid system and also co-
localize in neuronal cells (8). Using immuno-gold labeling, AP-4 complexes have been found 
at the Golgi complex as well as on early and late endosomes (37), pointing to a role for AP-4 
in sorting processes at these sites. Interestingly, co-expression of PTP-SL and β4-adaptin in 
Neuro-2a cells leads to an altered subcellular localization for PTP-SL. Under these conditions 
PTP-SL is displaced from the Golgi apparatus and vesicles and redistributes throughout the 
cytoplasm (8). Combined with the conspicuous overlap in subcellular localization of the AP-
4 complex and PTPRR isoforms, this finding is in line with a role for these PTPs in 
regulating the AP-4 complex itself. One may even envisage differential roles for PTPBR7 
and PTP-SL in the regulation of AP-4 mediated processes.  
In conclusion, we have shown that two PTPRR isoforms, which differ in their N-
terminal sequence, show a differential localization in the early endocytic compartments. PTP-
SL is localized to the Golgi apparatus and late endosomes, whereas PTPBR7 was additionally 
found at the plasma membrane, at membrane curvatures and invaginations and in the very 
early stages of endocytosis. These data suggest a specialized function for each of these 
phosphatases in the endocytic pathway. Whether the PTPRR isoforms are involved in 
localized tyrosine dephosphorylation of MAP kinases and/or function in cellular processes 
directly connected to the regulation of endocytosis remains to be established.  
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Over the past decades it has become clear that the biological processes of signal transduction 
and membrane trafficking are intertwined. At the onset of our studies, the protein tyrosine 
phosphatase PTP-SL, a signaling molecule, was found to be present on transport vesicles 
mainly belonging to the endocytic compartment (1). PTP-SL is involved in the ERK-MAPK 
signaling pathway (2-4), but interestingly, it was also found to interact with the β4-adaptin 
subunit of the AP-4 adaptor complex, an important component of the vesicular transport 
machinery. In the previous chapters of this thesis, we describe studies that further point to a 
possible role for PTP-SL, and other PTPRR family members, in vesicle trafficking between 
the Golgi-apparatus and endocytic compartments and localized signaling.  
 
 
The PTPRR protein family 
 
Previous work has revealed the existence of two PTPs in mouse, PTPBR7 and PTP-SL, that 
were in part identical, suggesting that they originated from the same gene, termed Ptprr 
(1,5,6). In this thesis, I report on the characterization of the various PTPRR isoforms in 
neuronal cells and demonstrate that the single copy mouse gene Ptprr gives rise to four 
mRNAs that encode PTPBR7, PTP-SL and two PTPPBSγ protein variants through the use of 
distinct promoters, alternative splicing and differential translation initiation starts (Chapter 3). 
In addition, the receptor-type PTPBR7 protein isoform was found to undergo N-terminal 
proteolytic cleavage at a furin-like convertase consensus site, adding an additional, fifth, 
member for which the name PTPBR7-65 was coined (Chapter 4). A schematic representation 
of the domain composition and intracellular distribution of all PTPRR isoforms is depicted in 
Figure 1.  
Localization studies that focused on the different PTPRR isoforms, described in 
Chapters 2 and 5, revealed that PTPBR7 and PTP-SL are both present and co-localize in late 
endocytic compartments and in the Golgi area. PTPBR7 shows an additional localization at 
the plasma membrane (1,7), and interestingly on early endosomes as well (Chapter 5). The 42 
and 37 kDa PTPPBSγ proteins are genuine cytosolic proteins (Chapter 3). The differential 
subcellular localization of all PTPRR isoforms within the dynamic vesicular network of the 
cell is portrayed in Figure 2.  
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Figure 1. Schematic representation of the set of protein products encoded by the gene Ptprr. Structural 
characteristics of the depicted domains are shown in the boxed inset. PTPBR7-65 is generated through 
proteolytic cleavage.  
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Figure 2. Schematic representation of the distribution of the individual PTPRR isoforms within the 
different endocytic compartments. The AP-4 complex is localized to the Golgi-apparatus and late endocytic 
vesicles. See also Figure 1 in chapter 1.  
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Sine this generation of multiple isoforms is conserved in other mammals (5,6,8), the 
question arises why so many different PTPRR isoforms exist. Generally speaking, the 
generation of multiple isoforms from a single gene is believed to warrant fine-tuning of 
cellular programs, both in time and space, thus adding to the phenotypic complexity of higher 
organisms (9). Because the catalytic activity of PTPs is generally exceeding that of the 
counteracting tyrosine kinases by several orders of magnitude, the need for tight regulation of 
PTP activity in vivo is evident. This can be accomplished by a number of mechanisms, 
including subcellular localization, post-translational modification, steady state protein levels, 
and dimerization (10,11). Clearly, by generating PTPRR isoforms that behave differently 
regarding these characteristics, the organism can achieve a high level of control.  
The PTPRR isoforms are identical in their C-terminal region that includes the single 
catalytic phosphatase (PTP) domain, the kinase interaction motif (KIM) and the kinase 
specificity region (KIS), but they differ in the length and sequence of their N-terminal part 
(Figure 1). As a consequence, the PTPRR subfamily turns out to comprise receptor-type 
transmembrane molecules, membrane-associated proteins and cytosolic variants that localize 
to different subcellular compartments (Figure 2). All subfamily members are subjected to 
post-translational modifications (Chapter 4). They all can be phosphorylated on the MAPK 
and PKA target sites as identified in PTP-SL and this may function as a checkpoint in the 
ERK-MAP kinase signaling pathway (2,3,12). Whether these serine/threonine phosporylation 
events have any direct effect on the PTPRR enzymatic activity still remains to be 
investigated. It should be noticed that the PTPRR isoforms are actually short-lived proteins, 
with half-lives of just several hours (Chapter 4) and this lability likely reflects the importance 
of their regulatory role. This may explain why we have not been able to generate stably 
transfected cell lines that constitutively overexpress PTPRR isoforms, and instead, were 
forced to use either transient assays or turn to inducible expression systems (Chapters 4-5).  
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Regulation of PTPRR isoform activity 
 
Interestingly, we found that the PTPRR-isoform PTPBR7 is subjected to N-terminal 
proteolytic cleavage (Chapter 4). This cleavage occurs predominantly at the cell membrane 
and is enhanced by serum-derived factors. Unlike for other receptor-type PTPs, like PTP-
LAR (13,14) or PTPµ (15), the resulting N-terminal ectodomain does not remain associated 
with the shortened PTPBR7 version, termed PTPBR7-65, but appears to be released into the 
surrounding medium. Occurrence of these truncated and shedded products of PTPBR7 not 
only adds to the structural diversity of the PTPRR family, but also to the complexity of its 
biological role. One of the intriguing questions now is whether or not the extracellular part 
functions as a ligand. Equally interesting is to find out whether there is some kind of ligand 
for PTPBR7 itself. If so, such a ligand may well regulate or fine-tune PTPBR7’s activity, 
reminiscent of the situation for growth factors for the receptor-type kinases. 
In the regulation of PTPBR7 activity at the cell membrane, dimerization of the protein 
could play a role in analogy to models now proposed for other PTPases (16-20). These 
studies were triggered by the observation that upon crystallization the active RPTP-α PTP 
domain adopts a homo-dimer conformation that results in the inhibition of its activity (18,21). 
Although the crystal structure of the PTPRR catalytic domain does not reveal signs of 
dimerization (22), it is still possible that PTPBR7 transmembrane chains are dimerized 
through ligand binding to the N-terminal region. In support of this, recent findings in our lab 
point to the existence of PTPBR7 / PTP-SL homo and heterodimers in transfected cells (Y. 
Noordman; personal communication). It will be a challenge to unravel the eventual 
regulatory effects of dimerization and proteolytic processing on the intrinsic catalytic activity 
of PTPBR7 at the plasma membrane.  
Taken together, the gene Ptprr generates multiplicity (by the use of alternative 
splicing, alternative promoter and alternative translation initiation sites), diversity (by post-
translational modifications) and specificity (by targeting the different isoforms to distinct 
subcellular compartments), and thus creates ample possibilities for spatial and temporal 
signaling, which will be discussed below. 
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PTPRR isoforms and endosomal transport 
 
Two isoforms encoded by the gene Ptprr (PTPBR7 and PTP-SL) reside on subcellular 
compartments belonging to the endocytotic transport system (Chapters 2 and 5). Since the 
endocytic process is coupled to many cellular processes including signal transduction 
(reviewed in (23-25)), their presence on endosomes could reflect basically two functions: 
participation in the regulation of the endocytotic transport route itself, and/or involvement in 
localized signaling events, i.e. the local dephosphorylation of MAP kinases. 
PTP-SL is present on the trans-Golgi and on vesicles participating in the later stages 
of endocytosis. Interestingly, the phosphatase domain of PTP-SL was found to interact with 
the β4-subunit of the AP-4 complex in a yeast two-hybrid system (Chapter 2). Four different 
heterotetrameric adaptor complexes, AP-1 to AP-4, have been described that are involved in 
the sorting of cargo proteins into transport vesicles that traffic between the different 
organelles of the cell (26,27). The precise role of the AP-4 complex in transport routes is not 
yet known but current data suggest that it mediates sorting processes at the trans-Golgi and 
endosomal membranes (28-30). Our microscopy studies revealed that PTP-SL and β4-adaptin 
localize to the Golgi-apparatus and vesicles throughout the cytoplasm in neuronal cells 
(Chapter 2). Co-transfection studies, however, failed to demonstrate a direct interaction 
between PTP-SL and β4-adaptin by immunoprecipitation. This may be explained by the 
intriguing finding that co-expression of PTP-SL and β4-adaptin in Neuro-2a cells resulted in 
an altered subcellular localization for PTP-SL: the phosphatase no longer resided at the 
Golgi-apparatus and vesicles but appeared dispersed throughout the cytoplasm. These 
findings point to a functional link between PTP-SL and β4-adaptin, but may also be taken as 
evidence that both proteins compete for the same subcellular localization. It would be 
interesting to test whether PTP-SL mutants, i.e. catalytic inactive ones, are also displaying 
this dispersion effect upon co-expression with β4-adaptin.  
It is intriguing why PTP-SL, but not β4-adaptin, is redistributed throughout the 
cytoplasm in such co-expression experiments. PTP-SL contains two hydrophobic regions and 
originally was predicted to be a transmembrane protein (31). However, a functional start-
transfer signal could not be identified (1), leaving the topology of PTP-SL as yet enigmatic. 
The observed redistribution into the cytosol further argues against PTP-SL being a 
transmembrane protein and, taken together, all data suggest a membrane-associated status 
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with displaceable binding characteristics. Future subcellular fractionation studies should add 
to this matter.  
PTPBR7 proteins were found at membrane curvatures and early endosomes in an 
endocytosis assay at the ultrastructural level, in which C-terminally-tagged PTPBR7-EGFP 
proteins were detected using an α-EGFP antiserum (Chapter 5). Surprisingly, we could not 
detect internalized PTPBR7 through biotinylation-internalization protocols (Chapter 4). Since 
PTPBR7 is subjected to N-terminal proteolytic cleavage at the cell surface (Chapter 4) it is 
conceivable that only cleaved PTPBR7 protein, i.e. PTPBR7-65, gets internalized. This 
shorter PTPBR7 variant lacks two-thirds of the residues that can be biotinylated in the small 
extracellular part, thus introducing a severe limitation for the detection of biotinylated and 
internalized PTPBR7 molecules.  
Assuming that the localization of PTPBR7 at coated membrane curvatures and early 
endosomes at the ultrastructural level is indicative for a regulatory role in internalization 
processes, its influence could be either positive or negative. In support of a negative 
regulatory role, preliminary experiments indicated a reduced uptake of dextran or transferin 
by neuronal cells stably expressing PTPBR7-GFP when compared to non-expressing control 
cells (own unpublished data). However, these experiments should be pursued further in order 
to establish the significance of this finding. If indeed PTPBR7 turns out to inhibit 
endocytosis, it will be extremely interesting to study whether catalytic activity or structural 
properties (i.e. proteolytic cleavage) of PTPBR7 is required for this. Likewise, knock-down 
of PTPBR7 proteins in cultured PC12 cells (the only neuroendocrine cell line known to 
express endogenous PTPBR7) by siRNA-mediated RNA interference might shed light on this 
possible role in endocytosis.  
In live imaging studies we demonstrated that PTPBR7 and PTP-SL vesicles are highly 
motile and that the motion is bi-directional, since PTPRR vesicles traveling both to and from 
the Golgi-apparatus were observed (Chapter 5). Also in other areas of the cell anterograde 
and retrograde transport of PTPRR vesicles was detected. The presence of PTPBR7 and PTP-
SL on highly motile vesicles of the endocytic pathway is in line with a dynamic role for these 
phosphatases in the regulation of endocytic transport routes in neurons. Intriguingly, serum 
deprivation of Neuro-2a cells stably expressing PTPBR7-GFP was found to result in 
behavioral changes of the PTPBR7 organelles (our unpublished data). In these preliminary 
live-imaging studies, we observed increased dynamic trafficking of PTPBR7 vesicles as well 
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as the formation of tubular structures upon serum deprivation. No such differences, in 
particular no tubule formation, were noted for PTP-SL vesicles.  
Dynamic tubular networks have been described for some biological membranes, such 
as those of the endoplasmic reticulum, the Golgi-apparatus, and endosomes (32,33). 
Microscopy of living cells has demonstrated that membrane tubules also participate in 
transport events between cellular compartments (34-36). Many intracellular membrane 
tubules are generated by microtubule motors that pull developing membrane tubules along a 
preformed microtubule track (37,38). We have demonstrated that PTPBR7 and PTP-SL 
vesicles are localized along microtubules (Chapter 5). It is very likely, therefore, that 
microtubules are involved in the formation of PTPBR7 tubular structures. Upon serum 
deprivation Neuro-2a cells start to differentiate; they leave the cell cycle, become flatter and 
form neurite-like extensions. The presence of PTPBR7 but not PTP-SL in the tubular 
structures during differentiation of Neuro-2a cells may therefore point to distinct roles of 
these PTPRR isoforms in neuronal differentiation.  
 
 
PTPRR isoforms and endosomal signaling 
 
Following up on the above, it is interesting to note that the expression of PTPBR7 messenger 
RNA in PC12 cells is transiently increased nine-fold following treatment with nerve growth 
factor (NGF), a well-known inducer of PC12 differentiation (39). NGF binds to and activates 
trkA receptors at the presynaptic terminal and, subsequently, the activated trkA-NGF 
complex is internalized into endocytic vesicles that fuse with a ‘signaling endosome’, 
eventually causing sustained activation of ERK-MAP kinases and induction of neuronal 
differentiation. In contrast, EGF stimulation of PC12 cells results in a transient activation of 
the ERK-MAPK pathway which leads to a mitotic response (40,41). Thus, the magnitude and 
duration of MAPK signals are critical determinants of the ultimate biological response.  
As stated, all PTPRR isoforms have an identical C-terminus containing a kinase 
interacting motif (42) allowing interaction with MAP kinases ERK1/2/5 and p38 (2,4,43). It 
remains to be determined whether PTPRR isoforms are required for regulating transient or 
sustained activation of MAPKs. However, up-regulation of PTPBR7 is apparently necessary 
for neuronal differentiation in PC12 cells and it is tempting to relate this to trkA signaling on 
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endosomes, with PTPBR7 enabling a negative feedback loop in NGF signaling. Finally, our 
data support the model in which the different PTPRR isoforms perform distinct tasks in 
localized signaling, with PTPBR7 counteracting receptors and MAP kinases at the cell 
surface and during early endocytosis, while PTP-SL acts in the later stages of endocytic 
transport, and PTPPBSγ isoforms preserve the unphosphorylated state of cytosolic MAP 
kinases. 
 
 
Physiological relevance 
 
Most of our understanding of the PTPRR subfamily of protein tyrosine phosphatases is based 
on studies with cells in culture. Although more work is needed to further extend our 
biochemical understanding of the regulation of - and regulation by PTPRR isoforms, there is 
also a need to translate this knowledge to the tissue and organism level. Two PTPRR 
isoforms are expressed in the Purkinje cells of the cerebellum ((1,44) and Chapter 3). 
Although PTPBR7 is initially expressed during Purkinje cell development, PTP-SL 
expression takes over post-natally and remains high in adult Purkinje cells (1). This specific, 
complementing, neuronal expression pattern of the two isoforms would be in line with an 
important regulatory role in the cerebellar nervous system. Such a role for PTPs in cerebellar 
development would not be unprecedented. For instance, tyrosine phosphatase activity of 
PTPβ/ζ was found to be required for proper Purkinje dendrite development (45) and PTPσ 
knock-out mice show behavioral deficits including abnormal limb flexion, fine intention 
tremor, ataxic gait and defects in proprioception (46). Very recently, a PTPRR knock-out 
mouse strain was generated in our lab and the first tests indeed point to motor coordination 
defects (R. Chirivi and C.E.E.M. van der Zee, personal communication), in support of a 
critical role for PTPRR in the development or physiological integrity of the cerebellum. It is 
conceivable that PTPRR isoforms are involved in neuronal plasticity, which is required for 
cerebellum-coordinated behavior, and therefore it will be interesting to study long-term 
potentiation (LTP) in hippocampal and cerebellar slice cultures from wild-type and PTPRR 
knock-out specimen. The impact of phosphorylation in the regulation of LTP is nicely 
demonstrated by, for example, the PKA-mediated phosphorylation of the active zone protein 
RIM1α, which induces presynaptic plasticity at cerebellar parallel fiber synapses (47). 
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Furthermore, the receptor-type RPTP-α appeared to be required for LTP in hippocampal slice 
cultures (48), and the STEP family of PTPs were shown to regulate hippocampal LTP either 
through direct dephosphorylation of the NMDA receptor or through an indirect mechanism 
that leads to inactivation of Src-family tyrosine kinases (49,50). Clearly, the identification of 
bona-fide substrates for PTPRR isoforms in neuronal tissue, eventually through the 
exploitation of materials derived from wild type and PTPRR knock-out animals and cells, 
will further shed light on the regulatory potential of this PTP subfamily on signaling 
processes within the neuronal circuitry. 
 
 
Future prospects 
 
It is clear that much more work needs to be done to fully understand how the many PTPRR 
isoforms are regulating complex cellular processes. This will require a combination of 
biochemical, structural, morphological, and advanced imaging approaches. Analysis of the 
composition of transport vesicles in brain by protein mass spectrometry may identify new 
PTPRR interacting proteins and help to elucidate the molecular mechanisms by which these 
PTPs might influence signaling and trafficking. Fluorescent imaging techniques will provide 
new perspectives on the movement of these proteins and their interactions with cellular 
components in living cells. It will be a challenge to visualize signal transduction-based 
protein dephosphorylation by PTPRR isoforms in living cells or tissues in order to learn more 
about their spatial and temporal characteristics in localized signaling. Fluorescent probes that 
allow the imaging of protein phosphorylation in living cells are now becoming available (51) 
and fluorescence resonance energy transfer (FRET) techniques enable the study of PTPRR - 
MAPK interactions in vivo. And last but not least, the ongoing analysis of PTPRR knockout 
mice will reveal further clues towards the significance of PTPRR protein isoforms for 
development, health and disease.  
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Abbreviations 
 
aCSF  arteficial cerebro-spinal fluid 
AP  adaptor complex 
BSA  bovine serum albumin 
c-AMP cyclic-adenosine monophosphate 
CLSM  confocal laser scanning microscopy 
COPI/II  coat protein complexes 
EDTA  ethylenediaminetetraacetate 
EGF  epidermal growth factor 
EGFP   enhanced green fluorescent protein  
EGFR  epidermal growth factor receptor 
ELISA  enzyme-linked immunosorbent assay 
Endo F  endoglycosidase F 
Endo H endoglycosidase H 
ER  endoplasmic reticulum 
ERK  extracellular regulated kinase 
FACS  fluorescence activated cell sorting 
FCS  fetal calf serum 
FRET  fluorescence resonance energy transfer 
GFP  green fluorescent protein 
GGA  Golgi-localized, γ-ear containing, ARF-binding protein 
JNK  c-Jun N-terminal kinase 
KIM  kinase interacting domain 
KIS  kinase specificity domain 
LTP  long-term potentiation 
MAPK  mitogen-activated protein kinase 
MEK  map kinase kinase 
MKK  map kinase kinase 
mRNA  messenger ribonucleic acid 
MVB  multi veiscular bodies 
NAGT  N-acetylglucosaminyltransferase 
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NGF  nerve growth factor 
NMDA N-methyl-D-aspartate 
NSF  N-ethylmaleimide-sensitive factor 
ORF  open reading frame 
PAGE  poly acryl amide gel electroforese 
PBS  phosphate buffered saline 
PFA   parafolmaldehyde 
PKA  protein kinase A 
PTP  protein tyrosine phosphatase 
PTPBR7 protein tyrosine phosphatase brain clone number 7 
PTPPBS protein tyrosine phosphatase PC12/Br7/SL 
PTPPBSγ protein tyrosine phosphatase  
PTP-SL protein tyrosine phosphatase STEP-like 
RNA  ribonucleic acid 
RTK  receptor tyrosine kinase 
RT-PCR reverse transcriptase-polymerase chain reaction 
SDS  sodium dodecyl sulfate 
Sef  acronym for similar expression to fgf genes 
STEP  striatal enriched phosphatases 
TGN  trans Golgi complex 
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Samenvatting 
 
Voor het optimaal functioneren van levende organismen moeten door de lichaamscellen 
eiwitten aangemaakt, getransporteerd, gemodificeerd en uiteindelijk weer afgebroken 
worden. Deze celbiologische processen worden zeer nauwkeurig gereguleerd o.a. door 
reversibele fosforylering van eiwitten. Eiwitfosforylering (binden van een fosfaatgroep aan 
een eiwit) gebeurt door enzymen die kinases genoemd worden, terwijl andere enzymen, 
fosfatases genaamd, de eiwitten kunnen defosforyleren. In de afgelopen decennia is gebleken 
dat reversibele fosforylering een essentiële rol speelt bij de overdracht van signalen in de cel. 
Kinases en fosfatases zijn dan ook betrokken bij een veelvoud van levensprocessen, 
waaronder embryonale ontwikkeling, celbeweging en neuronale celdifferentiatie. Een aantal 
van de kinases en fosfatases is gelokaliseerd op specifieke organellen in de cel, waaronder 
transportblaasjes. Dit suggereert dat deze enzymen, naast een rol bij locale 
communicatieprocessen  binnen de cel, ook een rol spelen bij de regulatie van het 
intracellulaire transport.  
Voordat ik mijn promotieonderzoek begon, was er vastgesteld dat de fosfotyrosine 
fosfatase PTP-SL voorkomt op transportblaasjes in de cel. Het PTP-SL eiwit behoort tot de 
PTPRR proteïne tyrosine fosfatase subfamilie en wordt in verband gebracht met 
signaaloverdrachtcascades via zogenaamde MAPKs (mitogen-activated protein kinases). In 
dit proefschrift worden studies beschreven waarin de moleculaire diversiteit van 
verschillende PTPRR familieleden onderzocht is, in het bijzonder voor wat betreft de 
isovorm-specifieke lokalisatie en de mogelijke betrokkenheid bij intracellulair transport. 
In hoofdstuk 2 wordt de verkenning van de (moleculaire) omgeving van een tweetal 
PTPRR-isovormen, te weten PTPBR7 en PTP-SL, beschreven. Bestudering van de 
subcellulaire localisatie van deze fosfatases in zenuwcellen liet zien dat PTPBR7 en PTP-SL 
in het Golgi-apparaat en in late endosomale structuren gevonden worden. Daarnaast bevindt 
het PTPBR7-eiwit zich ook op het celmembraan. De intracellulaire lokalisaties van PTPBR7 
en PTP-SL vertonen grote gelijkenis met die van het β4-adaptin eiwit, een subunit van het 
AP-4 adaptor complex. De heterotetramere adaptor complexen, AP-1 t/m AP-4, zijn 
betrokken bij het sorteren van eiwitten die door transportblaasjes vervoerd worden. Het 
tegelijkertijd tot expressie brengen van PTP-SL en β4-adaptin in zenuwcellen bleek een 
dramatische verandering in de lokalisatie van  PTP-SL tot gevolg te hebben: in plaats van 
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rond het Golgi-apparaat en transportblaasjes wordt PTP-SL dan vrij gevonden in het 
cytoplasma. De lokalisatie van β4-adaptine bleek overigens niet veranderd. Hoewel in het 
‘yeast 2-hybrid systeem’ zelfs aanwijzingen voor een directe interactie tussen PTP-SL en β4-
adaptine werden verkregen, kon een complex van deze twee eiwitten in neuronale cellen niet 
worden aangetoond. De genoemde resultaten wijzen echter wel op een mogelijk regulerende 
rol van PTPRR fosfatases in het blaasjestransport in cellen.  
Uit de literatuur en sequentie-databanken valt af te leiden dat er mogelijk meerdere 
eiwitten (isovormen) gecodeerd werden door het muizengen Ptprr. In hoofdstuk 3 hebben we 
een gedetailleerde analyse uitgevoerd waarbij zo volledig mogelijk de transcripten en 
eiwitproducten horende bij het gen Ptprr zijn bepaald. Uit deze experimenten is gebleken dat 
het gen Ptprr aanleiding geeft tot vier verschillende eiwit-isovormen (PTPBR7, PTP-SL, 
PTPPBSγ-42 en PTPPBSγ-37) door het gebruik van verschillende promoters, alternatieve 
splicing en meerdere translatie-initiatie sites. De vier isovormen verschillen in hun N-
terminale gedeelte, wat resulteert in PTPRR subtypes die ook op (sub)cellulair niveau 
verschillen: PTPBR7 is een receptorachtig transmembraan eiwit, PTP-SL blijkt 
membraangeassocieerd, en de twee PTPPBSγ isovormen zijn cytosolische eiwitten.   
Hoofdstuk 4 handelt over de posttranslationele modificaties die de PTPRR eiwit-
isovormen kunnen ondergaan. Alle isovormen blijken op een tweetal plekken gefosforyleerd 
te kunnen worden. Daarnaast is gebleken dat alle PTPRR isovormen een relatief korte 
levensduur, van enkele uren, hebben. Ook werd aangetoond dat PTPBR7 proteolytisch 
gekliefd kan worden op een furine-achtige convertase consensus site in het N-terminale 
gedeelte. De klieving gebeurt vooral extracellulair en neemt toe in aanwezigheid van serum 
in het medium. Hiermee wordt dus een vijfde PTPRR isovorm gecreëerd: PTPBR7-65.   
Een gedetailleerde analyse van de subcellulaire localisatie van PTPBR7 en PTP-SL, 
door middel van lichtmicroscopische (immunofluorescentie) en electronenmicroscopische 
studies (ultrastructureel), staat beschreven in hoofdstuk 5. Aangetoond wordt dat PTPBR7 en 
PTP-SL tegelijkertijd aanwezig kunnen zijn in dezelfde ‘late’ endosomen. Belangwekkend is 
ook dat de aanwezigheid van PTPBR7 op ‘vroege’ endosomen kon worden aangetoond met 
behulp van electronenmicroscopie. Deze resultaten zouden stroken met een model waarbij 
PTPBR7 en PTP-SL bij verschillende stadia van de endocytotische route betrokken zijn. Met 
behulp van microscopische studies aan levende cellen (live imaging) hebben we verder de 
bewegelijkheid van PTP-SL- en PTPBR7-positieve transportblaasjes onderzocht. Zowel 
Samenvatting 
 162
PTPBR7 als PTP-SL blaasjes vertonen een grote mate van mobiliteit, en transport van 
blaasjes van en naar het Golgi-apparaat kon worden waargenomen. Ook in andere delen van 
de cel is tweerichtingsverkeer van blaasjes waargenomen. De aanwezigheid van PTPBR7 en 
PTP-SL in zeer bewegelijke blaasjes in specifieke delen van de endocytotische route 
impliceert een dynamische rol voor deze fosfatases in intracellulair transport. 
Hoofdstuk 6 tenslotte, bevat een afrondende bespreking van de resultaten uit het in de 
voorafgaande hoofdstukken beschreven onderzoek en er worden enkele suggesties gedaan 
voor vervolgstudies. Vooral wordt hierbij gewezen op de nieuwe mogelijkheden voor het 
bestuderen van de fosforylering van signaaloverdrachteiwitten in levende cellen met 
geavanceerde microscopische beeldvormingtechnieken.  
Samengevat kan gesteld worden dat één enkel gen, Ptprr, in staat is om via 
verschillende mechanismen een groot repertoire aan functioneel verwante eiwitten te 
genereren.  Doordat deze eiwitten naar specifieke plaatsen in de cel gedirigeerd worden, 
ontstaat een veelvoud aan mogelijkheden voor locale en ‘tijdelijke’ communicatie op het 
raakvlak van signaaltransductie en eiwittransport. 
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Chapter 2. Fig. 2 PTP-SL containing vesicles partly colocalize with late endosomes but not with MVB and 
Lysosomes. Neuro-2a cells were transiently transfected with a construct encoding EGFP-tagged PTP-SL (A, D, G, 
J). Expression of PTP-SL-GFP was found at the Golgi area and at vesicles that are distinct from multi vesicular 
bodies (B) or lysosomes (E). MVBs were detected immunohistochemically using an antibody directed against LBPA 
(31). Lysosomes were stained with an antiserum against β-glucocerebrosidase (29). GFP fluorescence was recorded 
directly. After 5 min of Alexa-549-labeled transferrin uptake (H) no colocalization with PTP-SL-containing vesicles 
(G) is observed. After 10 min of transferrin uptake (K), suggestive for late endosomes, overlapping structures start 
to appear (L). Merged images are shown on the right (C, F, I, L), with PTP-SL-GFP fluorescence patterns in green 
and LBPA (C), β-glucocerebrosidase (F) or transferrin (I, L) signals in red. Experiments using GFP-tagged PTPBR7 
essentially led to the same conclusion (data not shown). Confocal sections of the fluorescence signals were collected 
by CLSM. Bar indicates 10 µm. 
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Chapter 2. Fig. 3 Co-transfection of PTP-SL and β4-adaptin results in an altered localization for PTP-SL. 
Analysis of localization patterns in mouse Neuro-2a cells co-transfected with constructs encoding PTP-SL and 
EGFP-Rab6B (A-C), PTP-SL and EGFP-NAGT (D-F), PTP-SL and EGFP-β4-adaptin (G-I), and β4-adaptin and 
EGFP-Rab6B (L). Panels J and K show single transfectants for PTP-SL and β4-adaptin, respectively. Untagged 
PTP-SL and β4-adaptin proteins were detected immunohistochemically using the antisera anti-SL and anti-β4-
adaptin, respectively. Note the cytoplasmic distribution for PTP-SL (G) upon co-transfection with β4-adaptin 
construct (H) as opposed to the vesicle-associated appearance in single transfected cells (J) and in cells co-
expressing Rab6B or NAGT (A, D). Merged pictures are shown on the right (C, F, I, L) with PTP-SL (A, D, G) or 
β4-adaptin (L) immunofluorescence in red and GFP-fusion protein signals (B, E, H, L) in green. Confocal sections 
of the fluorescence signals were detected by confocal laser scanning microscopy. Bar indicates 10 µm. 
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Chapter 2. Fig. 6 β4 adaptin and PTP-SL/PTPBR7 immunoreactivity in neurons of several brain regions.  
Immunohistochemical staining of sequential sections with antibodies against β4-adaptin (A, C, E), and PTP-SL (B, 
D, F). Colocalization is shown for mouse brain cortex (A, B), pyramidal cells of the hippocampus (C, D), and 
cerebellum (E, F). Bar indicates 100 µm. 
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Chapter 3. Fig. 6 Immunolocalization of PTPRR protein in mouse brain.  
Brain cryosections were stained using a mixture of three different monoclonal antibodies (1E3, 3E11 and 6A6) 
immunoreactive towards the common part in PTPRR isoforms and that cross-react with STEP. Positive staining is 
observed in the Purkinje cells of the cerebellum (A), both the neurons and neuropil of the striatum (B). Similar 
sections were incubated with monoclonal antibody 5E4, which does not cross-react with STEP. Exclusively Purkinje 
cell staining was observed (C), and no signal could be detected in the striatum (D). The STEP-absorbed α-SL serum 
also shows a clear Purkinje cell staining (E) and does not react with striatum (F), suggesting that staining of the 
striatum (B) reflects STEP immunoreactivity. 
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Chapter 5.  Fig. 2 PTPBR7 localizes to early and late endosomes.  
Neuro-2a cells were transiently transfected with construct pPTPBR7-EGFP. PTPBR7-EGFP fluorescence (A, D, and 
G) and Alexa549-labeled Dextran uptake (B, E, and H) after 5 min (A-C), 10 min (D-F) and 20 min (G-I) were 
recorded directly using confocal microscopy. Yellow color in panels C, F and I indicates overlap of PTPBR7-EGFP 
(green) and Alexa549 Dextran (red) signals. Arrows point to dextran-containing vesicles, which are also positive for 
PTPBR7  (D and E). Bar indicates 10 µm. 
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Chapter 5. Fig. 3 PTP-SL localizes to late endosomes.  
Neuro-2a cells were transiently transfected with construct pPTP-SL-EGFP. PTP-SL-EGFP fluorescence (A, D, and 
G) and Alexa549-labeled Dextran uptake (B, E, and H) after 5 min (A-C), 10 min (D-F) and 20 min (G-I) were 
recorded directly using confocal microscopy. The yellow color in panels C, F and I shows the overlap of PTP-SL-
EGFP (green) and Dextran (red) signals. Bar indicates 10 µm. 
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Chapter 5. Fig. 5. Some endocytic vesicles contain PTPBR7 as well as PTP-SL.  
Neuro-2a cells were co-transfected with pPTP-SL-EGFP and pSG8/PTPBR7-FL-VSV. EGFP fluorescence of PTP-
SL-EGFP was recorded directly (B and E) and PTPBR7 proteins were visualized immunohistochemically using the 
P5D4 antibody against the VSV tag (A and D). Yellow color in panel C indicates overlap of PTP-SL-EGFP (green) 
and PTPBR7 (red) signals. After 20 min of Alexa-633-labeled Dextran uptake triple-labeled vesicles that are 
positive for PTPBR7 (D), PTP-SL (E) and Dextran (F) can be detected  (arrows). Bar indicates 10 µm. 
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Chapter 5. Fig. 7 PTPBR7 and PTP-SL positive vesicles localize along microtubule tracks.  
Neuro-2a-SL (A-C) and Neuro-2a-BR7 (D-F) cells were cultured under doxycycline-free conditions for 2 days to 
induce expression of the EGFP fusion proteins. Fluorescence of PTP-SL-EGFP (B) and PTPBR7-EGFP (E) was 
recorded directly.  Microtubuli (A, D) were stained immunohistochemically using an antibody directed against β-
tubulin.  Panels C and F display merged images of EGFP-tagged PTPRR autofluorescence (green) and the 
microtubuli immunostaining (red). Bar indicates 10 µm. 
 
 
 
 
 
 
